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Interleukin-1β (IL-1β) is a key mediator in the inflammatory response essential to cellular 
defense against pathogen invasion and to the repair of tissue damage. While some 
studies suggest that IL-1β signaling is harmful to the injured central nervous system, 
others report neuroprotective effects that appear to be context-dependent. Previously, 
the Hewett laboratory demonstrated the importance of IL-1β-mediated increases in the 
cystine-glutamate transporter, system xc
-, as a novel contributor to inflammatory hypoxic 
neuronal injury, a model of the ischemic penumbra. The main focus of this doctoral 
research was to elucidate the specific cell type(s) in mixed cortical cultures that respond 
to IL-1β by enhancing the activity of system xc
-, the molecular mechanism by which this 
occurs, and the physiological and pathophysiological consequences of this regulation. 
IL-1β exposure (0.1-3 ng/ml) enhances expression of the substrate-specific light chain of 
system xc
-, xCT, in pure astrocyte cultures in a time-dependent manner. By utilizing 
pharmacological inhibitors and cells derived from animals harboring a mutation in the 
Slc7a11 gene (sut mice) that encodes for xCT, we now provide definitive evidence that 
alterations in system xc
- activity in astrocytes exclusively mediate the potentiation of 
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hypoxic neuronal injury by IL-1β and initiates hypoglycemic neuronal injury. Additionally, 
the neuronal cell death in these paradigms is non-cell autonomous. Even though the IL-
1β-mediated enhanced efflux of glutamate, which occurs by virtue of its obligate 
exchange, can be deleterious, cystine import via system xc
- is critical for the synthesis of 
the antioxidant glutathione (GSH). Since astrocytes function as the predominant provider 
of GSH in the CNS, we assessed whether IL-1β treatment altered astrocyte GSH levels. 
Pure cortical astrocyte cultures treated with IL-1β (3 ng/ml) exhibit a time-dependent 
increase in extracellular GSH levels, suggesting both enhanced synthesis and export 
that is associated with protection against oxidative stress in pure astrocyte cultures as 
well as mixed cultures exposed to tert-butyl hydroperoxide (tBOOH; 0.1-1.5 mM). Hence, 
IL-1β may be an important stimulus for increasing astrocytic GSH production, and thus, 
total antioxidant capacity in the brain. These findings unequivocally demonstrate that IL-
1β and astrocytic system xc
- contribute to neuronal injury and neuroprotection in a 
context-dependent manner.    
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CHAPTER 1 
 
General principles 
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1.1 Introduction 
 Inflammation is an intrinsically complex biological response mounted to 
combat pathogen invasion, protect against tissue damage and promote tissue 
repair. However, unabated inflammation can be deleterious and contribute to 
injury and pathology. Given that inflammation is a fundamentally protective 
response, it should not be surprising that inflammatory mediators can exert 
beneficial effects. This dissertation focuses specifically on the pleiotropic 
cytokine, interleukin-1β (IL-1β) described by some as “the master regulator of 
neuroinflammation” (Basu et al., 2004), and the ability of IL-1β to contribute to 
neuronal injury under conditions of energy deprivation and protect neurons 
against oxidative stress-induced injury via its regulation of an amino acid 
exchanger known as system xc
- which transports the amino acids cystine and 
glutamate.  
 
1.2  Glutamate 
 Glutamate is the major excitatory neurotransmitter in the CNS (Fonnum, 
1984). It is involved in developmental processes such as cell migration and 
differentiation, and also in most physiological processes in the brain including 
learning and memory via its interaction with AMPA and NMDA receptors, and 
energy metabolism, by serving as a precursor to α-ketoglutarate. Regulated 
control of glutamate release and efficient uptake of this transmitter are required 
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for glutamatergic signaling under physiological conditions. In the event of 
dramatic enhancements in extracellular glutamate, the prolonged stimulation of 
glutamate receptors can initiate cell death via a process termed excitotoxicity 
(see section 1.2.4).  
1.2.1 Glutamate Physiology 
  Glutamatergic neurons make up 90% of all neurons in the brain 
(Dingledine and McBain, 1999). In this subset of neurons, glutamate is packaged 
in synaptic vesicles and released via exocytosis upon depolarization of the nerve 
terminals. Once released, glutamate either binds to its receptors, diffuses away 
from the synapse, or is cleared from the synapse via excitatory amino acid 
transporters (EAAT1-5 also known as system XAG
-) which are localized to both 
neurons and astrocytes. Notably, astrocytic glutamate uptake via EAAT1/ GLAST 
and EAAT2/Glt-1 is the predominant route of glutamate clearance, with Glt-1 
responsible for clearance of 80% of glutamate in the hippocampus (Lehre and 
Danbolt, 1998). Glutamate that is internalized via astrocytic transporters can be 
converted to glutamine via the action of glutamine synthetase, an enzyme 
localized exclusively to astrocytes (Norenberg and Martinez-Hernandez, 1979). 
Conversion of glutamate to glutamine enables synaptically released glutamate to 
be recycled and shuttled back to neurons in a non-neuroactive form. Within the 
neuron glutamine is converted back to glutamate via glutaminase. Alternatively, 
glutamate can be converted to α-ketoglutarate, a key intermediate in the Kreb’s 
cycle, via the enzymatic action of glutamate dehydrogenase or glutamate 
oxaloacetate transaminase.  
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1.2.2 Glutamate Signaling  
 Glutamate binds to two distinct classes of receptors, ionotropic and 
metabotropic receptors. Ionotropic receptors flux cations following glutamate 
binding, whereas metabotropic receptors activate intracellular signaling via G-
protein-coupled second messenger systems. There are three types of ionotropic 
receptors named according to agonist pharmacology:  the N-methyl-D-aspartate 
(NMDA) receptor, the α-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptor, 
and the kainate receptor. Additionally there are 8 metabotropic receptors which 
are separated into three groups based on sequence homology, second 
messenger systems, and pharmacological agonist and antagonist profiles. Group 
I metabotropic glutamate receptors consist of mGluR1 and mGluR5 and typically 
activate phospholipase C pathways and increase intracellular Ca2+. Group II 
(mGluR2 and mGluR3) and Group III (mGluR4, mGluR6, mGluR7, and mGluR8) 
metabotropic receptors generally reduce adenylate cyclase activity [ for a 
detailed review see (Nakanishi et al., 1998; Dingledine et al., 1999; Featherstone 
and Shippy, 2008; Kim et al., 2008)]. 
 
1.2.3 Basal ambient extracellular glutamate 
 At its most basic level, ambient glutamate levels are dictated by the rate of 
release and the rate of glutamate clearance from the extracellular space. To fully 
appreciate ambient extracellular glutamate levels, one must first understand 
glutamate compartmentalization within the CNS. Neurons and astrocytes have 
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millimolar concentrations of intracellular glutamate, with neurons having higher 
levels of cytosolic glutamate due to the action of glutamine synthetase in 
astrocytes which converts glutamate to glutamine (Nedergaard et al., 2002). The 
concentration of glutamate in the cytosol of glutamatergic neurons can reach 10 
mM, with an estimated glutamate concentration of up to 100 mM in the synaptic 
vesicles (Riveros et al., 1986; Burger et al., 1989; Clements et al., 1992; Ottersen 
et al., 1992; Danbolt, 2001). Extracellular glutamate levels in the synapse 
fluctuate as a function of neuronal activity and range from 2 µM – 1 mM 
(Meldrum, 2000; Danbolt, 2001).  
 Numerous techniques have been employed to estimate extracellular 
glutamate levels in the brain with concentrations estimated to range between ≈25 
nM  to 5 µM (Danbolt, 2001; Baker et al., 2002b; Baker et al., 2003; Cavelier and 
Attwell, 2005; Nyitrai et al., 2006; Herman and Jahr, 2007) depending on the 
particular area analyzed and technique employed. For example, in vivo 
microdialysis measurements of extracellular glutamate levels range from 1-2 µM 
in the striatum (Rothstein et al., 1996; Baker et al., 2002b) to 5 µM in rat nucleus 
accumbens (Baker et al., 2002b; Baker et al., 2003). Importantly, micromolar 
concentrations of glutamate could activate glutamate receptors as the EC50 of the 
NMDA receptor for glutamate is 2 µM (Patneau and Mayer, 1990; Herman and 
Jahr, 2007). AMPA/kainate receptors are activated by glutamate at much higher 
concentrations and thus are not likely to be activated by ambient levels of 
extracellular glutamate (for EC50 values for other glutamate receptors see Table 
1). Alternatively, micromolar concentrations of glutamate could cause receptor 
6 
 
desensitization and the suppression of glutamate signaling. Sather and 
colleagues desensitized ≈80% of NMDA receptors with 1 µM glutamate in 
outside-out patches from embryonic mouse neurons (Sather et al., 1992). 
AMPA/kainate receptors desensitize at concentrations ranging from 3 – 13 µM 
(Featherstone and Shippy, 2008), making it possible that some subset of 
ionotropic glutamate transporters are tonically desensitized by ambient 
glutamate. 
 It is possible that microdialysis studies overestimate extracellular 
glutamate concentrations as the insertion of the microdialysis probe damages 
tissue, creates an artificial space surrounding the probe and in turn increases the 
distance between the probe and functional transporters (Benveniste and 
Huttemeier, 1990). Herman and Jahr measured currents produced by application 
of NMDA and glutamate in rat CA1 pyramidal neuronal slices and estimated a 
value of ≈25 nM ambient extracellular glutamate (Herman and Jahr, 2007).  
Since glutamate is rapidly taken up by the EAATs, the EC50 values obtained from 
dose-response curves for NMDA and glutamate were compared to create a 
conversion factor which was utilized to estimate ambient glutamate. The authors 
contend that ambient glutamate levels maintained at nanomolar concentrations 
would prevent NMDA receptor activation / desensitization (Herman and Jahr, 
2007).  
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ED50 of glutamate  on glutamate 
receptors (µM) 
 
NMDA 2-3 
AMPA 200-500 
Kainate  300-800 
mGluR1 9-13 
mGluR2 4-20 
mGluR3 4-5 
mGluR4 3-20 
mGluR5 3-10 
mGluR6 16 
mGluR7 1000 
mGluR8 0.02 
 
Table 1. ED50 values for glutamate activation of glutamate receptors. Values 
obtained from (Conn and Pin, 1997; Meldrum, 2000; Featherstone and Shippy, 
2008). 
 
 Based on analysis of the stoichiometric transport of the anionic form of 
glutamate, 3 Na+, and 1 H+ and the counter transport of 1 K+ in EAAT3 
transfected oocytes, EAAT / system XAG
- transporters are predicted to have the 
capacity to theoretically reduce extracellular glutamate to ≈ 2 nM  (Zerangue and 
Kavanaugh, 1996). Yet, only one study has calculated extracellular glutamate to 
lie near this theoretical lower limit (Herman and Jahr, 2007). Naturally, it raises 
the question of the true concentration of ambient glutamate and the source(s) 
maintaining glutamate levels 4in the extracellular compartment. 
 Inhibition of glutamate uptake by the application of DL-threo-beta-
benzyloxyaspartate (TBOA) in organotypic hippocampal slices results in 
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increased extracellular glutamate. This glutamate is not synaptically released, 
and is not dependent on Na+ and Ca2+ (Jabaudon et al., 1999). Further, 
increasing levels of astrocytic intracellular glutamate via inhibition of glutamine 
synthetase enhances glutamate accumulation following inhibition of glutamate 
uptake suggesting a glial source (Jabaudon et al., 1999).  
 Application of cystine (1 mM) to cerebellar and cortical slices produces an 
inward, glutamate dependent current in Purkinje and pyramidal cells and the 
hypothesis that a cystine-glutamate exchanger regulates extracellular glutamate 
levels emergedd (Warr et al., 1999). Additional supportive evidence was noted in 
microdialysis studies in the striatum. Reverse dialysis of a cystine-glutamate 
transporter antagonist reduces extracellular glutamate by 60% (Baker et al., 
2002b). Further, the function of this transporter is conserved across species as 
genetic disruption of the same cystine-glutamate transporter via insertion of a 
mutation in the first exon of the genderblind (gb) gene in Drosophila produces a 
50% reduction in extracellular glutamate (Augustin et al., 2007).   
 Importantly, basal extracellular glutamate levels dictate the density of 
post-synaptic ionotropic glutamate receptor clustering in Drosophila. Mutant 
genderblind Drosophila with reduced ambient glutamate levels have increased 
glutamate receptor immunoreactivity and enhanced spontaneous excitatory 
currents at the neuromuscular junction (Augustin et al., 2007). Glutamate 
receptor density was restored with physiological levels of glutamate (Augustin et 
al., 2007). Additionally, ambient basal extracellular glutamate tonically activates 
mGluR2/3 receptors  to negatively modulate glutamatergic and dopaminergic 
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signaling in the striatum and nucleus accumbens (Baker et al., 2002b; Moran et 
al., 2005). Interestingly, cocaine administration reduces extracellular glutamate in 
the rat nucleus accumbens and this alteration in glutamatergic tone is associated 
with drug-seeking behavior (i.e. susceptibility to relapse) following cocaine 
withdrawal (Baker et al., 2002b; Kalivas, 2009).  
 
1.2.4 Glutamate Excitotoxicity 
 Extracellular glutamate levels must be carefully regulated as prolonged 
stimulation of its cognate receptors will lead to neuronal cell death. The concept 
of excitoxicity is described as the excessive and toxic activation of excitatory 
amino acid receptors that culminates in cell death (Olney, 1969; Choi, 1992). 
Normally, glutamate concentrations in the extracellular space are maintained at 
low levels, however, if levels rise dramatically as a result of increased release or 
an impairment in the clearance of glutamate, a calcium-dependent cascade is 
initiated (Sattler and Tymianski, 2001). Ultimately, the prolonged activation of 
glutamate receptors enhances Na+ and Ca2+ flux into the cells (Figure 1.1). The 
ensuing Ca2+ dysregulation activates kinases, proteases, and lipases, and 
increases the production of reactive oxygen and nitrogen species which impairs 
mitochondrial function and results in cell death [reviewed extensively in (Choi, 
1988; Sattler and Tymianski, 2000, 2001)].  
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1.2.6 Sources of extracellular glutamate 
 Glutamate originating in neurons can be released via exocytosis following 
depolarization or as a consequence of cell lysis. Glutamate is released from 
astrocytes via Ca2+-dependent and Ca2+-independent processes (Parpura et al., 
1994; Araque et al., 1998; Jabaudon et al., 1999). Astrocytes express several 
proteins required for exocytosis including synaptobrevin II and syntaxin (Parpura 
et al., 1994; Parpura et al., 1995; Araque et al., 1998), and ligands such as 
prostaglandin E2, ATP, glutamate, and bradykinin are known to induce glutamate 
release (Parpura et al., 1994; Bezzi et al., 1998; Jeremic et al., 2001). Further, 
the reverse operation of glutamate transporters (system XAG
-) could enhance 
extracellular glutamate levels (Nicholls and Attwell, 1990; Szatkowski et al., 
1990; Longuemare and Swanson, 1995), however this likely only operates under 
pathological conditions when the Na+ and K+ gradient across the plasma 
membrane is reduced such as occurs under cerebral ischemic conditions. 
Glutamate efflux can arise as a consequence of activation of volume sensitive 
organic anion channels as a component of volume regulation (Kimelberg et al., 
1990; Longuemare et al., 1999; Liu et al., 2006). Interestingly, inhibition of a 
VSOAC with 5-nitro-2-3-phenylpropylamino benzoate (NPPB) can attenuate 
receptor-mediated glutamate release from astrocytes (Jeremic et al., 2001). 
Other sources of glutamate release include: P2X7 channels (Duan et al., 2003), 
hemichannels (Ye et al., 2003; Takeuchi et al., 2006), and system xc
- (Warr et al., 
1999), however this dissertation is particularly interested in release of glutamate 
via system xc
-, and as such will focus on the cystine-glutamate exchanger as the 
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primary source of the excitotoxic levels of extracellular glutamate observed in the 
paradigms described herein.   
 
1.3   System xc
-  
 System xc
- was first identified in 1980 in the IMR-90 human fibroblast cell 
line as a sodium-independent electroneutral transporter of the amino acids 
cystine and glutamate (Bannai and Kitamura, 1980). Cystine and glutamate both 
significantly decrease transport of each other, whereas minimal inhibition of 
cystine and glutamate transport by other amino acids is observed, demonstrating 
the specificity of the transporter. The Km for cystine is reported as 40-50 µM in 
fibroblasts (Bannai and Kitamura, 1980) which is consistent with the value of ≈ 30 
µM obtained for cystine in the mixed cortical cultures routinely used in our 
laboratory (Fogal et al., 2007).  The import of cystine via system xc
- is directly 
coupled to glutamate export, occurring in a Na+-independent, Cl--dependent 
manner with 1:1 stoichiometry (Bannai, 1986). Further, transport is limited to the 
anionic forms of these amino acids with exchange being electroneutral.   
  System xc
- is a member of the heteromeric amino acid transporter family in 
which transporters consist of a heavy and light subunit joined via an extracellular 
disulfide bond (for a detailed review see (Chillaron et al., 2001)). With respect to 
system xc
-,  xCT is the light chain that confers substrate specificity, and 4F2hc 
(heavy chain of the 4F2 surface antigen also known as CD98) is the heavy chain 
that is thought to target the transporter to the plasma membrane (Sato et al., 
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1999; Bassi et al., 2001). Alternatively, xCT can interact with RBAT (related to 
the bo,+ amino acid transporter), an alternate heavy chain to produce a functional 
transporter in experimental systems in which the cDNA of both subunits is 
injected into Xenopus oocytes (Bassi et al., 2001). However, it remains to be 
determined if this interaction occurs naturally in vivo.   
 
 
  
  
 
Figure 1.2. Structure of system x
xc
- is a heteromeric amino acid transport system consisting of two 
subunits: xCT (white) --
-- and a heavy chain (4F2hc
to target the transporter to the plasma mem
Bassi et al., 2001). The subunits are joined via an extracellular disulfide 
bond. The import of 
glutamate export, occurring in a Na
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2001; Shih et al., 2006)
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1.3.1 Structure of system xc
- 
 The light subunit of system xc
- , xCT, was first identified and cloned by 
Sato and colleagues in 1999 from mouse peritoneal macrophage cells (Sato et 
al., 1999). Later, human xCT was identified (Sato et al., 2000; Bassi et al., 2001; 
Kim et al., 2001) with full length human xCT cloned from an undifferentiated 
human teratocarcinoma cell line. The human xCT gene, also known as solute 
carrier family 7 member 11 (Slc7a11),  is located on chromosome 4q28-31, and 
produces a 501 amino acid protein which shares 89% sequence identity and 93-
96% similarity with the 502 amino acid-containing mouse xCT (Bassi et al., 2001; 
Bridges et al., 2001). An additional truncated xCT clone  thought to be a splice 
variant has been observed, but its function remains to be determined (Sato et al., 
2000; Kim et al., 2001). As shown in Figure 1.2, xCT has 12 putative membrane 
spanning domains, with both the N- and C-  termini localized intracellularly 
(Gasol et al., 2004). Structural data remains elusive with respect to the location 
of substrate binding. Gasol and colleagues believe that substrate binding occurs 
within loops 2 and 3 as biotinylation of His110 does not occur in the presence of 
the system xc
-  substrates cystine and glutamate, or the non-transportable 
system xc
- inhibitor (S)-4-carboxyphenylglycine (4-CPG) (Gasol et al., 2004). The 
same group found that the 8th putative transmembrane domain close to Cys327 
also participates in substrate binding and /or permeation (Jimenez-Vidal et al., 
2004). Traditionally, the light subunits of the Slc7 family are not glycosylated, 
although species-specific differences in glycosylation are reported as human xCT 
possesses a site for N-linked glycosylation (Asn314) in the extracellular loop 
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between transmembrane domains 7 and 8, whereas mouse-derived xCT does 
not (Bridges et al., 2001).   
 4F2hc (also known as CD98) is a type II glycoprotein with a single 
transmembrane domain, a molecular weight of ≈ 85-kDa (Jimenez-Vidal et al., 
2004; Palacin and Kanai, 2004). Importantly, the 4F2hc subunit is thought to be 
in excess compared to xCT and, as such, need not be dynamically regulated like 
its light chain partners (Nakamura et al., 1999; Verrey et al., 2000). 4F2hc is 
widely expressed and the tissue and cell-type distribution demonstrate its 
importance in a myriad of biological activities. xCT and 4F2hc interact via an 
extracellular disulfide bond at residue Cys158 of xCT (Gasol et al., 2004). The 
heavy chain of system xc
-, 4F2hc, interacts with numerous other amino acid 
transporter light chains via a disulfide bridge and functions to traffic the 
heterodimer to the plasma membrane (Nakamura et al., 1999). Other roles for 
4F2hc have been described such as involvement in cell adhesion/polarity and 
functioning as an extracellular  signaling molecule (Nguyen et al., 2008; Yan et 
al., 2008). In transfected Xenopus oocytes, it has been eloquently demonstrated 
that both the light and heavy chains of system xc
- are required for transporter 
function (i.e. injection of xCT alone or 4F2hc alone cannot produce functional 
cystine uptake, whereas co-injection can) (Sato et al., 1999). Similar findings are 
observed with human xCT. However, mouse xCT can interact with either heavy 
chain 4F2hc or RBAT and have functional transporter activity as assessed by 
cystine uptake (Wang et al., 2003), whereas co-expression of human xCT with 
human RBAT fails to produce functional transporter activity (Bassi et al., 2001). 
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1.3.2 System xc
- expression  
 System xc
- is widely distributed in a variety of tissues and is almost 
ubiquitously expressed in cultured mammalian cells. xCT mRNA and/or protein is 
present in the brain, liver, kidney, stomach, intestines, ovary, spleen, and 
numerous other organs and cell types (Lo et al., 2008). Within the CNS, system 
xc
- is expressed in neurons (Murphy et al., 1990; Burdo et al., 2006; Dun et al., 
2006), astrocytes (Bender et al., 2000; Gochenauer and Robinson, 2001; Pow, 
2001; Burdo et al., 2006), microglia (Piani and Fontana, 1994), and glioma cell 
lines (Cho and Bannai, 1990; Ye et al., 1999). Further, system xc
- is present at 
the CNS-periphery interface and highly expressed in vascular endothelial cells, 
meningeal cells, and ependymal cells (Burdo et al., 2006) and in situ 
hybridization studies show strong expression of xCT mRNA in the area 
postrema, subfornical organ, hypothalamus and the meninges (Sato et al., 2002). 
  
1.3.3  System xc
- function: Glutathione biosynthesis 
 In addition to its role in regulating ambient extracellular glutamate, system 
xc
- has traditionally been studied with respect to its involvement in the 
biosynthesis of the antioxidant molecule glutathione (GSH; Figure 1.3). In fact, in 
early studies performed by Bannai and Kitamura in IMR-90 cells, approximately 
60% of radiolabeled cystine transported into the cells via system xc
- is reduced to 
cysteine within five minutes, while 15% of imported cystine is rapidly incorporated 
into GSH in the same time frame (Bannai and Kitamura, 1980). Thus, the 
function of system xc
- is intimately related to intracellular glutathione levels. 
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Similar findings have demonstrated that enhanced activity of system xc
- 
increases intracellular GSH in an endothelial cell line (MBEC4), a rat retinal 
Müller cell line (TR-MUL), and in BHK21 cells derived from the Syrian hamster 
kidney (Hosoya et al., 2002; Sasaki et al., 2002; Tomi et al., 2003). Conversely, 
in numerous neural cell types, including neurons, gliomas, and oligodendrocyte 
precursors, inhibition of cystine transport in with system xc
- antagonists such as 
glutamate, homocysteic acid, and quisqualate results in diminished intracellular 
stores of GSH and subsequent cell death (Murphy et al., 1989; Murphy et al., 
1990; Kato et al., 1992; Oka et al., 1993; Sagara et al., 1993; Ratan et al., 1994; 
Back et al., 1998; Chung et al., 2005).  
 GSH is a peptide composed of glutamate, cysteine, and glycine, and is the 
most abundant non-protein thiol in mammalian cells.  GSH is best known as a 
potent antioxidant molecule that directly detoxifies free radicals, but also serves 
as a cofactor for the antioxidant enzyme glutathione peroxidase which 
neutralizes hydrogen peroxide and other organic peroxide species. GSH also 
plays important roles in cell metabolism and proliferation, gene expression, and 
signal transduction (Poot et al., 1995; Dringen, 2000; Wu et al., 2004; Shih et al., 
2006). Glutathione also participates in signal transduction by modifying redox-
sensitive proteins in the face of alteration in oxidative and/or nitrosative 
homeostasis (Stamler and Hausladen, 1998; Klatt and Lamas, 2000). Hence, 
understanding GSH synthesis, metabolism, and regulation is of great import.  
 Given the inability of GSH to cross the BBB (Cornford et al., 1978), de 
novo GSH synthesis within the CNS is essential. The concentration of cysteine in 
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the extracellular space is low as its disulfide bond is rapidly oxidized in this 
compartment, thus intracellular GSH concentrations are critically dependent on 
cystine, the best extracellular precursor for cysteine. Numerous amino acid 
transporters  have the ability to import cystine (Kakuda and MacLeod, 1994; 
Knickelbein et al., 1997), however, in the CNS, cystine is predominantly 
transported via system xc which is the focus of this dissertation (Bender et al., 
2000; Shanker and Aschner, 2001; McBean, 2002).  
GSH synthesis occurs in the cytosol via a two-step enzymatic reaction, 
catalyzed by γ-glutamylcysteine ligase and glutathione synthetase,  with cysteine 
as the rate-limiting substrate (Meister and Anderson, 1983; Deneke and Fanburg, 
1989; Sagara et al., 1993; Kranich et al., 1996). Once produced glutathione can 
be exported from the cell, cleaveg by γ-glutamyltranspeptidase into the γ-glutamyl 
moiety and a cysteinylglycine dipeptide, which can be further catabolized via the 
action of aminopeptidase N (Dringen et al., 2001).  
 The concentration of GSH is estimated to range from 1-3 mM in the CNS 
and approaches 8 mM in rat astrocyte primary cultures (Dringen and Hamprecht, 
1998; Dringen, 2000; Franco et al., 2008). Since astrocytes function as 
indispensible support cells for neurons, it may not be surprising that astrocytes 
possess higher GSH levels than neurons (Desagher et al., 1996; Wang and 
Cynader, 2000), and protect neurons against H2O2, dopamine, and NO-mediated 
oxidative insults (Desagher et al., 1996; Tanaka et al., 1999; Chen et al., 2001; 
Shih et al., 2003; Jakel et al., 2007). In fact, 10% of astrocytic GSH / hour is 
exported to the extracellular compartment (Sagara et al., 1996; Minich et al., 
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2006), with the multidrug resistant protein (Mrp1) transporting approximately 60% 
of this GSH released from astrocytes as determined using a competitive Mrp1 
inhibitor, MK-571 (Hirrlinger et al., 2002). Importantly, export of GSH and its 
extracellular catabolism provides GSH precursors which are utilized for GSH 
biosynthesis in neurons. As a result of neuronal dependence on astrocytic GSH, 
deficiencies in astrocytic GSH render neurons more susceptible to oxidant-
induced injury (Gegg et al., 2005), presumably due to reduced export of GSH 
which negatively influences neuronal GSH synthesis (Raps et al., 1989; Sagara 
et al., 1993; Kranich et al., 1996; Dringen et al., 1999; Minich et al., 2006; Sun et 
al., 2006). 
  
  
  
 
 
 
Figure 1.3. Schematic of glutathione biosynthesis and metabolism.
structure of reduced glutathione (GSH) is depicted. Modified from 
Butterfield, 2010). 
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1.3.4 System xc
- and disease 
 The link between system xc
- activity and CNS pathology in vivo has been 
extensively studied in the context of the biology of gliomas. System xc
- is 
expressed in rodent and human glioma cell lines and patient-derived gliomas (Ye 
et al., 1999; Ye and Sontheimer, 1999; Chung et al., 2005; Lyons et al., 2007; 
Ogunrinu and Sontheimer, 2010). Interestingly, the activity of system xc
- 
facilitates tumor growth and expansion within the confines of the skull via 
glutamate-mediated excitotoxic neuronal cell death. In fact, glioma cultures can 
raise extracellular glutamate concentrations to 500 µM within 12 hr (Ye and 
Sontheimer, 1999). This in vitro finding was substantiated in vivo by the finding 
that implantation of glioma cells in rats could produce substantial increases in 
extracellular glutamate as measured via microdialysis (Behrens et al., 2000). 
Further, there is evidence that disruption of system xc
- via siRNA-mediated gene 
knockdown of xCT reduces glioma-derived glutamate release and reduces 
edema and neuronal injury (Savaskan et al., 2008). Additionally, in vitro studies 
implicate system xc
- activity as contributory to injury in a variety of disease states 
including cerebral ischemia (Fogal et al., 2007), Alzheimer’s disease (Barger and 
Basile, 2001; Qin et al., 2006), and multiple sclerosis (Domercq et al., 2007). 
Further, new in vivo studies note enhanced expression of system xc
- following 
experimental autoimmune encephalomyelitis (EAE) and speculate a role for 
system xc
- in demyelinating diseases as oligodendrocytes are also susceptible to 
glutamate excitotoxicity (Pampliega et al., 2011). 
.  
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1.3.5 Animal models deficient in system xc
- function 
 The subtle gray (sut) mouse arose via a natural mutation in the slc7a11 
gene which encodes for xCT, the light chain of system xc
-. Sut mice possess a 
large ≈500,000 base deletion that extends from intron 11 through exon 12 and 
into the intergenic region adjacent to the Pcdh18 gene (Chintala et al., 2005). As 
a result of this mutation, no xCT protein is produced and the mice have a subtle 
coat color phenotype secondary to the inability to create pheomelanin, a 
red/yellow pigment produced by the addition of cysteine to dopaquinone 
(Chintala et al., 2005). In particular, there is a reduction in the intensity of yellow 
pigment in agouti mice such that the coat color is gray, rather than brown with 
yellow highlights. In addition to alterations in coat color, these mutant animals 
also have prolonged bleeding times which are associated with abnormalities in 
platelet dense granules (Swank et al., 1996). Sut mice show evidence of 
neurodegeneration that is apparent by 13 weeks of age and is characterized by 
ventricular enlargement, striatal atrophy, and cortical thinning (Shih et al., 2006).  
 In 2005, Sato and colleagues generated an xCT knock-out (KO) mouse 
where the xCT gene was disrupted in all cell types via deletion of the translation 
initiation site and exon one (Sato et al., 2005). No abnormalities are noted in any 
of the organs examined in 8 week old mice including the brain, lung, liver, 
pancreas, and kidney. It raises the possibility that the neurodegeneration 
observed in sut/sut mice may arise due to the C3H/HeSnJ background, and not 
as a function of the loss of xCT gene function. xCT KO mice are viable, fertile, 
and healthy in appearance at 6 months. Interestingly, plasma cystine 
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concentrations in the xCT KO mice are double the concentrations seen in WT 
mice and there are no other differences in amino acid concentrations. The 
plasma concentration of GSH in KO mice is half the concentration detected in 
WT mice. However, there are no genotype-specific differences in GSH content in 
the liver or brain. Remarkably, adaptive compensatory responses must have 
been initiated to allow survival of xCT-null animals, because fibroblasts, 
melanocytes, and astrocytes derived from xCT mutants [both xCT KO mice and 
the spontaneous (sut/sut) mutant mice] fail to thrive in culture in the absence of a 
reducing agent such as β-mercaptoethanol (Appendix Figure A1), however, 
viability can be rescued with the addition of a reducing agent, such as β-
mercaptoethanol, in the tissue culture media (Chintala et al., 2005; Sato et al., 
2005; Shih et al., 2006).   
 Of note, while system xc
- is often studied in the context of its contributions 
to glutathione synthesis, closer examination of the transporter shows that its role 
as a regulator of extracellular glutamate levels is likely more important in vivo as 
loss of transporter function dramatic alters extracellular glutamate levels with no 
effects of tissue glutathione in the striatum or hippocampus (Massie et al., 2010b; 
De Bundel et al., 2011). Irrespective of which biological function is qualitatively 
more important, alterations in system xc
- activity and/or expression is associated 
with pathology thus it is important to understand how this transporter is regulated.  
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1.3.6 Regulators of system xc
- activity  
 The activity of system xc
- can be dynamically regulated in both positive 
and negative fashions. For instance, cellular deprivation of several amino acids 
(e.g. cystine, arginine, and tryptophan) or exposure to lipopolysaccharide (LPS), 
nitric oxide (NO), dibutyryl cAMP (dBcAMP), or electrophilic reagents such as 
diethyl maleate (DEM), increase xCT expression and/or system xc
- activity 
(Bannai and Kitamura, 1982; Bannai, 1984a; Kim et al., 1987; Miura et al., 1992; 
Sato et al., 1999; Bridges et al., 2001; Gochenauer and Robinson, 2001; Kim et 
al., 2001; Sato et al., 2001; Nosoya et al., 2002; Tomi et al., 2002; Sato et al., 
2004).  
 In the CNS, secreted amyloid precursor protein (sAPP), amyloid β-peptide 
(Aβ), chronic dBcAMP treatment, and TNF-α, but not IL-1β, can enhance system 
xc
- activity in microglial cells (Piani and Fontana, 1994; Barger and Basile, 2001; 
Qin et al., 2006; Seib et al., in press). Chronic treatment of astrocytes with 
dibutyryl cAMP (dBcAMP) enhances the activity of system xc
-  (Gochenauer and 
Robinson, 2001). Previous data from our laboratory indicate that the cytokine IL-
1β mediates an enhancement of system xc
- activity in mixed cortical cell cultures 
predominately containing neurons and astrocytes, although cell-type specificity 
was not determined in these studies (Fogal et al., 2007).  
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1.4.1 Interleukin-1β (IL-1β)  
 IL-1β is a member of the canonical interleukin-1 (IL-1) family that consists 
of two agonists IL-1α and IL-1β, an endogenous antagonist IL-1ra, and two 
receptors (IL-1RI and IL-1RII). Currently there are 11 known members of the IL-1 
family with additional members added to the family based on conservation of key 
amino acid sequences and similar three-dimensional structures [reviewed by 
(Dinarello, 2009; Sims and Smith, 2010)]. Further discussion will be limited to IL-
1β, the key cytokine discussed in this thesis. [For a more detailed review of other 
IL-1 family members see (Arend et al., 2008; O'Neill, 2008; Sims and Smith, 
2010)].  
 IL-1β is a pleiotropic cytokine with a variety of effects on numerous cell 
types. Although IL-1 was the first member of the group of peptides known as 
cytokines to be described, it was originally known by more colorful and 
functionally descriptive names that demonstrate the role of IL-1β in the 
inflammatory response, such as lymphocyte activating factor, B-cell 
differentiation factor, and endogenous pyrogen, among others (Dinarello, 1988). 
The last name listed, endogenous pyrogen, highlights the role of IL-1β as a 
mediator which influences cells within the immune system but also within the 
central nervous system (CNS). Specifically, IL-1β exerts its effects at the level of 
hypothalamus to alter body temperature via prostaglandin-mediated induction of 
fever [thoroughly reviewed in (Dinarello et al., 1999; Dinarello, 2004)].  
 The gene encoding IL-1β is located on chromosome 2 in humans and 
mice (Webb et al., 1986) and IL-1β is generated as a 31-kDa precursor protein 
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referred to as pro-IL-1β. Pro-IL-1β is inactive until cleaved by the intracellular 
cysteine protease, caspase-1/ interleukin-1-converting enzyme (ICE), which 
produces the mature, functionally active 17-kDa protein (Jobling et al., 1988; 
Howard et al., 1991). First, there is a priming step where IL-1β mRNA expression 
is enhanced without a concomitant increase in IL-1β protein (Schindler et al., 
1990), whereby various stimuli, such as the complement component C5a, 
hypoxia, or adherence of monocytes to glass or plastic surfaces induces large 
amounts of IL-1β mRNA without significant translation into protein (Haskill et al., 
1988; Ghezzi et al., 1991; Dinarello, 1998). Without a signal for translation, IL-1β 
is rapidly degraded with a half-life ranging from 2 – 4.5 hr (Schindler et al., 1990).  
Importantly, mature protein is only detected extracellularly suggesting that the 
processing of pro-IL-1β is temporally coordinated with IL-1β release (Hogquist et 
al., 1991). 
Importantly, the IL-1β precursor protein lacks an N-terminal hydrophobic 
signal denoting a cleavage site which would target it for processing by the 
endoplasmic reticulum (ER)/Golgi apparatus (Gray et al., 1986) and subsequent 
secretion from the cell. In the absence of such a signaling sequence, 
immunoelectron microscopy utilizing an antibody against human IL-1β 
demonstrates accumulation of the cytokine within the cytoplasm,  whereas none 
is detected in the ER/Golgi complex or in secretory vesicles of human monocytes 
(Singer et al., 1988). Thus, a classical pathway of exocytosis is not utilized for IL-
1β release.  
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Some consensus has been reached in that many agree that IL-1β 
secretion is dependent on ATP, its purinergic receptor P2X7 (Sanz and Di 
Virgilio, 2000; Solle et al., 2001; Bianco et al., 2005; Clark et al., 2010), and 
calcium (MacKenzie et al., 2001; Andrei et al., 2004). Importantly, macrophages 
lacking P2X7 receptors fail to secrete IL-1β following ATP exposure, but secretion 
induced by the K+ ionophore, nigericin, is not altered in the P2X7-deficient cells 
suggesting the involvement of an additional regulatory pathway(s) (Solle et al., 
2001). Additionally, IL-1β is not secreted from lumbar spinal cord slices derived 
from P2X7-null mice or in the presence of a P2X7 receptor antagonist (Clark et 
al., 2010). There are several schools of thought as to how IL-1β is released 
(Figure 1.4). The most parsimonious model of IL-1β release is that it is 
transported through uncharacterized transporters located in the plasma 
membrane (Brough and Rothwell, 2007).  MacKenzie and colleagues propose a 
model of release dependent on ATP-induced shedding of IL-1β-containing 
microvesicles within seconds of P2X7 receptor activation (MacKenzie et al., 
2001). This is similar to a proposed mechanism where exosome-containing 
multivesicular bodies release IL-1β containing exosomes into the extracellular 
space (Qu et al., 2007).  However, the mechanism by which IL-1β traverses the 
microvesicle membrane remains elusive. Qu and colleagues have speculated 
that microvesicle membranes, like the plasma membrane, also contain P2X7 
receptors which initiate microvesicle lysis in the presence of ATP (Bianco et al., 
2005) or that vesicle lysis is mediated by the action of phospholipases and 
proteases from the secretory lysosome (Qu et al., 2007). Notably, Qu and 
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colleagues were unable to detect IL-1β-containing microvesicles in the tissue 
culture supernatant. Andrei and colleagues present an alternate model where 
ATP-mediated depletion of intracellular K+ activates caspase-1 and 
phophatidylcholine-specific phospholipase C. Ultimately, the activation of 
phophatidylcholine-specific phospholipase C and cytosolic phospholipase A2 
(cPLA2) trigger lysosome exocytosis and the release of IL-1β, caspase-1, and 
other lysosomal enzymes (Andrei et al., 2004). Finally, a novel caspase-1 
dependent form of cell death called pyroptosis has been hypothesized to 
participate in release of IL-1β via plasma membrane pores under ischemic 
conditions and after infection (Bergsbaken et al., 2009). Of note, a study of 
diarylsulfonurea-mediated inhibition of cytokine release from human 
mononuclear cells (irrespective of the initiating stimuli) demonstrates that 
glutathione S-transferase may be involved in the release of IL-1β into the 
extracellular space (Laliberte et al., 2003).  Further study of the mechanism of 
release is warranted, as the full picture remains elusive.    
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Figure 1.4. Four models of non-classical IL-1β secretion. Pathway 1 
depicts the direct efflux of cytosolic IL-1β (and other inflammasome 
components) through uncharacterized transporters. Pathway 2 depicts 
microvesicular shedding / blebbing. Pathway 3 depicts Ca2+-dependent 
secretory lysosome exocytosis. Pathway 4 depicts the multivesicular 
bodies (MVB) / exosome model. Modified from (Qu et al., 2007). 
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1.4.2 IL-1 Signaling 
 Indisputably, IL-1β bind to two receptors, the type I or type II receptor 
referred to as IL-1RI or IL1-RII, respectively (Sims et al., 1988).  Both the IL-1RI 
and IL1-RII receptors are located on chromosome 2 in humans and chromosome 
1 in mice (Mantovani et al., 1998). These two receptors are similar in that both 
receptors possess three extracellular immunoglobin-like domains, however the 
cytosolic domains differ greatly.  IL-1RI possesses an ≈ 200 amino acid 
intracellular domain whereas the intracellular domain of IL-1RII consists of ≈ 29 
amino acids (Dinarello, 1991). As one might expect, receptor function varies as a 
consequence of the structural differences in the cytosolic domain. A long 
intracellular domain allows IL1-RI to signal (Sims et al., 1993), whereas the 
absence of a signaling domain in IL1-RII renders it a “decoy receptor”, thought to 
serve as a negative regulator (McMahan et al., 1991; Colotta et al., 1994).  
 IL-1RI signaling culminates in the activation of several signaling pathways 
including the nuclear factor-κB (NF-κB) pathway,  the p38 mitogen activated 
protein (MAP) kinase pathway, and the c-Jun N-terminal kinase (JNK) pathway 
(for a more detailed review see (O'Neill and Greene, 1998; Ichijo, 1999; Dunne 
and O'Neill, 2003)). Since IL-1β preferentially activates NF-κB in astrocytes 
(Srinivasan et al., 2004), the classical activation of NF-κB will be the only 
pathway discussed and is as follows:  IL-1β binds to IL-1RI which induces a 
conformational change in IL-1RI (Vigers et al., 1997) facilitating the interaction 
with its accessory protein, IL-1RAcP (Greenfeder et al., 1995). The interaction 
between IL-1RI and the accessory protein recruits the adaptor protein myeloid 
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differentiation primary response gene 88 (MyD88) (Lord et al., 1990) to the Toll-
IL-1 receptor (TIR) domain of the IL-1RI/IL1RAcP complex, and deletion of this 
domain causes a loss of IL-1 signaling/ functional activity (Heguy et al., 1991; 
Brikos et al., 2007). The N-terminal death domain of MyD88 then interacts with 
IL-1R-associated kinases (IRAKs) which become phosphorylated and activate 
tumor necrosis factor receptor associated factor 6 (TRAF6). TRAF6 then 
activates the inhibitor of NF-κB kinase (IKK), which phosphorylates the inhibitor 
of NF-κB (IκB) which is ubiquitinated and degraded by the proteasome allowing 
p65 and p50 (NF-κB) to enter the nucleus. Signaling is terminated via 
internalization of the signaling receptor complex and the activation of negative 
regulators such as Toll-interacting protein (Tollip) which interacts with IRAK1 and 
is believed to facilitate termination of IL-1RI signaling  [For a more detailed 
review see (Carroll et al., 2005; Brissoni et al., 2006; Weber et al., 2010)].  
 The IL-1 system is tightly regulated and inhibition of IL-1β-mediated 
signaling can be accomplished via IL-1ra occupation of the IL-1β binding site on 
IL-1RI. Importantly, the endogenous antagonist IL-1ra cannot induce the 
conformational change in IL-1RI required to promote an interaction with the 
accessory protein IL-1RAcP (Greenfeder et al., 1995). Additionally, the decoy 
receptor IL1-RII competes with IL1-RI for IL-1β binding (Colotta et al., 1993; Re 
et al., 1994). IL-1RII can interact with the accessory protein, IL-1AcP which would 
interfere with the normal IL-1RI / IL-1AcP complex formation (Lang et al., 1998; 
Wang et al., 2010). Finally, both IL1-RI and IL-1RII can be shed from the 
membrane to sequester ligands (Penton-Rol et al., 1999; Orlando et al., 2000) 
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 Of note, there are three studies that propose the existence of an additional 
IL-1 responsive signaling receptor in the CNS that remains to be conclusively 
identified (Parker et al., 2002; Touzani et al., 2002; Andre et al., 2006). Touzani 
and colleagues demonstrate that IL-1β enhances injury in IL-1RI-null mice 
following middle cerebral artery occlusion (MCAO) and that injury is not 
attenuated by the concomitant administration of IL-1β and its endogenous 
antagonist IL-1ra (Touzani et al., 2002). Furthermore, Andre and colleagues 
found that IL-1β increases the expression of approximately 400 genes in mixed 
glial cultures derived from IL-1RI-null mice compared to vehicle treated mixed 
glial cultures (that have alterations in the expression of almost 1300 genes in 
response to IL-1β) (Andre et al., 2006). Importantly, contaminants such as 
endotoxin in the recombinant IL-1β preparation could produce identical results in 
an IL-1RI-independent manner, however this possibility was not discussed. 
 
1.4.3 IL-1β and CNS physiology 
 IL-1β has important functions within a normal, but immunologically 
challenged organism, and its role in the regulation of temperature and sickness 
behavior, and in the initiation of the inflammatory response has been extensively 
studied and will not be discussed here [for a detailed review see (Dinarello, 2004; 
Dantzer and Kelley, 2007)]. Since cytokines function as intercellular messages, 
additional functions of IL-1β outside the traditional realm of inflammation have 
been reported. IL-1β induces changes that may protect neurons and promote 
growth and/or survival via stimulated production of neurotrophic factors, 
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chemokines and cytokines, and their receptors including GRO-α, tumor necrosis 
factor (TNF-α), IL-6, and the growth factors nerve growth factor (NGF), ciliary 
neurotrophic factor (CNTF), vascular endothelial growth factor (VEGF), fibroblast 
growth factor 2 (FGF-2), hepatocyte growth factor (HGF), and granulocyte 
colony-stimulating factor (G-CSF) (Gadient et al., 1990; Albrecht et al., 2002; 
Meeuwsen et al., 2003; John et al., 2005).  
 Long-term potentiation is defined as a “form of synaptic plasticity which is 
characterized by a persistent increase in synaptic efficacy following tetanic 
stimulation of an afferent pathway. On the basis of its properties, LTP has been 
proposed as a biological substrate for learning and memory” (Lynch, 1998). 
Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) 
demonstrates that IL-1β expression is enhanced one hour after LTP induction in 
rat hippocampal slices, and similar findings are observed in vivo in the ipsalateral 
hippocampus of rats that had robust potentiation lasting at least 8 hr (Schneider 
et al., 1998). IL-1RI knockout mice have deficits in hippocampal dependent 
spatial learning suggesting that endogenous IL-1β may promote LTP and 
learning (Avital et al., 2003) This is particularly interesting in light of the finding 
that TNFα, a cytokine induced by IL-1β,  promotes astrocytic glutamate release 
by regulating the number of readily releasable glutamatergic vesicles adjacent to 
the plasma membrane (Santello et al., 2011) Others have found that IL-1ra has 
no effect on the induction of LTP, whereas administration of IL-1ra after LTP 
induction impairs the maintenance phase (Schneider et al., 1998; Coogan et al., 
1999). Additionally, lipopolysaccharide (LPS), a potent inducer of IL-1β 
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expression, can produce learning and memory deficits (Tanaka et al., 2006). 
While LPS-treatment was associated with an increase in IL-1β as assessed via 
immunohistochemistry, it remains to be ascertained whether this phenomenon is 
IL-1β-dependent.  which have been hypothesized to occur via inhibition of Ca2+ 
currents in hippocampal neurons (Plata-Salaman and Ffrench-Mullen, 1992, 
1994), or via the enhancement of GABA currents (Miller et al., 1991). In sum, 
endogenously produced IL-1β appears necessary for the expression and 
maintenance of LTP in hippocampal slices (Schneider et al., 1998; Avital et al., 
2003). In contrast, higher concentrations of IL-1β applied exogenously or induced 
via LPS, which mimic pathological IL-1β expression, inhibit LTP (Bellinger et al., 
1993; Cunningham et al., 1996; Murray and Lynch, 1998; Coogan et al., 1999; 
Avital et al., 2003; Ross et al., 2003). 
 
1.4.4  IL-1β and CNS disease 
 There is a place for IL-1β in normal physiology, however, dramatic 
deviations from low levels of basal expression are thought to underlie the ability 
of IL-1β to facilitate injury.  IL-1β is dramatically upregulated in a variety of acute 
and chronic neurological diseases and disorders [for a thorough review see 
(Allan et al., 2005; Gosselin and Rivest, 2007; Fogal and Hewett, 2008)]. The 
strongest evidence for the participation of IL-1β in neuronal injury in a disease 
state stems from experimental ischemia models. Like numerous other 
neurological diseases and disorders, IL-1β mRNA and protein are increased after 
transient and permanent middle cerebral artery occlusion (MCAO) in rodents 
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(Minami et al., 1992; Liu et al., 1993; Buttini et al., 1994; Sairanen et al., 1997; 
Davies et al., 1999; Pearson et al., 1999). Yamasaki demonstrated that 
intraventricular injection of IL-1β enhances neuronal injury in rats following 
MCAO (Yamasaki et al., 1995). In contrast, intracerebroventricular administration 
and genetic overexpression of IL-1ra, the endogenous antagonist, before MCAO, 
is protective and reduces infarct size (Relton and Rothwell, 1992; Betz et al., 
1995; Loddick and Rothwell, 1996; Yang et al., 1997; Mulcahy et al., 2003). 
Finally, animals lacking both IL-1α and IL-1β (but not either ligand alone) (Boutin 
et al., 2001; Ohtaki et al., 2003), the signaling receptor IL-1RI (Basu et al., 2005; 
Fogal et al., 2007), or ICE/capase-1, the enzyme required for IL-1β processing 
(Hara et al., 1997a; Hara et al., 1997b; Schielke et al., 1998; Liu et al., 1999), are 
protected against hypoxic/ischemic injury. Additionally, administration of an IL-1β 
neutralizing antibody improves outcomes following ischemia in rats (Yamasaki et 
al., 1995).  
 From a clinical research perspective, IL-1β levels in humans increase 
following cerebral ischemia in a manner consistent with findings from 
experimental studies. The concentration of IL-1β measured in the CSF of stroke 
patients is increased 2 days post stroke, which then declines over time to control 
values, with no observable alterations in plasma IL-1β concentration (Griffin et 
al., 1994; Tarkowski et al., 1995). Impressively, clinical trials have demonstrated 
that intravenous administration of recombinant human IL-1ra can penetrate the 
blood brain barrier (BBB) following stroke and improve clinical outcomes three 
months post-stroke (Emsley et al., 2005).  
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 Our laboratory is interested in understanding the mechanism by which IL-
1β contributes to neuronal injury following cerebral ischemia. As such, we have 
developed an in vitro model of the metabolically active, yet functionally impaired 
tissue surrounding the ischemic core, which is referred to as the ischemic 
penumbra. Using in vitro cortical preparations we have devised a model that 
recapitulates the injury that is observed in the ischemic prenumbra. Notably, 
treatment of cultures with exogenous IL-1β, to mimic release from microglia and 
deprivation of oxygen leads to a potentiation of neuronal cell death (Fogal et al., 
2005a; Fogal et al., 2007). Injury can be blocked with the endogenous 
antagonist, IL-1ra or a IL-1β blocking antibody. Injury is dependent on glutamate-
mediated excitotoxicity, astrocytes, and extracellular cystine. As such, we 
identified system xc
- as a target of IL-1β whereby inhibition of this transporter 
attenuates injury (Fogal et al., 2007).   
 While the deleterious role of IL-1β in ischemia is clear, similar to the 
dichotomy observed with system xc
-, enhanced levels of IL-1β need not 
contribute to injury in all disorders. In fact, elevations in IL-1β expression may 
function to promote tissue repair.  Mice lacking IL-1β show reduced remyelination 
in a cuprizone model of demyelination, with the inability to properly remyelinate 
occurring secondary to a reduction in insulin-like growth factor-1 (IGF-1) (Mason 
et al., 2001). Further support of the beneficial role of IL-1β comes from the finding 
that chronic overexpression of IL-1β reduces pathology in a mouse model of AD 
(Shaftel et al., 2007). Interestingly, mice deficient in IL-1RI had less neuronal 
sprouting and functional recovery after 6-hydroxydopamine-mediated injury to the 
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substantia nigra pars compacta, compared to their wild-type counterparts (Parish 
et al., 2002). Importantly, in vitro findings further support the assertion that IL-1β 
can promote positive outcomes by reducing excitotoxic neuronal cell death 
induced by the ionotropic glutamate receptor agonists NMDA, AMPA, and 
kainate (Strijbos and Rothwell, 1995; Ohtsuki et al., 1996; Wang et al., 2000; 
Pringle et al., 2001; Bernardino et al., 2005). 
 
1.5 Significance 
 A variety of neurological diseases and disorders are associated with 
excitotoxicity, oxidative stress, and enhanced expression of IL-1β (Fogal and 
Hewett, 2008) and system xc
- unites all these components. Although system xc
- is 
best known for its role in the synthesis of the antioxidant molecule GSH 
(Watanabe and Bannai, 1987; Bannai et al., 1989; Miura et al., 1992; Sato et al., 
1995a; Bridges et al., 2001; Dun et al., 2006; Lewerenz et al., 2009a), enhanced 
transporter activity and subsequent efflux of glutamate in the CNS has been 
demonstrated to contribute to neuronal and oligodendrocyte injury both in vitro 
and in vivo  (Barger and Basile, 2001; Chung et al., 2005; Qin et al., 2006; 
Domercq et al., 2007; Fogal et al., 2007; Savaskan et al., 2008; Sontheimer, 
2008). Hence, the activity of system xc
- must be tightly controlled. However, it is 
plausible that enhanced activity of the transporter may arise as a protective 
mechanism to limit oxidative stress – and excitotoxicity is the unfortunate 
consequence of a protective response gone awry. Understanding the regulation 
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of system xc
- will be required to devise therapies to increase system xc
- and 
intracellular GSH to reduce oxidative injury, and when appropriate, to employ 
strategies to reduce its activity to decrease the probability of excitotoxic neuronal 
injury.   
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1.6  Specific Aims 
 Because enhanced activity of system xc
- can facilitate excitotoxic injury or 
promote the synthesis of the antioxidant glutathione depending on the context, it 
is important to understand how the transporter is regulated. Our laboratory has 
demonstrated that the cytokine interleukin-1β (IL-1β) ─ which is upregulated in 
numerous neurological diseases/disorders ─ enhances the activity of the amino 
acid transporter system xc
-, mediating an increase in extracellular glutamate and 
in cellular cyst(e)ine, a constituent of the tripeptide antioxidant molecule 
glutathione (GSH). Thus, the objective of this dissertation was to elucidate the 
cellular, molecular, and biochemical mechanisms by which IL-1β regulates 
system xc
-. Further, the functional consequences of system xc
- activity under 
pathophysiological and physiological conditions were evaluated.  
 
1.6.1 Specific Aim #1: To determine the cell type(s) responsible for enhanced 
system xc
- activity in response to IL-1β. 
 The Hewett laboratory previously demonstrated that interleukin-1β (IL-1β) 
increases system xc
- (cystine/glutamate antiporter) activity in mixed cortical cell 
cultures containing neurons and astrocytes in a manner dependent on astrocyte 
IL-1RI activation (Fogal et al., 2007), yet the specific cell type(s) responding to IL-
1β via an enhancement in system xc
- activity was not ascertained. Thus the goal 
of this specific aim was to identify which specific cell type(s) responds to IL-1β by 
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enhancing the expression and functional activity of system xc
- by exposing 
purified populations of neurons, astrocytes, and microglia to IL-1β (Chapter 2). 
 
1.6.2 Specific Aim #2:  To elucidate the consequences of system xc
- activity 
under pathological (Chapter 3) and physiological (Chapter 4) conditions. 
 The Hewett lab previously demonstrated that IL-1β potentiates hypoxic 
and hypoglycemic neuronal injury (Fogal et al., 2005a). The IL-1β-mediated 
enhancement in system xc
- activity in mixed cortical cell cultures resulted in a 
potentiation of hypoxic neuronal injury when glutamate clearance was impaired 
(Fogal et al., 2007). Despite longstanding evidence that hypoglycemic neuronal 
injury is also mediated by glutamate excitotoxicity, the role of system xc
- in this 
paradigm had not been assessed. Specifically, mixed cortical cell cultures were 
deprived of glucose for up to 8 hr and pharmacological and genetic techniques 
were employed to assess the involvement of system xc
- in hypoglycemia-induced 
neuronal injury. 
 Additionally, the enhancement in system xc
- activity by IL-1β under 
physiological (normoxic and normoglycemic) conditions was assessed by treating 
astrocytes with IL-1β and measuring intracellular and extracellular glutathione 
levels. Other cellular proteins participating in GSH biosynthesis, export, and 
metabolism in response to IL-1β were also evaluated to see if IL-1β alters their 
expression. Finally, we assessed if the IL-1β-mediated enhancement of system 
xc
- activity could confer protection against an oxidative stressor.  
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CHAPTER 2 
 
Regulation of system xc
- activity and expression in astrocytes by 
interleukin-1β: implications for hypoxic neuronal injury 
 
 
 
 
 
 
 
This chapter is a near duplicate of the previously published work: 
 
Jackman N. A., Uliasz T. F., Hewett J. A. and Hewett S. J. (2010) Regulation of 
system xc
-  activity and expression in astrocytes by interleukin-1β: implications for 
hypoxic neuronal injury. Glia 58, 1806-1815. 
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2.1  Summary  
We recently demonstrated that interleukin-1β (IL-1β) increases system xc
- 
(cystine/glutamate antiporter) activity in mixed cortical cell cultures, resulting in 
an increase in hypoxic neuronal injury when glutamate clearance is impaired. 
Herein, we demonstrate that neurons, astrocytes and microglia all express 
system xc
- subunits (xCT, 4F2hc, RBAT) and are capable of cystine import. 
However, IL-1β stimulation increases mRNA for xCT─  the light chain that 
confers substrate specificity─  in astrocytes only; an effect blocked by the 
transcriptional inhibitor actinomycin D. Additionally, only astrocytes show an 
increase in cystine uptake following IL-1β exposure; an effect associated with a 
change in xCT protein. The increase in cystine uptake that follows IL-1β is 
lacking in astrocytes derived from mice harboring a mutation in Slc7a11 (sut 
gene), which encodes for xCT, and in wild-type astrocytes treated with the 
protein synthesis inhibitor cycloheximide. IL-1β does not regulate the light chain 
of the amino acid transporter, LAT2, or the expression and function of astrocytic 
excitatory amino acid transporters (EAATs), demonstrating some target 
selectivity. Finally, the enhanced neuronal vulnerability to hypoxia that followed 
IL-1β treatment in our mixed culture system was not observed in chimeric 
cultures consisting of wild-type neurons plated on top of sut astrocytes. Nor was 
it observed in wild-type cultures treated with a system xc
- inhibitor or an NMDA 
receptor antagonist. Overall, our data demonstrate that IL-1β selectively 
regulates system xc
- activity in astrocytes and that this change is specifically 
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responsible for the deleterious, excitotoxic effects of IL-1β found under hypoxic 
conditions.  
 
2.2  Introduction 
System xc
- is a heteromeric amino acid transporter consisting of two 
subunits: xCT ─ the light chain that confers substrate specificity ─ and a heavy 
chain (4F2hc or RBAT) thought to target the transporter to the plasma membrane 
(Sato et al., 1999; Bassi et al., 2001). The import of cystine via system xc
- is 
directly coupled to glutamate export, occurring in a Na+-independent, Cl--
dependent manner with 1:1 stoichiometry (Bannai, 1986; Reichelt et al., 1997).  
Although, system xc
- is best known for its role in the synthesis of the antioxidant 
molecule glutathione (GSH) (Watanabe and Bannai, 1987; Bannai et al., 1989; 
Miura et al., 1992; Sato et al., 1995a; Bridges et al., 2001; Dun et al., 2006; 
Lewerenz et al., 2009a), enhanced transporter activity has been reported to 
contribute to neuronal and oligodendrocyte injury both in vitro and in vivo (Barger 
and Basile, 2001; Chung et al., 2005; Qin et al., 2006; Domercq et al., 2007; 
Fogal et al., 2007; Savaskan et al., 2008; Sontheimer, 2008). 
System xc
- subunits and activity have been demonstrated to be 
dynamically regulated. For instance, xCT expression and/or the activity of system 
xc
- is enhanced following deprivation of certain cellular amino acids or exposure 
to lipopolysaccharide (LPS), nitric oxide (NO), dibutyryl cAMP (dBcAMP), or to 
electrophilic reagents such as diethyl maleate (DEM) (Miura et al., 1992; Bridges 
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et al., 2001; Gochenauer and Robinson, 2001; Sato et al., 2004). Recently, we 
demonstrated that the cytokine, IL-1β, enhances system xc
- activity (i.e. 
increases Vmax) in a mixed cortical cell culture system (Fogal et al., 2007).  While 
increased activity is not toxic alone, presumably because system XAG
-  (glutamate 
transport) is sufficient to prevent the toxic accumulation of extracellular glutamate 
− under conditions where glutamate uptake is compromised (i.e., hypoxia), this 
IL-1β-mediated enhancement of system xc
- activity contributed to an 
enhancement of extracellular glutamate levels, which resulted in excitotoxic 
neuronal cell death (Fogal et al., 2005a; Fogal et al., 2007). Although we 
previously determined that this enhancement in hypoxic neuronal injury in mixed 
cortical cell culture was dependent on astrocyte IL-1RI signaling, the cell type 
that demonstrated an increase in transporter activity was not ascertained (Fogal 
et al., 2007). As our cultures contain predominantly neurons and astrocytes with 
some contaminating microglia, the cellular and molecular target of system xc
- 
enhancement by IL-1β was examined herein using purified populations of 
primary astrocyte, neuron, and microglial cultures. Results indicate that IL-1β 
regulates the expression and activity of system xc
- in astrocytes exclusively and 
that glutamate released via astrocytic system xc
- directly underlies the neurotoxic 
propensity of IL-1β under hypoxic conditions.  
Part of the work has been published in abstract form (Jackman et al., 2009; 
Jackman and Hewett, 2009).  
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2.3  Materials and Methods 
2.3.1 Cell culture 
 Cell culture media and experimental buffer compositions were as follows: 
Media stock (MS): L-glutamine-free modified Eagle’s medium (Earl’s salt; 
MediaTech) supplemented with L-glutamine, glucose, and sodium bicarbonate to 
a final concentration of 2.0, 25.7, and 28.2 mM, respectively; Glial plating media: 
MS containing 10% fetal bovine serum (FBS; Hyclone) and 10% calf serum (CS; 
Hyclone), 10 ng/ml epidermal growth factor (Invitrogen), 50 IU penicillin, and 50 
µg/ml streptomycin (Gibco/BRL); Neuronal plating media: Neurobasal media 
containing 1x B27 (Invitrogen), 2 mM L-glutamine, 50 IU penicillin and 50 µg/ml 
streptomycin; Mixed culture plating media: MS containing 5% CS, 5% bovine 
growth serum (BGS, Hyclone), 50 IU penicillin, and 50 µg/ml streptomycin. 
Microglia growth media: DMEM (high glucose; Gibco) containing 5% FBS, 2mM 
L-glutamine, 50 IU penicillin, 50 µg/ml streptomycin and 50% LADMAC (ATCC) -
conditioned media to supply colony stimulating factor-1 (Sklar et al., 1985). To 
produce LADMAC conditioned media, the LADMAC cell line (CRL-2420, ATCC,) 
was grown to confluence in DMEM containing 5% FBS, 2 mM L-glutamine, 50 IU 
penicillin and 50 µg/ml streptomycin in 75 cm2 flasks for ~14 days followed by 
harvesting, centrifugation (720 x g; 3 min) and filtering of the culture supernatant, 
which is then stored at -80°C. Maintenance media: MS containing 10% CS and 
50 IU penicillin/ 50 µg/ml streptomycin; HBSS (mM): 120 NaCl, 5.4 KCl, 0.8 
MgCl2, 1.8 CaCl2, 15 glucose, 20 HEPES, 10 NaOH, and 0.01 glycine (pH 7.4). 
Balanced Salt Solution [BSS (mM)]: 116 NaCl, 5.4 KCl, 0.8 MgCl2, 1 NaH2PO4, 
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26.2 NaHCO3, 1.8 CaCl2, 0.01 glycine, 2 L-glutamine, 1x MEM amino acids 
(Invitrogen), and 5 or 20 mM glucose (BSS5 or BSS20, respectively).  
 Primary astrocyte cultures were derived from pooled cortices of day 1-3 
postnatal CD1 mouse pups (Charles River Laboratories) or from mouse pups 
derived from sut heterozygous breeding pairs (JAX; Stock # 001310) or sut 
control mice (C3H/HeSnJ; JAX; Stock # 000661) essentially as described 
(Trackey et al., 2001). Additionally, wild-type (WT) and sut (xCT-deficient) 
astrocytes were cultured from cortices of single pups derived from sut/+ breeding 
pairs (JAX; Stock # 001310). β-mercaptoethanol (β-ME; 55 µM) was added to the 
glial plating medium of sut cultures to support growth and to WT cultures for 
control purposes (Shih et al., 2006). The rest of the brain was used for 
genotyping: WT primers (230 bp product) 5’- GAA GTG CTC CGT GAA GAA GG 
3’ (forward), 5’- ATC TCA ATC CTG GGC AGA TG-3’ (reverse); sut primers 
(≈2280 bp product) 5’-CCA CTG TTG TAG GTC AGC TTA GG-3’ (forward), 5’-
CAG GAC CTG TGA ATA TGA TAG GG 3’ (reverse). Il1r1 wild-type and null 
mutant astrocytes were cultured from cerebral cortices of single pups derived 
from Il1r1 heterozygous breeding pairs (JAX; stock # 003245). Following 
dissection of the cerebral cortices, the rest of the brain was used for genotyping 
as described [http://jaxmice.jax.org/strain/003245.html]. Cells from cerebral 
cortices were dissociated, plated (Falcon Primaria; BD Biosciences) and once 
confluent,  then treated with 8 µM β-D-arabinofuranoside (AraC; Sigma) once for 
4-7 days to reduce the number of microglia. Purified astrocyte cultures were 
generated by removing residual microglia by treatment with 75 mM L-leucine 
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methyl ester for 60-90 min, one day prior to experimentation (Hamby et al., 
2006a). Cultures were ≤ 35 days in vitro at the time of experimentation. Microglia 
cultures were prepared by plating dissociated cortical cells from CD1 mouse 
pups (1-3 days) in T25 tissue culture flasks (2 hemisphere/5 ml/flask) in glial 
plating medium. Fourteen to 21 days later, the culture medium was 
supplemented with HEPES buffer to a final concentration of 25 mM and flasks 
shaken overnight at 150 rpm (37°C). The supernatant containing dislodged 
microglia was collected, spun (3 min; 720 x g) and the resulting pellet 
resuspended in microglial growth media and plated in 15 mm 24-well plates 
(Corning) (Hamby et al., 2006b). Primary neuronal cultures were derived from 
dissociated cortical cells of embryonic day 15 CD1 mouse fetuses using a 
modification of the protocol of Brewer and colleagues (Brewer et al., 1993). Two 
days after plating in neuronal plating medium, cultures were treated once with 1 
µM AraC for two days, then media was partially replenished (½ volume 
exchange) twice weekly. Experiments were performed on pure neuronal cultures 
after 7-10 days in vitro. Mixed cortical cell cultures containing predominantly 
neurons and astrocytes with a small amount of contaminating microglia were 
prepared by isolating cortices obtained from embryonic day 15 mouse fetuses 
and plating them on a confluent layer of astrocytes in mixed culture plating media 
(Trackey et al., 2001). After 7 days in vitro, mixed cultures were treated with 8 µM 
AraC for 2 days then switched into maintenance media. The media was changed 
after 5 and 9 days in vitro, and one day prior to experimentation, cells were 
placed into MS. Experiments were performed on mixed cortical cultures after 13-
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14 days in vitro. All cultures were maintained at 37°C in a humidified 6% CO2-
containing atmosphere. 
 
2.3.2 IL-1β Treatment 
Cells were treated with 3 ng/ml recombinant murine IL-1β (R&D Systems) 
for various times in an incubation buffer of MS (neurons and astrocytes) or 
microglial growth media (microglia) both supplemented with 0.1% fatty-acid free 
BSA (Sigma). Cells were then returned to a humidified 37˚C normoxic (21% O2) 
incubator containing 6% CO2. 
 
2.3.3 Radiolabeled L-cystine and D-aspartate uptake 
System xc
- specific 14C-L-cystine (PerkinElmer) and system XAG
--mediated 
3H-D-aspartate (PerkinElmer) uptake was performed as previously described 
(Fogal et al., 2007). Cultures were washed into HBSS (3 x 750 µL) and allowed 
to equilibrate for 10 min (25˚C). For cystine uptake, cells were incubated in HBSS 
containing 3 µM 14C-L-cystine (1 µCi/ml), 27 µM unlabeled cystine, 1mM D-
aspartate and 0.5 mM acivicin (Biomol). D-aspartate and acivicin were included 
in the uptake buffer to block system XAG
- and γ-glutamyltranspeptidase, 
respectively. Uptake was terminated by washing in ice-cold PBS (3 x 750 µL). 
For D-aspartate uptake, cells were incubated in HBSS containing 0.1 µCi/ml 3H-
D-aspartate and varying concentrations of unlabeled D-aspartate (25˚C) for 5 min 
and uptake terminated by washing cells with an ice-cold Na+-free choline stop 
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buffer containing in mM: 116 choline chloride, 0.8 MgSO4, 1 KH2PO4, 10 HEPES, 
5 KOH, 10 glucose, 0.9 CaCl2, and 5 non-radioactive D-aspartate. Varying 
concentrations of unlabeled D-aspartate were used to span the Km of the 
different astrocytic glutamate transporters (Danbolt, 2001), ensuring that the 
concentration of non-radioactive D-aspartate used was not rate-limiting. Cells 
were lysed with warm 0.5% SDS and accumulated radioactivity estimated using 
a liquid scintillation counter. Uptake was normalized to total protein as 
determined by the BCA Assay (Pierce).  
 
2.3.4 Reverse transcriptase-PCR analysis 
Three or four wells of cells grown in 24 well tissue culture plates were 
combined, the RNA was extracted (TRIzol, Invitrogen) and then suspended in 20 
µL RNase-free water. First-strand cDNA was synthesized from 0.5-1µg RNA 
using M-MLV reverse transcriptase (400 U, Invitrogen) and oligo (d)T primers 
(Promega) as previously described (Hewett et al., 1999). Reactions were 
performed in 20 µL volumes at 40-42°C for 1 hr. Each RNA sample was 
incubated similarly in the absence of reverse transcriptase to test for genomic 
DNA contamination (none detected). PCR amplimer pairs for analysis of specific 
cDNAs are as follows:  
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PCR was performed on 1 µL of cDNA using Taq DNA polymerase (1 U, 
Invitrogen) in a total volume of 25 µL. Each cycle consisted of a denaturation 
step (94 °C; 30 sec), an annealing step (45 sec), and a primer extension step (72 
°C, 1 min). PCR products were separated by electrophoresis in 2% agarose with 
1 kb size markers (Invitrogen) and visualized by ethidium bromide (BioRad) using 
a UV transilluminator. 
 
2.3.5 Quantitative Real-time PCR (qPCR) 
RNA was isolated and first-strand cDNA synthesized as described above. 
qPCR was performed using mouse-specific primer pairs [Taqman Gene 
Expression Assays, Applied Biosystems: xCT (Mm00442530_m1); 4F2hc 
(Mm00500521_m1); RBAT (Mm00486218_m1); EAAT-1 (Mm00600697_m1); 
EAAT-2 (Mm00441457_m1); LAT2 (Mm00444250_m1)] per manufacturer’s 
instructions. Reactions were run in the Applied Biosystems Fast Real-Time PCR 
System and relative quantification performed using the comparative cycle 
Amplimers         Annealing Temp. 
  
xCT  5′-AAACTTGCTAAGCTCTGTGTTGG-3′ (sense)   63 ˚C  
  5′-CACATCACATGTTTGTACACTCG-3′ (antisense)   
4F2hc  5'-GCCCAATTCACAAGAACCAG-3'   (sense)   60 ˚C  
  5'-CCTAGTGACTAGGGATTCAG-3' (antisense) 
RBAT 5’-TTGCCATTTATCCAGGAAGC-3’ (sense)   60 ˚C  
  5’-AGTTTGTGGGTAGCCAGGTG-3’ (antisense) 
β-actin  5’-GTGGGCCGCTCTAGGCACCAA-3’ (sense)   63 ˚C  
  5’-CTCTTTGATGTCACGCACGATTTC-3’ (antisense) 
Table 2.1- PCR amplimer pairs for RT-PCR. 
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threshold method (∆∆CT), where CT values of the transcript of interest were 
normalized to β-actin CT values from the same sample, then compared to a 
calibrator CT value (untreated cells) to determine the relative fold increase in 
mRNA. β-actin CT values were unaffected by IL-1β treatment. Statistics were 
performed on the logarithmic retransformation (i.e. geometric means) of 2-∆∆CT 
values. Preliminary experiments were performed to establish that the 
amplification efficiency for each of the primer pairs was >94%.  
 
2.3.6 Immunoblotting 
Protein expression was determined by Western Blot analysis. Astrocytes 
in 24-well plates were washed twice with ice-cold PBS then incubated in 50 µL 
lysis buffer [50 mM Tris, pH 8.0, 1.0% Nonidet-P40 (NP40), 150 mM NaCl, and 
protease inhibitor cocktail (Roche)] for 30 minutes on ice. Cells were harvested 
by scraping, lysates from eight wells pooled, cellular debris removed by 
centrifugation (10,000 x g; 15 min; 4°C), and the resulting supernatants stored at 
-20°C. After thawing, proteins were concentrated via ethanol precipitation. The 
pelleted protein was resuspended in 1x urea buffer (50 mM Tris, pH 6.8, 2.5% 
glycerol, 5% SDS, 4 M Urea, 10 mM DTT, 0.02% bromophenol blue). One 
hundred µg protein (BCA assay; Pierce) was separated by 10% SDS-PAGE 
under reducing conditions and electrophoretically transferred to a nitrocellulose 
membrane (0.2 µm; Bio-Rad). Proteins of interest were detected sequentially 
using species-specific Western Breeze Immunodetection kits (Invitrogen) per 
manufacturer’s instructions. Primary antibodies and incubation times were as 
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follows: xCT (2 µg/ml; rabbit polyclonal; Novus Biologicals; 2 h at 37° C),  β-actin 
(0.3 µg/ml; mouse monoclonal; Sigma; 2 h at 37° C) or CD98 (4F2hc; 0.4 µg/ml; 
goat polyclonal; Santa Cruz; overnight at 4° C). Results were recorded on X-ray 
film (FujiFilm). Digitized images were analyzed by computer-assisted 
densitometry (Gel-Pro Analyzer) and xCT and 4F2hc protein normalized to their 
respective β-actin levels.  
 
2.3.7 Hypoxia 
Mixed cortical cell cultures were placed into an anaerobic chamber 
(Thermolabs) containing a gas mixture of 5% CO2, 10% H2, and 85% N2 (<0.2% 
O2). Culture medium was replaced by thorough exchange with a deoxygenated 
balanced salt solution (BSS5). Cells were placed in a 37°C incubator within the 
chamber for 4-5 hr and then returned to a 37°C, 6% CO2-containing normoxic 
(21% O2) incubator. Parallel cultures within the same plate were placed into 
deoxygenated BSS20 to assess for neuronal injury unrelated to the experimental 
paradigm. Importantly, in the presence of 20 mM glucose, cells can resist 
neuronal injury for nearly 12 hr of oxygen deprivation (Fogal et al., 2005b). 
Neuronal cell death was assessed 20-24 hr later. 
 
2.3.8 Measurement of neuronal cell death 
Neuronal cell death was quantitatively determined by measurement of 
lactate dehydrogenase (LDH) released into the culture supernatant as described 
previously (Uliasz and Hewett, 2000). Data are expressed as a percentage of 
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total neuronal LDH activity (defined as 100%), determined by assaying the 
supernatant of parallel cultures exposed to 200 µM NMDA for 20-24 hr. Since 
primary cortical astrocytes do not contain NMDA receptors (Backus et al., 1989; 
Chan et al., 1990; Janssens and Lesage, 2001) nor have been shown by us to 
be injured by oxygen deprivation times up to 12 hr (Fogal et al., 2005a), changes 
in LDH activity can be used as a specific marker of neuronal injury in this system. 
 
2.3.9 Statistical Analysis 
All statistical analyses were performed using GraphPad Prism (Version 
4.03, GraphPad Software, Inc.) as described in each figure legend. Percentage 
data were first transformed via arcsin square root. For qPCR, statistics were 
performed on the logarithmic retransformation (i.e. geometric means) of 2-
∆∆CT
 
values. In all experiments, data are expressed as the mean ± SEM. Significance 
was assessed at p < 0.05.  
 
2.4 Results 
We previously demonstrated in a mixed cortical cell culture system that IL-
1β potentiated neuronal injury induced by hypoxia (Fogal et al., 2005a) via a 
process dependent on increased system xc
- activity and impaired glutamate 
clearance (Fogal et al., 2007). Although, it was determined that this increase 
required astrocyte IL-1 receptor I (IL-1RI) signaling, the specific cell type(s) 
responding was not ascertained (Fogal et al., 2007). Hence, initial experiments 
55 
 
utilized purified cell culture preparations of neurons, astrocytes, and microglia to 
identify which cell types express xCT ─ the system xc
- light chain ─and 4F2hc 
and RBAT ─the system xc
- heavy chains ─ demonstrate functional cystine 
uptake, and respond to IL-1β by increasing system xc
- activity.  
Under basal conditions, xCT, 4F2hc, and RBAT transcripts are present in 
mixed cortical cell cultures and in each of the purified populations of cells: 
astrocytes, neurons, and microglia (Figure 2.1). Further, all culture preparations 
functionally express system xc
- as determined by their ability to import 
radiolabeled cystine (Figure 2.2A-C; white bars). However, only astrocytes 
respond to IL-1β treatment (3 ng/ml; 20-24 hr) with an enhancement in cystine 
uptake (Figure 2.2A; black bars). No change in uptake was observed in pure 
neuronal or microglial cultures following IL-1β exposure at any time point 
assessed (Figure 2.2B,C).  
Since IL-1β is known to regulate the expression of various genes, we next 
assessed whether its treatment (3 ng/ml) alters xCT steady-state mRNA 
expression in purified astrocyte, neuronal, and microglial cultures using 
quantitative PCR. Consistent with the uptake data, IL-1β elicits a time-dependent 
increase in xCT mRNA in astrocyte (Figure 2.3A), but not neuron or microglial 
cultures (Figure 2.3B), such that a 4-8 hr incubation produces ≈12-fold increase 
in astrocytic xCT mRNA (Figure 2.3A). Transcripts for the system xc
- heavy 
chains do not increase following IL-1β stimulation (Figure 2.3C).  
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The increase in astrocytic steady-state xCT mRNA that follows IL-1β 
treatment (3 ng/ml; 6 hr) is not observed in astrocytes derived from IL-1RI -/- 
mice (Figure 2.4A). Further, simultaneous exposure of pure astrocytes with IL-1β 
(3 ng/ml; 6 hr) and the transcriptional inhibitor actinomycin D (10 µg/ml; 6 hr) 
blocks the IL-1β-mediated increase in xCT mRNA expression; basal levels 
remain unchanged (Figure 2.4B). Consistent with the qPCR data, IL-1β treatment 
enhances protein levels of astrocyte xCT (Figure 2.5A,B), whereas 4F2hc levels 
are unaffected (Figure 2.5A,C). Finally, concomitant exposure of astrocytes to IL-
1β (3 ng/ml) and actinomycin D (12.5 µg/ml; 24 hr), prevents the IL-1β-mediated 
enhancement in cystine uptake, as does incubation with the protein synthesis 
inhibitor cycloheximide (1 µg/ml; 24 hr) (Figure 2.6).  
 
  
Figure 2.1. Cellular system x
from unstimulated mixed cortical cell cultures (mix; lanes 1
astrocytes (lanes 3-5), pure neurons (lanes 6
9-11), reverse transcribed, and PCR performed using specific primers for 
xCT (33 cycles), 4F2hc (33 cycles), RBAT (33 cycles) and 
cycles) in separate reactions
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Figure 2.2. Astrocytes increase cystine uptake following IL-1β 
treatment. Astrocytes (A; n=4), neurons (B; n=4-8) and microglia (C; 
n=6-10) were treated with vehicle (white bars) or IL-1β (3 ng/ml; black 
bars) for 20-24 hr following which cells were washed and incubated with 
a buffer containing 14C-L-cystine (3 µM) and uptake was determined over 
time as indicated. Data are expressed as mean ± SEM 14C-L-cystine 
uptake in pmol/ mg protein. An asterisk (*) indicates a significant 
between-group difference as determined by a two-way ANOVA followed 
by Bonferroni’s post hoc test. Significance was set at p < 0.05.  
 
59 
 
 
0 1 2 4 8
0
5
10
15 * *
*
A
S
T
R
O
C
Y
T
E
 x
C
T
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
A
0 1 2 4 8
0
5
10
15
N
E
U
R
O
N
A
L
 x
C
T
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
0 1 2 4 8
0
5
10
15
M
IC
R
O
G
L
IA
L
 x
C
T
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
B
0 1 2 4 8
0
5
10
15
TIME (h)
A
S
T
R
O
C
Y
T
E
 4
F
2
h
c
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
0 1 2 4 8
0
5
10
15
A
S
T
R
O
C
Y
T
E
 R
B
A
T
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
C
 
Figure 2.3. IL-1β selectively increases astrocytic xCT mRNA. (A) Pure 
astrocytes (n=4) (B) neurons (n=4) and (inset) microglia (n=4) were treated 
with IL-1β (3ng/ml) or its vehicle for the indicated durations and xCT mRNA 
assessed via qPCR. Data are expressed as mean ± SEM fold change in 
xCT mRNA compared to untreated cells (0 h) (C) Astrocytes (n=3) were 
treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and 
4F2hc and RBAT (inset) mRNA expression was assessed via qPCR. Data 
are expressed as mean ± SEM fold change in 4F2hc and RBAT mRNA 
compared to untreated cells (0 h). An asterisk (*) denotes values different 
from 0 hr as assessed by one-way ANOVA. Significance was set at p < 0.05. 
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Figure 2.4. IL-1R1 signaling and transcription are required for the 
enhancement in astrocyte xCT mRNA expression. (A) Astrocytes (n=4-5) 
were treated with IL-1β (3 ng/ml) or its vehicle for 6 h. Thereafter, total RNA 
was isolated, reverse transcribed and xCT and β-actin expression assessed 
using quantitative PCR. Data are expressed as mean ± SEM fold change in 
xCT mRNA compared to Il1r1 +/+ untreated cells (-IL-1β). (B) Astrocytes (n= 
5) were treated with IL-1β (3 ng/ml) or its vehicle in the presence and 
absence of actinomycin D (Act D; 10 µg/ml) and xCT mRNA expression 
assessed via qPCR 6 hr later. Data are expressed as mean ± SEM fold 
change in xCT mRNA compared to untreated cells (-IL-1β, -Act D). An 
asterisk (*) denotes values different from control and a pound sign (#) 
indicates values that significantly differ from IL-1β-treated conditions as 
assessed by two-way ANOVA followed by Bonferroni’s post hoc test. 
Significance was set at p <0.05. 
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Figure 2.5. IL-1β increases xCT protein expression. (A) Pure astrocyte 
cultures were incubated with vehicle or 3 ng/ml IL-1β in the absence or 
presence of cycloheximide (CHX 1 µg/ml) for 20-24 hr. Protein from 
unstimulated C6 glioma cells was used as a positive control for xCT protein. 
Lane 1, Basal; Lane 2, IL-1β; Lane 3, IL-1β+CHX, Lane 4, C6 positive 
control. Representative of two western blots. (B,C) Films were scanned and 
densitometry performed using Gelpro Analyzer software. (B) xCT and (C) 
4F2hc protein levels were normalized to their corresponding β-actin protein 
levels and expressed as a fold increase (mean ± SEM; n = 2) over control 
(basal; set to 1).  
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We next set out to ascertain whether the astrocytic excitatory amino acid 
transporters (EAATs / system XAG
-) are coordinately regulated by IL-1β, since 
glutamate efflux via system xc
- is balanced by system XAG
--mediated glutamate 
uptake (Danbolt, 2001; McBean, 2002). Treatment of astrocytes with IL-1β (3 
ng/ml) does not enhance EAAT-1 (aka GLAST) or EAAT-2 (aka GLT-1) mRNA 
expression (Figure 2.7A) in the same time frame as it does xCT (Figure 2.3A). 
Additionally, there is no difference in astrocytic 3H-D-aspartate uptake−used here 
as a measure of EAAT activity− following a 24 hr exposure to IL-1β as compared 
to control (Figure 2.7B). Finally, the mRNA expression of LAT-2, a light chain of 
the System L amino acid transporter, is also unchanged by IL-1β stimulation 
(Figure 2.7A), further demonstrating target specificity of the IL-1β response.  To 
elucidate the functional importance of these findings and definitively test whether 
astrocyte-mediated alterations in system xc
- activity contribute to the 
development and progression of inflammatory (IL-1β-enhanced) hypoxic 
neuronal injury, astrocytes derived from sut mice − which carry a functional 
mutation in xCT (Chintala et al., 2005) − were utilized. Since no PCR genotyping 
protocol currently exists to detect the truncated slc7a11 (sut) gene, astrocytes 
were derived from the pooled cortices of the progeny obtained from 
heterozygous breeders (sut/+).   
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Figure 2.6. Protein synthesis is required for the enhancement of 
astrocyte system xc
- activity that follows IL-1β treatment. Pure 
astrocyte cultures (n =11-12) were treated with actinomycin D (ACT D; 12.5 
µg/ml) or cycloheximide (CHX; 1 µg/ml) in the absence (white bars) or 
presence (black bars) of IL-1β (3 ng/ml) for 20-24 hr following which 14C-L-
cystine uptake (3 µM labeled + 27µM unlabeled; 25˚C) was determined. 
Data are expressed as mean ± SEM 14C-L-cystine uptake in pmol/30 
min/mg protein. An asterisk (*) denotes values different from control (-IL-
1β) and a pound sign (#) indicates values different from IL-1β-treated 
conditions as assessed by two-way ANOVA followed by Bonferroni’s post 
hoc test. Significance was set at p < 0.05. 
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Figure 2.7. IL-1β does not regulate mRNA expression or activity of 
system XAG
- amino acid transporters. (A) Pure astrocyte cultures (n= 3-4) 
were treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and 
EAAT-1, EAAT-2, and LAT2 mRNA expression assessed via qPCR. Data 
are expressed as mean ± SEM fold change in mRNA compared to untreated 
cells (0 h). (B) Pure astrocyte cultures (n =10) were treated with vehicle 
(white bars) or IL-1β (3 ng/ml; black bars) for 20-24 hr following which 3H-D-
aspartate (0.1 µCi/ml labeled + 1-100 µM unlabeled; 25˚C) uptake was 
determined. Data are expressed as mean ± SEM 3H-D-aspartate uptake in 
cpm x 103/5 min/mg protein. No significant between-group differences were 
found via two-way ANOVA.  
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According to Mendelian inheritance (¼ +/+, ½ sut/+, ¼ sut/sut), cultures 
should have ≈50% reduction in functional sut gene expression. Indeed, 
astrocytes derived from sut animals demonstrate 61 ± 6% less cystine uptake 
compared to WT astrocytes when cultured under basal conditions (Figure 2.8A). 
Moreover, sut astrocytes do not respond to IL-1β with an increase in cystine 
uptake as do cultures derived from wild-type controls (Figure 2.8A). Finally, the 
enhanced neuronal vulnerability to hypoxia that follows IL-1β treatment in our 
mixed culture system (Fogal et al., 2007) −which is recapitulated herein (Figure 
2.8B, 2.9)− is not observed in chimeric cultures consisting of wild-type neurons 
plated on top of sut astrocytes (Figure 2.8B, Appendix Figure A2). Nor is it 
observed in wild-type cultures treated with a system xc
- inhibitor (50 µM 
LY367385) or an NMDA receptor antagonist (10 µM MK-801) (Figure 2.9), as 
was similarly demonstrated by us previously (Fogal et al., 2007). Together, these 
data demonstrate that IL-1β selectively regulates system xc
- activity in astrocytes 
and that this change is specifically responsible for the deleterious, excitotoxic 
effects of IL-1β found under hypoxic conditions.  
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Figure 2.8.  Cystine uptake and hypoxic neuronal cell death are reduced 
in cultures containing sut astrocytes. (A) Pure astrocyte cultures (n = 5-6) 
derived from either wild-type (white bars) or sut mice (black bars) [all cultured 
w/ 55 µM β-ME] were treated with vehicle or IL-1β (3 ng/ml) for 20-24 hr after 
which 14C-L-cystine uptake was determined. Data are expressed as mean ± 
SEM 14C-L -cystine uptake in pmol/30 min/mg protein. (B) Chimeric mixed 
cortical cell cultures were obtained by plating WT neurons on astrocytes 
derived from sut mice (black bars). These and control cultures (WT neurons on 
WT astrocytes; white bars) were treated with 1 ng/ml IL-1β or vehicle for 20-24 
hr, washed, and then deprived of oxygen for 5 hr. The percentage of total 
neuronal cell death was determined 20-24 hr later (n = 4 cultures pooled from 
two independent experiments). An asterisk (*) indicates a significant within-
group difference, while a pound (#) sign indicates a significant between-group 
difference as determined by a two-way ANOVA followed by Bonferroni’s post 
hoc test. Significance was set at p < 0.05. 
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Figure 2.9. Ionotropic glutamate receptor and system xc
- antagonism 
prevent IL-1β-mediated hypoxic neuronal injury. Mixed cortical cell 
cultures were treated with 3 ng/ml IL-1β for 20-24 hr, washed, and then 
deprived of oxygen for 4 hr. The ionotropic glutamate receptor antagonist MK-
801 (10 µM) and the system xc
- antagonist LY367385 (50 µM) were added at 
the initiation of hypoxia. The percentage of total neuronal cell death was 
determined 20-24 hr later (n = 5-6 cultures pooled from 2 independent 
experiments). An asterisk (*) denotes values different from control untreated 
cultures (hypoxia) and a pound sign (#) indicates values different from IL-1β-
treated conditions as assessed by one-way ANOVA followed by a Student-
Newman-Keul’s post hoc test. Significance was set at p < 0.05. 
 
68 
 
2.5 Discussion  
 Several studies have demonstrated that system xc
- is an important 
contributor to the ambient extracellular glutamate levels that bathe the central 
nervous system (Jabaudon et al., 1999; Warr et al., 1999; Baker et al., 2002a; 
Baker et al., 2002c; Melendez et al., 2005; Augustin et al., 2007; Featherstone 
and Shippy, 2008). Additionally, system xc
- activity has been demonstrated to 
control synapse strength and courtship behavior in drosophila (Grosjean et al., 
2008), as well as, drug seeking and sensitization behavior in rodents (Baker et 
al., 2002a; Moran et al., 2005; Baker et al., 2008). Finally, its activity can also 
contribute to neuropathology. For instance, export of glutamate via system xc
- 
produces an excitotoxic necrosis that aids in glioma tumor growth, migration, and 
invasion (Ye et al., 1999; Ye and Sontheimer, 1999; Lyons et al., 2007; 
Savaskan et al., 2008; Sontheimer, 2008). Further, the deleterious effect of Aβ-, 
secreted β-amyloid precursor protein (sAPP)- or LPS-treated microglia or IL-1β-
treated mixed cultures on neuronal and oligodendrocyte survival in vitro has been 
shown to be caused by system xc
- -mediated excitotoxicity (Piani and Fontana, 
1994; Barger and Basile, 2001; Qin et al., 2006; Domercq et al., 2007; Fogal et 
al., 2007). Thus, understanding the regulation of system xc
- at the cellular and 
molecular level is of great import. Toward this end, the central observation of this 
study is that IL-1β enhances the functional expression of system xc
- in astrocytes 
specifically and selectively via a process dependent on IL-1R1 signaling and de 
novo protein synthesis. Of pathological relevance, this IL-1β-mediated increase 
in astrocytic system xc
- activity enhances neuronal injury initiated by hypoxia.  
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Demonstration of the expression of xCT, 4F2hc and RBAT mRNA in 
purified populations of neurons, astrocytes and microglia indicate that each cell 
type has the molecular machinery necessary for the formation of a functional 
system xc
- antiporter (Figure 2.1). That these transcripts are translated to 
functional protein is demonstrated by the ability of each cell type to take up 
cystine in a system xc
- -dependent manner (Figure 2.2). While others have 
demonstrated xCT mRNA expression in neurons (Dun et al., 2006; Ogawa et al., 
2008) and retinal Muller cells (Tomi et al., 2003; Mysona et al., 2009), this is the 
first report of xCT mRNA expression in astrocytes and microglia, although xCT 
protein expression has been demonstrated in all three cell types (Burdo et al., 
2006; Dun et al., 2006; Domercq et al., 2007; La Bella et al., 2007).  Previous 
studies have also demonstrated functional system xc
- activity in neurons (Murphy 
et al., 1990; Dun et al., 2006), astrocytes (Cho and Bannai, 1990; Bender et al., 
2000; Pow, 2001; Tang and Kalivas, 2003; Lewerenz et al., 2009a), and 
microglia (Piani and Fontana, 1994; Barger and Basile, 2001; Nakamura et al., 
2003; Barger et al., 2007; Domercq et al., 2007).  
 Interestingly, of the three cell types studied, only astrocytes respond to IL-
1β by increasing the mRNA of the system xc
- light chain xCT − though not the 
heavy chains (Figure 2.3A,C) − and by increasing cystine uptake (Figure 2.2A). 
Additionally, IL-1β induces expression of xCT protein in astrocytes (Figure 2.5). 
As increases in mRNA do not always translate to similar changes in protein 
expression, it is not surprising that ≈12-fold increase in xCT mRNA expression 
(Figures 2.3, 2.4) only resulted in an approximate four-fold change in xCT protein 
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expression (Figure 2.5). Additionally, the discrepancy between changes in 
protein levels (4 fold) and the increase in cystine uptake (2 fold) (Figures 2.6) 
may occur as a function of the experimental system utilized to specifically isolate 
cystine transport via system xc
-. The presence of 1mM D-aspartate −used to 
inhibit XAG
--mediated cystine uptake − is known to alter the driving force required 
for optimal system xc
-  activity (Reichelt et al., 1997).   
Conclusive demonstration that the IL-1β-mediated enhancement in cystine 
uptake is mediated by astrocytic system xc
- comes from our observation that 
astrocytes derived from sut animals (Swank et al., 1996; Chintala et al., 2005) fail 
to demonstrate this effect (Figure 2.8A). Both of these results are consistent with 
several studies, in neural and non-neural systems, which demonstrate an 
association between xCT mRNA expression and system xc
- activity (Bridges et 
al., 2001; Sato et al., 2001; Tomi et al., 2003; Sato et al., 2004; Dun et al., 2006; 
Mysona et al., 2009). The lack of coordinate regulation of the subunits might not 
be too surprising as the heavy chains are utilized by other transport systems and 
as such exist in cells in excess (Stevens and Vo, 1998; Verrey et al., 2004). It 
should be noted, however, that there is at least one study that describes a 
parallel increase in xCT and 4F2hc mRNA occurring in response to LPS (Sato et 
al., 2001).  
The fact that microglia system xc
- components (Figure 2.3B) and activity 
(Figure 2.2C) are unaffected by treatment with IL-1β is consistent with other 
studies utilizing cells of the macrophage/monocyte lineage (Piani and Fontana, 
1994; Sato et al., 1995a). This finding may be due to the fact that microglia have 
71 
 
a low ratio of signaling (i.e. IL-1RI) to decoy (i.e. IL-1RII) receptors making them 
relatively unresponsive to IL-1β (Pinteaux et al., 2002). Whether this same 
mechanism accounts for the inability of IL-1β to alter system xc
- in neurons 
remains to be determined. Additionally, it is possible that the differential signaling 
that follows IL-1RI activation in neurons and astrocytes (Srinivasan et al., 2004) 
fosters xCT regulation in one cell type and not the other. 
 The IL-1β-mediated increase in steady-state xCT mRNA is due, at least in 
part, to the initiation of transcription following IL-1RI activation (Figure 2.4). 
Whether the latter occurs via activation of transcription factors known to facilitate 
transcription of the xCT promoter in response to amino acid deprivation, LPS, 
and oxidative stress (e.g., Nrf2 and ATF4) (Sasaki et al., 2002; Sato et al., 2004; 
Lewerenz et al., 2009a) remains to be determined. The failure of IL-1β to 
increase xCT protein expression (Figure 2.5) and cystine uptake (Figure 2.6) in 
the presence of cycloheximide suggests that de novo synthesis and subsequent 
insertion of a functional transporter into the membrane are required. 
Cycloheximide also prevented the enhancement of transporter activity mediated 
by LPS in mouse microglia (Piani and Fontana, 1994), by glucose/glucose 
oxidase (i.e. oxidative stress) in human endothelial cells (Miura et al., 1992), and 
by an NO donor in retinal pigment epithelial cells (Bridges et al., 2001). 
Nevertheless, the requirement of transcription and translation may be cell, 
species, and/or stimulus-specific (Barger et al., 2007). Additionally, post-
transcriptional regulation of system xc
- components and activity in astrocytes in 
response to the antibiotic ceftriaxone has recently been described (Lewerenz et 
72 
 
al., 2009a). 
 Not only does IL-1β demonstrate cellular specificity, but it appears to show 
target specificity as well.  IL-1β had no effect on the expression of the system L 
transporter light chain, LAT2, or the expression and function of astrocytic 
excitatory amino acid transporters, EAAT-1 and EAAT-2 (Figure 2.7). System L, 
and LAT-2 in particular, was chosen as a potential target as it is expressed in 
brain (Segawa et al., 1999), it mediates the uptake of the neutral amino acids 
cysteine and methionine (Oxender et al., 1977; Sato et al., 1987; Segawa et al., 
1999), and because methionine can be converted in the brain to cysteine via 
transulfuration, a process linked to GSH biosynthesis/homeostasis (Vitvitsky et 
al., 2006). EAATs were assessed as it is possible that glutamate import 
machinery could be cooperatively regulated to maintain low extracellular 
glutamate levels. The lack of effect on the EAATs may not be surprising 
considering the abundance at which they are expressed in astrocytes (Bergles 
and Jahr, 1997; Lehre and Danbolt, 1998). Additionally, this agrees with previous 
studies that note no alterations in system XAG
- function in the face of increased 
system xc
- activity (Lewerenz et al., 2009a; Mysona et al., 2009).  
 The data described herein coupled with our previous studies (Fogal et al., 
2005a; Fogal et al., 2007) suggest the following scenario (Figure 2.10). As 
System xc
- is an obligate exchanger, the import of cystine is coupled to glutamate 
export. Under physiological conditions, the accumulation of glutamate is 
prevented by its rapid clearance from the extracellular space via system XAG
-. 
Consequently, no neuronal toxicity is observed ─ demonstrating that increased 
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activity of system xc
- is not inherently injurious (Fogal et al., 2005a).  In contrast, 
when glutamate uptake is impaired, increased system xc
- activity can result in the 
accumulation of extracellular glutamate and subsequent excitotoxic neuronal cell 
death (Fogal et al., 2007). This work advances our previous study by 
demonstrating unequivocally that IL-1β enhances system xc
- activity in astrocytes 
exclusively (Figure 2.2) and that this increase is responsible for the potentiation 
of neuronal injury found under hypoxic conditions. To wit, sut astrocytes ─ with 
impaired functional system xc
- ─ neither increase cystine uptake in response to 
IL-1β (Figure 2.8A) nor support the ability of IL-1β to mediate hypoxic neuronal 
injury when co-cultured with neurons (Figure 2.8B).   
In summary, we have analyzed expression of xCT mRNA and the activity 
of system xc
- in purified astrocyte, neuron, and microglial cultures in the presence 
and absence of IL-1β, a cytokine known to be upregulated in and to contribute to 
various neurological disorders [for review see (Fogal and Hewett, 2008)]. The 
results unequivocally demonstrate that astrocytes increase system xc
- expression 
and activity in response to IL-1β, whereas neurons and microglia do not. The 
enhancement in astrocytic transporter activity requires transcription and 
translation, demonstrates specificity for the xCT subunit, and is responsible for 
the increase in hypoxic inflammatory (IL-1β-mediated) neuronal cell death. 
  
  
 
Figure 2.10. Schematic of the system x
normoxic and hypoxic conditions. 
directly coupled to glutamate export, occurring in a Na
dependent manner with 
cell to maintain the driving force for system x
panel).  Under hypoxic conditions, enhanced export of glutamate via system 
xc
- in combination with reduced glutamate clearance by system X
produces an accumulation of extracellular glutamate which contributes to 
excitotoxic neuronal cell death (right panel). [Based on results described 
herein as well as those found in Fogal et a
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CHAPTER 3 
 
Non-cell autonomous influence of astrocyte system xc
- on 
hypoglycemic neuronal cell death 
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3.1  Summary 
           Despite longstanding evidence that hypoglycemic neuronal injury is 
mediated by glutamate excitotoxicity, the cellular and molecular mechanisms 
involved remain incompletely defined. Here, we demonstrate that the excitotoxic 
neuronal injury that follows glucose deprivation is mediated by glutamate 
extruded from astrocytes via system xc
- ─ an amino acid transporter that imports 
L-cystine and exports L-glutamate.  Specifically, we find that depriving mixed 
cortical cell cultures of glucose for up to 8 hr results in increased extracellular 
glutamate [glutamate]e levels that injure neurons, but not astrocytes. Neuronal 
injury is prevented by ionotropic glutamate receptor antagonism but is insensitive 
to tetanus toxin. Removal of amino acids during the deprivation period prevents 
— whereas addition of L-cystine restores — the enhancement of [glutamate]e 
and neuronal injury, implicating the cystine/glutamate antiporter, system xc
-. 
Drugs known to inhibit system xc
- also suppress glucose deprivation-induced 
enhancement of [glutamate]e and neuronal injury.  Further, a dramatic reduction 
in neuronal injury is observed in chimeric cultures consisting of neurons derived 
from wild-type mice plated on top of astrocytes derived from sut mice, which 
harbors a naturally occurring null mutation in the gene (Slc7a11) which encodes 
the substrate specific light chain of system xc
- (xCT). Finally, enhancement of 
astrocytic system xc
- expression and function via exposure to IL-1β potentiates 
hypoglycemic neuronal injury, the process of which is prevented by removal of L-
cystine and/or addition of system xc
- inhibitors. Thus — under the conditions of 
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glucose deprivation — our studies demonstrate that astrocytes, via system xc
- , 
have a direct, non–cell autonomous effect on cortical neuron survival.  
 
3.2 Introduction  
Hypoglycemia is a medical emergency that arises as a serious 
complication of insulin therapy in diabetic patients. It is also prevalent in 
neonates, in patients with insulin-producing tumors, and can occur as a 
consequence of brain ischemia. Severe hypoglycemia, defined as less than 2 
mM blood glucose, essentially renders the brain aglycemic, leading to cognitive 
impairments and frank neuronal injury (Ryan et al., 1990; Langan et al., 1991). 
Evidence indicates that hypoglycemic/aglycemic neuronal cell death is mediated 
by glutamate excitotoxicity (Wieloch, 1985; Monyer et al., 1989). Following 
activation of glutamate receptors, a cascade of biochemical events is initiated 
that ultimately leads to neuronal cell death via processes dependent on reactive 
oxygen species, neuronal zinc release, activation of poly(ADP-Ribose) 
polymerase-1 (PARP), and alterations in mitochondrial function. Inhibition of 
these downstream targets of glutamate receptor activation show some success 
in reducing hypoglycemic brain injury [for review see (Suh et al., 2007)]. 
However, the cellular and molecular mechanisms surrounding glutamate 
release/accumulation remain incompletely defined.   
System xc
- is a heteromeric amino acid transporter consisting of two 
subunits: xCT ─ the light chain conferring substrate specificity ─ and a heavy 
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chain thought to target the transporter to the plasma membrane (Sato et al., 
1999; Bassi et al., 2001). The import of cystine via system xc
- is directly coupled 
to glutamate export, which occurs in a Na+-independent manner (Bannai and 
Kitamura, 1980). Enhanced system xc
- activity has been previously reported to 
contribute to excitotoxic neuronal injury in numerous experimental paradigms 
(Piani and Fontana, 1994; Ye et al., 1999; Barger and Basile, 2001; Qin et al., 
2006; Fogal et al., 2007; Savaskan et al., 2008; Sontheimer, 2008; Jackman et 
al., 2010; Massie et al., 2010a). Herein, we describe astrocytic system xc
- as the 
source of glutamate required for the initiation of non-cell autonomous neuronal 
injury following glucose deprivation in vitro.  
 
3.3  Materials and Methods 
3.3.1 Cell culture 
All media including media stock (MS), glial plating medium, mixed culture 
plating medium, maintenance medium, and glucose-free balanced salt solution 
(BSS) have been fully described (see Chapter 2.3.1). For most experiments, 
BSS0 contains purchased 1x MEM amino acids (Invitrogen). Amino acids were 
reconstituted individually for the removal and addition experiments.   
Primary astrocyte cultures were derived from cerebral cortices of day 1-3 
postnatal CD1 mouse pups (Charles River) as described (Trackey et al., 2001; 
Jackman et al., 2010). Wild-type (WT) and sut (xCT-deficient) astrocytes were 
cultured from cortices of single pups derived from sut/+ breeding pairs (JAX; 
Stock # 001310). β-mercaptoethanol (β-ME; 55 µM) was added to the glial 
79 
 
plating medium of sut cultures to support growth and to WT cultures for control 
purposes (Shih et al., 2006). The rest of the brain was used for genotyping: WT 
primers (230 bp product) 5’- GAA GTG CTC CGT GAA GAA GG 3’ (forward), 5’- 
ATC TCA ATC CTG GGC AGA TG-3’ (reverse); sut primers (≈2280 bp product) 
5’-CCA CTG TTG TAG GTC AGC TTA GG-3’ (forward), 5’-CAG GAC CTG TGA 
ATA TGA TAG GG 3’ (reverse).  
Mixed cortical cell cultures containing predominantly neurons and astrocytes 
were prepared by culturing dissociated cells from embryonic day 15 mouse 
fetuses onto a confluent layer of astrocytes in mixed culture plating media as 
previously described (Trackey et al., 2001; Jackman et al., 2010). Experiments 
were performed on mixed cortical cultures after 13-14 days in vitro.  
 
3.3.2 Glucose Deprivation 
Mixed cortical cell cultures were washed thoroughly (8 x 750 µL) into 
BSS0. Glucose (final concentration=10mM) was immediately added to parallel 
cultures to serve as controls and added back to experimental conditions to 
terminate glucose deprivation at the times indicated in each figure legend. 
Inhibitors — with the exception of an overnight incubation with tetanus toxin — 
were given at the initiation of glucose deprivation.  
 
3.3.3 Glutamate Uptake 
System XAG
--mediated 3H-D-aspartate (PerkinElmer) uptake was 
performed as previously described (Fogal et al., 2007; see Chapter 2.3.3) using 
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0.1 µCi/ml 3H-D-aspartate and 50 µM unlabeled D-aspartate (5 min; 25˚C). 
Accumulated radioactivity was estimated using a liquid scintillation counter and 
values normalized to protein [BCA Assay (Pierce)].  
 
3.3.4 Measurement of cell death 
Cell death was quantitatively determined by spectrophotometric 
measurement of lactate dehydrogenase (LDH) as described previously (Uliasz 
and Hewett, 2000). Data are expressed as a percentage of total neuronal LDH 
activity (defined as 100%) determined by exposing parallel cultures to 250 µM 
NMDA (20-24 hr). Since primary cortical astrocytes neither express NMDA 
receptors nor are injured by glucose deprivation up to 8 hr (Figure 3.1 inset), 
changes in LDH activity can be used as a specific marker of neuronal injury. In 
general, basal LDH released from control cultures was subtracted from values 
obtained in experimental conditions to yield the signal specific to hypoglycemic 
injury. Astrocyte injury was quantified as a percentage of total astrocytic LDH 
activity (defined as 100%) determined by exposure of parallel cultures to 5 µM 
Calphostin C for 20-24 hr (Ikemoto et al., 1995).  
 
3.3.5 Measurement of glutamate 
Samples of the bathing media from the mixed cortical cultures were stored 
at -80°C until analyzed. Two hundred microliters were assayed for glutamate via 
HPLC  by an investigator blinded to the treatment conditions as described (Fogal 
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et al., 2007). Glutamate levels were calculated by normalizing to glutamate 
standards which were linear over the range of 0.1–100 µM. 
 
3.3.6 IL-1β Treatment 
To selectively enhance astrocytic system xc
-  expression/activity (Jackman 
et al., 2010), cultures were treated with 0.01-1 ng/ml recombinant murine IL-1β 
(R&D Systems) in an incubation buffer of MS supplemented with 0.1% fatty-acid 
free BSA (Sigma).  
 
3.3.7 Quantitative Real-time PCR (qPCR) 
Quantitative PCR was performed using mouse-specific primer pairs 
[Taqman Gene Expression Assays, Applied Biosystems: xCT 
(Mm00442530_m1)] per manufacturer’s instructions using the comparative cycle 
threshold method (∆∆CT) with β-actin as the housekeeping control as described 
(Jackman et al., 2010). β-actin CT values were unaffected by IL-1β treatment. 
Amplification efficiency was >94%. 
 
3.3.8 Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Software 
(Version 4.03) as described in each figure legend. Percentage data were first 
transformed via arcsin square root. For qPCR, statistics were performed on the 
logarithmic retransformation (i.e. geometric means) of 2-∆∆CT values. In all 
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experiments, data are expressed as the mean ± SEM. Significance was 
assessed at p < 0.05.  
 
3.4 Results 
Following glucose deprivation, there is a time-dependent increase in 
neuronal injury in the mixed cortical cultures (Figure 3.1A), whereas purified 
astrocytes (Figure 3.1 inset) and astrocytes in mixed cultures are resistant for up 
to 8 hr, the longest time-point assessed. Neuronal injury is associated with 
accumulation of glutamate in the tissue culture supernatant (Figure 3.1B) and is 
prevented by ionotropic glutamate receptor antagonism (Figure 3.1C). Overnight 
incubation with 300 ng/ml tetanus toxin — a concentration which cleaves 
neuronal synaptobrevin-2 (data not shown) and blocks depolarization-induced 
glutamate release in our system (Taylor and Hewett, 2002; Fogal et al., 2005b) 
— failed to attenuate neuronal damage (Figure 3.1D). Alterations in classical 
glutamate re-uptake transporter function also did not appear to contribute to the 
observed accumulation of [glutamate]e as 
3H-D-aspartate uptake under control 
conditions and following 6 h of glucose deprivation in astrocytes (Figure 3.2A) 
and in mixed cultures (Figure 3.2B) did not differ statistically. Notably, in mixed 
cultures with concentrations of cold D-aspartate that span the Km’s of all 
glutamate transporters, no difference in uptake was observed under 
hypoglycemic conditions (Figure 3.2B). Further, glucose deprivation did not alter 
system xc
- activity as assessed via the uptake of radiolabeled cystine (Figure 
3.3).  
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Both neuronal injury and glutamate accumulation resulting from glucose 
deprivation was, however, inhibited by 4-CPG or LY367385 (each at 50 µM) but 
not YM298198 (10 µM) (Figure 3.4). The former are drugs that inhibit both 
system xc
- and mGluR1α, whereas the latter is a selective mGluR1α antagonist 
(Fogal et al., 2007). Complete removal of amino acids during the deprivation 
period prevented — whereas addition of L-cystine alone restored — the 
enhanced [glutamate]e and hypoglycemic neuronal injury, further supporting a 
role for system xc
- (Figure 3.5A,C). Likewise, the solitary removal of L-cystine 
during the glucose deprivation period prevented hypoglycemic neuronal cell 
death. Removal and/or addition of L-methionine had no effect (Figure 3.5 A-C), 
attesting to the requirement of L-cystine.  
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Figure 3.1. Non-synaptically released glutamate contributes to 
hypoglycemic neuronal injury. Mixed cortical cultures or astrocytes (inset) were 
incubated in media containing (hatched bars) or lacking (black bars) glucose. The 
percentage of total cell death (A) and glutamate accumulation in the tissue culture 
supernatant (B) were determined at the times indicated. Between group 
differences (*) were determined by one-way (astrocytes) or two-way ANOVA 
(mixed cultures) followed by Bonferroni’s post hoc test (n=11-12 cultures from four 
different experiments). (C) Mixed cortical cultures were washed into BSS0 
containing vehicle, MK-801 (10 µM), or MK-801 plus CNQX (30 µM) for 8 hr (GD). 
Neuronal injury was determined 20-24 hr later. (*) indicates values significantly 
different from control conditions (10.56 ± 3.02%); (#) represents a significant 
diminution of GD-induced injury [one-way ANOVA followed by Student-Newman-
Keul’s post hoc test. (n=11 cultures from three separate experiments)]. (D) Mixed 
cultures were incubated overnight with vehicle or tetanus toxin (TeNT; 300 ng/ml), 
then washed into BSS0. Eight hr later, glucose (10 mM) was added and the 
cultures were placed back into the incubator, after which neuronal injury was 
assessed (20-24 hr). (*) indicates values significantly different from control 
conditions (5.71 ± 2.03%) [one-way ANOVA followed by Student-Newman-Keul’s 
post hoc test]. No between-group differences exist (n = 8-9 cultures from three 
separate experiments).  
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Figure 3.2 Hypoglycemia does not impair glutamate uptake in 
astrocytes or mixed cultures. (A)  Pure astrocytes (n=10 culture wells 
from 2 independent experiments) were incubated in media containing 
(hatched bars) or lacking (black bars) glucose for 1-6 hr after which 3H-D-
aspartate (0.1 µCi/ml labeled + 50 µM unlabeled; 25˚C) uptake was 
determined in the presence and absence of the competitive, non-
transportable EAAT inhibitor TBOA (500 µM). (B) Mixed cortical cultures (n 
=6 from 2 independent experiments) were incubated in media containing 
(hatched bars) or lacking (black bars) glucose. for 6 hr after which 3H-D-
aspartate (0.1 µCi/ml labeled + 1-100 µM unlabeled; 25˚C) uptake was 
determined. Data are expressed as mean ± SEM 3H-D-aspartate uptake in 
cpm /5 min/mg protein. No significant between-group differences were 
found via two-way ANOVA. 
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Figure 3.3. Hypoglycemia does not increase the activity of system xc
- . 
Mixed cortical cultures (n =6) were deprived of glucose for 0-8 hr after which 
they were incubated in a buffer containing 14C-L-cystine (3 µM; 25˚C) and 
uptake was determined over 0inutes. Data are expressed as mean ± SEM 14C-
L-cystine uptake in pmol/mg protein. No significant differences were found via 
one-way ANOVA. 
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Figure 3.4. System xc
- antagonism prevents glutamate accumulation and 
neuronal cell death. (A,B) Mixed cortical cultures were washed into BSS0 in 
the presence or absence of 4-CPG (50 µM), LY367385 (50 µM), or YM298198 
(10 µM). Eight hr later, supernatant was collected for measurement of 
neuronal cell death (A) and glutamate accumulation (B). (*) indicates values 
that are significantly different from control conditions (7.98 ± 0.89 % neuronal 
injury; 9.56 ± 2.29 µM glutamate), while (#) represents a significant diminution 
from GD-induced (A) neuronal injury or (B) glutamate accumulation [one-way 
ANOVA followed by Student-Newman-Keul’s post hoc test. (n=11-12 cultures 
from three different experiments)]. (Right) Representative phase micrographs 
of mixed cortical cultures: (a) control; (b) 8 h GD; (c) GD + 4-CPG (50 µM); (d) 
GD + YM298198 (10 µM). 
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To determine whether cell-autonomous/non-cell autonomous alterations in 
system xc
- activity underlie the initiation and/or progression of neuronal injury 
following glucose deprivation, we prepared chimeric cultures consisting of WT 
neurons plated on top of astrocytes derived from mice harboring a null mutation 
in Slc7a11 (sut gene), which encodes for xCT, the light subunit of system xc
-  
(Chintala et al., 2005).  In comparison to cultures containing both WT neurons 
and astrocytes, neuronal injury following glucose deprivation is dramatically 
reduced in chimeric cultures consisting of wild-type neurons plated on top of sut 
astrocytes (Figure 3.6). Notably, the comparable LDH levels measured following 
an NMDA exposure that results in 100% neuronal cell death (Figure 3.6 inset) 
demonstrate that neurons plated on wild-type or sut astrocytes have similar 
growth properties / cell densities and that wild-type neurons plated on sut 
astrocytes are sensitive to NMDA. Finally, treatment of mixed cultures with IL-1β 
to enhance xCT expression (Figure 3.7A) and system xc
- activity in astrocytes 
(Jackman et al., 2010a) — potentiates hypoglycemic neuronal injury (Figure 
3.7B) such that injury now occurs at an earlier time point. This enhanced 
neuronal injury is blocked by system xc
- antagonism and/or by removal of the 
substrate, L-cystine (Figure 3.7C).  
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Figure 3.5. Hypoglycemic neuronal injury is dependent on cystine.  
Cultures were deprived of glucose (4 hr) in a medium containing (GD) or lacking 
(-AA) MEM amino acids save for supplementation with L-cystine (+CYSS) or L-
methionine (+MET). (*) indicates values different from control (2.87 ± 0.38 % 
injury; 5.7± 0.74 µM glutamate) while (#) represents a significant diminution from 
GD-induced (A) neuronal injury or (B) glutamate accumulation [one-way ANOVA 
followed by Student-Newman-Keul’s post hoc test. (n = 4)]. (C) Cultures were 
deprived of glucose (4 hr) in a medium containing (GD) or lacking (-AA) MEM 
amino acids, L-cystine (-CYSS) alone, or L-methionine (-MET) alone. (*) 
indicates values significantly different from control (0.55 ± 0.28 % injury); (#) 
represents a significant diminution from GD-induced neuronal injury [one-way 
ANOVA followed by Student-Newman-Keul’s post hoc test. (n=24 cultures from 
six separate experiments)].  
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Figure 3.6. Hypoglycemic neuronal injury is dependent on astrocyte system 
xc
- Chimeric cultures were obtained by plating WT neurons on astrocytes derived 
from sut mice (hatched white bars). These and control cultures (WT neurons on WT 
astrocytes; black bars) were washed into BSS0 (8 hr), glucose added (10 mM), and 
then neuronal cell death determined 20-24 hr later. (*) indicates a significant within-
group difference, while (#) indicates a significant between-group difference [two-way 
ANOVA followed by Bonferroni’s post hoc test. (n = 15-18 cultures from three 
separate experiments)]. Inset: LDH absorbance values for chimeric and control 
cultures treated with 250 µM NMDA for 20-24 hr. 
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Figure 3.7. Enhanced system xc
- activity potentiates hypoglycemic 
neuronal injury. (A) Pure astrocytes (n = 3 from three experiments) were 
incubated with IL-1β or vehicle for 6 hr, after which xCT mRNA expression 
was assessed. (*) denotes values different from 0 hr [one-way ANOVA 
followed by Dunnett’s post hoc test]. (B) Mixed cultures were incubated with 
IL-1β for 20-24 hr then washed into BSS0. Glucose was added after 3.5 hr 
and neuronal cell death determined 20-24 hr later. (*) indicates values 
different from control (0 ng/ml IL-1β) [one-way ANOVA followed by Dunnett’s 
post hoc test (n = 16 cultures from four separate experiments)]. (C) Mixed 
cultures were incubated with IL-1β (GD + IL-1β) or vehicle (GD) for 20-24 hr, 
then washed into BSS0 containing 4-CPG (50 µM) or LY367385 (50 µM) or 
one lacking cystine (-CYSS) for 4 hr. (*) indicates values different from GD. 
(#) represents a significant diminution from the IL-1β-mediated potentiation of 
GD-induced neuronal injury [one-way ANOVA followed by Student-Newman-
Keul’s post hoc test (n=6-16 cultures from four separate experiments)]. 
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3.5 Discussion  
When blood glucose concentrations fall below 2 mM (normal = 4-7 mM), 
brain glucose levels approach zero (Silver and Erecinska, 1994; Choi et al., 
2001),  precipitating neuronal injury. Neurons are highly sensitive to glucose 
deprivation (Auer et al., 1984), whereas astrocytes have been demonstrated to 
be more resistant (Monyer et al., 1989; Lyons and Kettenmann, 1998). This is in 
accordance with the findings that rapid ATP depletion occurs exclusively in 
neurons following glucose deprivation in vitro (Choi et al., 2008) and that 
astrocytes contain glycogen stores that can be rapidly mobilized to meet 
metabolic needs during conditions of glucose deprivation (Cataldo and 
Broadwell, 1986; Swanson and Choi, 1993).  
Despite this, cell death does not appear to be a direct result of energy 
failure. In fact, several studies demonstrate that hypoglycemic neuronal injury 
occurs secondary to glutamate excitotoxicity, as insulin-induced hypoglycemia 
results in a two-three fold increase in glutamate accumulation in the rat 
hippocampus and striatum as measured by microdialysis (Sandberg et al., 1986; 
Silverstein et al., 1990). The data presented herein are in agreement with a two-
fold change in extracellular glutamate. Further, ionotropic glutamate receptor 
antagonists are protective both in vivo and in vitro (Wieloch, 1985; Monyer et al., 
1989). Nevertheless, questions concerning the cellular source and molecular 
mechanisms surrounding glutamate release/accumulation following 
hypoglycemia remain.  
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Although, in vivo deafferentation studies suggest some neuronal 
contribution to hypoglycemic neuronal injury (Wieloch et al., 1985), we find that 
synaptic release of glutamate did not contribute to toxicity, as glucose-
deprivation-induced neuronal injury was not prevented by incubation with tetanus 
toxin at a concentration that cleaves neuronal synaptobrevin-2 and blocks 
depolarization-induced glutamate release/injury in our system (Taylor and 
Hewett, 2002; Fogal et al., 2005b). This contrasts with earlier work demonstrating 
40% protection against glucose deprivation-induced neuronal injury following 
tetanus toxin exposure, albeit at a concentration 10x higher (Monyer et al., 1992). 
Even when tested at the highest concentration utilized by Monyer and 
colleagues, there was only 15% protection (data not shown), suggesting that in 
our system synaptically-released glutamate is a minor source of excitotoxic levels 
of glutamate. Additionally, we did not observe a reduction in glutamate (3H-D-
aspartate) uptake following 6 h of glucose deprivation. This agrees with literature 
demonstrating no change in glutamate uptake in primary mouse cortical 
astrocytes following 2 h of glucose deprivation (Bakken et al., 1998) and only a 
20% loss after 24 h (Swanson and Benington, 1996).  This begs the question as 
to the cellular source of glutamate.  
Studies have demonstrated that system xc,
 the antiporter that extrudes 
glutamate while importing cystine, is an important contributor to the ambient 
extracellular glutamate levels that bathe the central nervous system (Warr et al., 
1999; Baker et al., 2002b; Augustin et al., 2007; Massie et al., 2010b; De Bundel 
et al., 2011). Importantly, the activity of system xc
- has also been linked to 
94 
 
excitotoxic neuronal injury in a number of paradigms (Piani and Fontana, 1994; 
Barger and Basile, 2001; Qin et al., 2006; Fogal et al., 2007). For instance, the 
export of glutamate via system xc
- produces an excitotoxic necrosis that aids in 
glioma tumor growth and invasion (Savaskan et al., 2008; Sontheimer, 2008) and 
IL-1β-mediated hypoxic neuronal injury and 6-hydroxydopamine-mediated 
dopaminergic toxicity are dependent on system xc
- (Fogal et al., 2007; Jackman 
et al., 2010; Massie et al., 2010a). We now report that hypoglycemic neuronal 
toxicity is cystine-dependent and abrogated by system xc
-- antagonism (Figure 
3.5A, C) or when wild-type neurons were plated on top of sut (xCT-deficient) 
astrocytes (Figure 3.6). Somewhat to our surprise, we were unable to measure 
any changes in system xc
--mediated cystine uptake in our model system (Figure 
3.3). However, this is in accord with findings in mouse 3T3 cells (Sato et al., 
2004). Thus, basal activity of system xc
- under conditions of energy deprivation 
appears sufficient to facilitate neuronal injury. This is not unprecedented as the 
glutamate concentrations needed to kill energy-deprived neurons are far less 
than those required to kill healthy neurons (Novelli et al., 1988). Given that 
extracellular levels of glutamate rise, we hypothesize that system xc
- activity 
initiates injury whereas secondary release of intracellular glutamate from dying 
neurons propagates it (Fogal et al., 2005b). In support, we find that glucose 
deprivation-induced neuronal injury is positively correlated with neuronal cell 
density (r2=0.85), with sparse cultures routinely having less neuronal injury than 
dense cultures (Figure 3.8).  
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While elimination of astrocytic system xc
- is sufficient to prevent glucose 
deprivation-induced neuronal injury, we also found that enhancement of 
astrocytic system xc
- could potentiate injury (Figure 3.7B). While IL-1β was 
utilized as a tool, it is notable that diabetics have increased IL-1β serum levels 
compared to healthy individuals (Dogan et al., 2006). Given the increasing 
evidence of crosstalk between the peripheral immune and central nervous 
systems, it is intriguing to speculate that there may be some physiological 
relevance.  
Overall, our data demonstrate that inhibition of system xc
- through 
pharmacological or genetic means is sufficient to dramatically reduce excitotoxic 
neuronal injury occurring secondary to glucose deprivation. These data highlight 
the role of astrocytes in non-cell autonomous hypoglycemic neuronal injury and 
further underscore their potential to serve as therapeutic targets for reducing 
excitotoxic neuronal injury in vivo.   
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Figure 3.8. Glucose deprivation-induced injury is dependent on 
neuronal density. (A) Mixed cortical cultures containing neuronal densities 
ranging from 1.5-3.5 hemispheres / 10 ml were washed thoroughly into 
BSS0. Five and a half (n  = 12) or eight hr later (n=6) , supernatant was 
collected for measurement of neuronal cell death. Data are expressed as 
raw LDH values as a function of neuronal density (A) and percentage of 
neuronal cell death as a function of raw LDH values (B).  
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CHAPTER 4 
IL-1β-mediated neuroprotection against oxidant stress 
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4.1  Summary 
Astrocytes produce and export the antioxidant glutathione (GSH), which serves 
as the principal source of substrate for neuronal GSH biosynthesis. Previously, 
we found that interleukin-1β (IL-1β) enhances the expression of astrocyte system 
xc
-, the transporter delivering the rate-limiting substrate for GSH synthesis —
cyst(e)ine. Herein, we demonstrate that IL-1β mediates a system xc
- and time-
dependent increase in extracellular GSH levels in cortical astrocyte cultures, 
suggesting both enhanced synthesis and export. To determine whether this 
increase could provide protection against oxidative stress in astrocytes and/or 
neurons, pure astrocyte cultures, as well as, mixed cultures containing both 
neurons and astrocytes were exposed to tert-butyl hydroperoxide (tBOOH). 
Astrocytes were incubated with IL-1β (3 ng/ml) or vehicle for 48 hr, after which 
cells were incubated with tBOOH (0.1- 0.7 mM; 2.5 h). tBOOH exposure 
produced a concentration-dependent injury, which was significantly attenuated by 
prior IL-1β treatment. Neurons and astrocytes in mixed cortical cultures were also 
protected from a toxic tBOOH exposure (1.5 mM; 90-120 min) following 
treatment with IL-1β. Further, astrocyte cultures were exposed to IL-1β (3 ng/ml; 
0-24 h) after which mRNA and protein for molecules participating in GSH 
biosynthesis, export, and metabolism were quantitatively determined. IL-1β 
enhances mRNA and protein expression of xCT and decreases expression of γ-
glutamyltranspeptidase, the ectopeptidase responsible for extracellular 
catabolism only. Taken together, these data suggest that IL-1β may increase 
extracellular astrocytic GSH levels via the enhancement of substrate import 
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coupled with the reduction in product catabolism. Hence, while the beneficial 
effects of IL-1β are largely underappreciated, we show that IL-1β may be an 
important stimulus for increasing astrocyte GSH production, and potentially, total 
CNS antioxidant capacity. 
 
4.2  Introduction  
Depending on the context, alterations in astrocyte physiology following 
neurological injury can promote survival or facilitate death (Liberto et al., 2004; 
John et al., 2005). Inflammatory mediators like the cytokine interleukin-1β (IL-1β) 
can act on astrocytes to induce changes in gene expression that modify 
phenotype and function to produce these dichotomies (Zhao and Schwartz, 
1998; Nguyen et al., 2002). For instance, endogenously produced IL-1β appears 
necessary for the expression and maintenance of long term potentiation in 
hippocampal slices (Schneider et al., 1998; Avital et al., 2003), while higher 
concentrations — applied exogenously to mimic pathological expression — 
inhibit it (Ross et al. 2003, Avital et al. 2003, Bellinger et al. 1993).  Several 
studies demonstrate that IL-1β-stimulated astrocytes support neuronal survival 
via production of neurotrophic factors (Albrecht et al., 2002; John et al., 2005), 
although others demonstrate that IL-1β can interfere with neurotrophin signaling 
(Soiampornkul et al., 2008; Tong et al., 2008). Further, IL-1β has been shown to 
both exacerbate injury and protect against excitotoxic stimuli [reviewed in 
(Pinteaux et al., 2009)]. It is hypothesized that these dichotomous effects might 
100 
 
result from cell-specific and/or concentration-dependent actions of IL-1β 
(Pinteaux et al., 2009). 
Additionally, work from our laboratory would suggest the protective versus 
deleterious effects of IL-1β can be context-dependent. For instance, IL-1β 
upregulates the activity of the cystine-glutamate amino acid antiporter system xc
- 
on astrocytes, which produces excitotoxic neuronal cell death only in the context 
of energy deprivation (Fogal et al., 2007; Jackman et al., 2010). However, this 
upregulation is in and of itself not cytotoxic. Interestingly, the same transporter 
fluxing the glutamate which produces excitotoxicity during periods of energy 
deprivation has a Janus-face and participates in the uptake of cystine for the 
synthesis of the neuroprotective antioxidant molecule glutathione (Meister and 
Anderson, 1983; Bannai and Tateishi, 1986).  
Glutathione (GSH) is synthesized from the amino acids glutamate, 
cysteine, and glycine via two sequential reactions catalyzed by γ-gammacysteinyl 
ligase (GCL) followed by glutathione synthetase (GSS)(Meister and Anderson, 
1983). Astrocytes release ≈10% of GSH/hour into the extracellular compartment 
(Sagara et al., 1996; Minich et al., 2006), with most GSH being fluxed via 
multidrug resistance protein 1 (Mrp1)(Hirrlinger et al., 2002). Once in the 
extracellular space, γ-glutamyltranspeptidase (GGT1) initiates GSH catabolism, 
which serves to provide precursors utilized by both neurons and astrocytes for 
their GSH biosynthetic needs (Dringen et al., 1997; Kranich et al., 1998). In this 
respect, astrocytes function as indispensible support cells by protecting against 
oxidative insults (Tanaka et al., 1999; Shih et al., 2003; Jakel et al., 2007) since 
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both astrocytes and neurons are more susceptible to oxidant-induced injury when 
astrocytic GSH is deficient (Gegg et al., 2005). 
Given the fundamentally protective nature of the inflammatory response, 
we hypothesized that IL-1β-treated astrocytes could increase GSH. As such, the 
ability of IL-1β to regulate the metabolic cycle of GSH in astrocytes and the 
susceptibility of cells to oxidative stress in the presence and absence of IL-1β 
was evaluated herein.   
 
4.3 Materials and Methods 
4.3.1 Cell culture 
 All media including media stock (MS), glial plating medium, mixed culture 
plating medium, maintenance medium, and glucose-free balanced salt solution 
(BSS) have been fully described in section 2.3.1.  
Primary astrocyte cultures were derived from cerebral cortices of day 1-3 
postnatal CD1 mouse pups (Charles River) as described (Trackey et al., 2001; 
Jackman et al., 2010).  
Mixed cortical cell cultures containing predominantly neurons and astrocytes 
were prepared by culturing dissociated cells from embryonic day 15 mouse 
fetuses onto a confluent layer of astrocytes in mixed culture plating media as 
previously described (Trackey et al., 2001; Jackman et al., 2010). Experiments 
were performed on mixed cortical cultures after 13-14 days in vitro.  
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4.3.2 IL-1β Treatment 
 Astrocytes and mixed cultures were treated with recombinant murine IL-
1β (3 or 10 ng/ml respectively; R&D Systems) in an incubation buffer of MS 
supplemented with 0.1% fatty-acid free BSA (Sigma) for the times indicated in 
the figure legends. Cells were then returned to a humidified 37˚C normoxic (21% 
O2) incubator containing 6% CO2. 
 
4.3.3 Glutathione measurement 
Total glutathione [GSx = reduced GSH + glutathione disulfide (GSSG)] 
concentrations were determined using the GSH-Glo glutathione assay (Promega) 
per manufacturer’s instruction. Media was collected for analysis of the 
supernatant fraction and GSH-Glo reaction buffer was added to the cells. 
Additional lysis buffer was made per manufacturer’s instructions and 200 µL was 
added per well as a dilution factor to keep relative light units within the dynamic 
range of the standards. All GSSG within the sample was converted to GSH with 
the reducing agent TCEP-HCl (final concentration = 1 mM; 10 minutes; room 
temperature; Thermo Scientific). One hundred microliters of each sample was 
transferred to a 96-well plate and luciferin buffer was added for 10 minutes with 
gentle agitation. Luciferase activity was measured in a luminometer (Optocomp 
II; MGM Instruments). Cellular and tissue culture supernatant levels of GSx were 
normalized to standards prepared in water and MS, respectively.  Standards 
were linear over the range of 0–5 µM.   
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4.3.4 Quantitative Real-time PCR (qPCR)  
RNA was isolated and first-strand cDNA synthesized as previously 
described (Jackman et al., 2010). qPCR was performed using mouse-specific 
primer pairs [Taqman Gene Expression Assays, Applied Biosystems: xCT 
(Mm00442530_m1), GCLC (Mm00802655_m1), GCLM (Mm00514996_m1), 
GSS (Mm00515065_m1), Mrp1/Abcc1 (Mm00456156_m1), GGT1 
(Mm00492322_m1)] per manufacturer’s instructions. Reactions were run in the 
Applied Biosystems Fast Real-Time PCR System and relative quantification 
performed using the comparative cycle threshold method (∆∆CT), where CT 
values of the transcript of interest were normalized to β-actin CT values from the 
same sample, then compared to a calibrator CT value (untreated cells) to 
determine the relative fold increase in mRNA. β-actin CT values were unaffected 
by IL-1β treatment.  
 
4.3.5 Immunoblotting  
Protein expression was determined by Western Blot analysis. Astrocytes 
in 24-well plates or T25 flasks were washed twice with ice-cold PBS then 
incubated in lysis buffer [50 mM Tris, pH 8.0, 1.0% Nonidet-P40 (NP40), 150 mM 
NaCl, and protease inhibitor cocktail (Roche)] for 30 minutes on ice. Cells were 
harvested by scraping, lysates collected, cellular debris removed by 
centrifugation (10,000 x g; 15 min; 4°C), and the resulting supernatants stored at 
-20°C. After thawing, proteins were concentrated via ethanol precipitation. The 
pelleted protein was resuspended in 1x urea buffer (50 mM Tris, pH 6.8, 2.5% 
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glycerol, 5% SDS, 4 M Urea, 10 mM DTT, 0.02% bromophenol blue). Thirty µg 
protein (BCA assay; Pierce) was separated by SDS-PAGE electrophoresis under 
reducing conditions then electrophoretically transferred to a nitrocellulose 
membrane (0.2 µm; Bio-Rad). Proteins of interest were detected using species-
specific Western Breeze Immunodetection kits (Invitrogen) per manufacturer’s 
instructions. Primary antibodies were incubated with membranes overnight at 4° 
C at the following concentrations: α-GGT1 (1 µg/ml; mouse monoclonal; Santa 
Cruz), α-β-actin (0.3 µg/ml; mouse monoclonal; Sigma) or α-GSS (1 µg/ml; rabbit 
polyclonal; Abcam). Results were recorded on X-ray film (FujiFilm). Digitized 
images were analyzed by computer-assisted densitometry (Gel-Pro Analyzer) 
and GGT1 and GSS protein normalized to their respective β-actin levels.  
 
4.3.6 Tert-butyl hydroperoxide (tBOOH) treatment 
Following vehicle or IL-1β exposure, tBOOH (Acros Organics; final 
concentration: 0.1-1.5 mM) was added to the cultures in an incubation buffer of 
MS for the times indicated in the figure legends. Experiments were terminated 
2.5 - 2.75 hr later by the addition of MTT. Tissue culture supernatant was 
removed for measurement of lactate dehydrogenase (LDH; see section 4.3.7) 
immediately before the addition of MTT. In mixed-culture experiments the 
tBOOH-containing media was replaced with MS at the indicated times (0.5 – 2 
hr). Supernatants were collected for measurement of LDH before media 
replacement and immediately before addition of MTT to assess immediate and 
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delayed injury. Total neuronal injury was quantified via summation of early and 
delayed LDH activity measurements.    
 
4.3.7 Measurement of cell death and viability  
Cell death was quantitatively determined by spectrophotometric 
measurement of lactate dehydrogenase (LDH) as described previously (Uliasz 
and Hewett, 2000). Data are expressed as a percentage of total neuronal  or 
astrocytic LDH activity (defined as 100%) determined by exposing parallel 
cultures to 250 µM NMDA or 5 µM Calphostin C (Ikemoto et al., 1995), 
respectively, for 20-24 hr. In mixed culture experiments, cell death values greater 
than 100% reflect astrocytic LDH release such that all of the neurons and some 
of the astrocytes are injured. Cell viability was quantified via colorimetric analysis 
of Thiazolyl blue tetrazolium bromide (MTT; Sigma) reduction as previously 
described (Lobner, 2000). Briefly, cultures were incubated with 40 µL MTT 
solution/well (3 mg/ml MTT in PBS; final concentration = 300 µg/ml) for at least 4 
h at 37 ºC. The MTT solution was carefully aspirated, crystals were solubilized in 
acidified isopropanol (90% isopropanol; 10% 1 N HCl; 400 µL/well) and 200 µL 
was transferred to a 96-well plate. Absorbance at 540 nm was measured with 
690 nm background subtraction using a plate reader (SpectraMax M2, Molecular 
Devices).  Viability was expressed as a percentage of maximal MTT reduction 
(i.e. highest absorbance = 100%) within the plate. Parallel cultures incubated with 
5 µM Calphostin C for 24-48 hr defined a complete loss of viability (defined as 
0%).  
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4.3.8 Statistical Analysis  
All statistical analyses were performed using GraphPad Prism (Version 
4.03, GraphPad Software, Inc.) as described in each figure legend. Percentage 
data were first transformed (arcsin square root) before analyses. For qPCR, 
statistics were performed on the logarithmic retransformation (i.e. geometric 
means) of 2-∆∆CT values. In all experiments, data are expressed as the mean ± 
SEM and significance was assessed at p < 0.05.  
 
4.4 Results 
  We previously demonstrated in a mixed cortical cell culture system that IL-
1β increased system xc
- activity, then localized the phenomenon to occur 
exclusively in astrocytes, not neurons or microglia (Fogal et al., 2007; Jackman 
et al., 2010). Due to the enhanced delivery of cyst(e)ine via system xc
-, it was 
hypothesized that IL-1β would enhance intracellular glutathione levels. 
Interestingly, following 24 and 48 hr of IL-1β exposure (3 ng/ml), astrocytes 
exhibit a modest increase in intracellular GSH levels detectable at 24 h (Figure 
4.1A). A dramatic increase in extracellular GSH levels is observed at both 24 and 
48 h (Figure 4.1B) demonstrating enhanced synthesis and export of GSH.  
Further, the enhancement in supernatant GSH is dependent on system xc
- as this 
effect is lost when astrocytes are treated concomitantly with IL-1β and 4-CPG (50 
µM) but not YM298198 (10 µM) (Figure 4.2B). The former drug inhibits both 
system xc
- and mGluR1α, whereas the latter is a selective mGluR1α antagonist 
(Fogal et al., 2007), demonstrating that system xc
- antagonism alone prevents the 
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increase in extracellular GSH. Importantly, 4-CPG and YM298198 have no effect 
on intracellular GSH levels (Figure 4.2A). 
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Figure 4.1. IL-1β increases supernatant GSH. Pure astrocytes (n = 6 
from three experiments) were incubated with IL-1β (3 ng/ml) or vehicle 
(-IL-1β) for 24-48 hr, after which total intracellular (A) and supernatant 
(B) glutathione levels were assessed (GSx = GSH + GSSG). Data are 
expressed as mean ± SEM total GSx (µM) compared to vehicle-treated 
cells. An asterisk (*) denotes values different from untreated (-IL-1β) 
astrocytes as assessed by two-way ANOVA followed by Bonferroni’s 
post hoc test.  
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Figure 4.2. The IL-1β-mediated increase in supernatant GSH is 
dependent on system xc
-.  Pure astrocytes (n = 4 from two 
experiments) were incubated with IL-1β (3 ng/ml) or vehicle for 24 hr in 
the presence or absence of 4-CPG (50 µM) or YM298198 (YM; 10 µM), 
after which intracellular (A) or supernatant (B) GSx levels were 
assessed. Data are expressed as mean ± SEM total GSx (µM) 
compared to vehicle-treated (CTL) cells. An asterisk (*) denotes values 
different from untreated astrocytes, while (#) represents a significant 
diminution from the IL-1β-mediated enhancement of supernatant GSx 
levels as assessed by one-way ANOVA followed by Student-Newman-
Keul’s post hoc test.  
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Given the interconnectedness between system xc
- and cellular GSH levels, the 
ability of IL-1β to influence other components of the GSH metabolic pathway was 
assessed. Under basal conditions, the key metabolic transcripts involved in GSH 
synthesis (GCLC, GCLM, GSS), export (Mrp1), and extracellular catabolism 
(GGT1) are all expressed in primary cortical mouse astrocytes (Figure 4.3A). 
Consistent with previous findings, IL-1β (3 ng/ml; 0-24 h) elicits a time-dependent 
increase in xCT mRNA in astrocytes that peaks at 4 h then slowly declines over 
time [Figure 4.3B and (Jackman et al., 2010)]. No notable changes in the 
expression of GCLC, GCLM, or Mrp1 were observed (Figure 4.3C,D,F), and the 
biological significance of the small (≈1.5-fold), but statistically significant increase 
in GCLC mRNA remains to be ascertained.  The relative expression of GSS 
mRNA exhibits a time-dependent increase that peaks after 8 hr IL-1β exposure, 
followed by a decrease and return to baseline levels by 24 hr (Figure 4.3E). 
Finally, an ≈80% reduction in GGT1 mRNA expression is observed 4 hr after IL-
1β treatment which persists until 24 hr, the final time point assessed in these 
studies (Figure 4.3G). Since we had previously demonstrated that the IL-1β-
mediated increase in xCT mRNA was paralleled by an increase in xCT protein 
expression (Jackman et al., 2010),  protein levels of GSS and GGT1 following IL-
1β treatment were evaluated. Consistent with the qPCR data, 12-24 hr IL-1β 
treatment reduces GGT1 protein levels (Figure 4.4), yet this treatment fails to 
alter GSS protein expression (Figure 4.5).  
  
                             
A 
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Figure 4.3. IL-1β regulates xCT, GSS, and GGT1 mRNA 
expression. (previous page) 
(A) Total RNA was isolated from unstimulated astrocytes, reverse 
transcribed, and PCR performed using specific primers for xCT, 
GCLC, GCLM, GSS, Mrp1, and GGT1 in separate reactions. ( All 
reactions were for 33 cycles save for GGT1 and β-actin which were for 
31 and 23 cycles respectively). (B-G) Pure astrocytes (n=3-6) were 
treated with IL-1β (3ng/ml) or its vehicle for the indicated durations and 
relative mRNA expression assessed via qPCR. Data are expressed as 
mean ± SEM fold change in mRNA compared to untreated cells (0 hr). 
An asterisk (*) denotes values different from untreated cells as 
assessed by one-way ANOVA. 
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Figure 4.4. IL-
Pure astrocyte cultures were incubated with vehicle or 3 ng/ml IL
1β for 12-48 hr. 
were scanned and densitometry performed using Gelpro Analyzer 
software and GGT1 protein levels were normalized to their 
corresponding β
change (mean ± SEM) relative to control (0 h; set to 1). 
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Figure 4.5 IL-1β does not alter GSS protein expression
astrocyte cultures were incubated with vehicle or 3 ng/ml IL
hr. Representative of 4
densitometry performed using Gelpro Analyzer software and GSS protein 
levels were normalized to their corresponding 
expressed as a fold change (mean ± SEM) relative to control (0 h; set to 
1). 
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It was hypothesized that the IL-1β-mediated changes in GSH metabolism could 
confer protection against an oxidative stressor. Since catalase cannot neutralize 
organic hydroperoxides, tert-butyl hydroperoxide (tBOOH) was utilized as its 
elimination is dependent on GSH and GSH-peroxidase (Dringen et al., 1998; 
Kussmaul et al., 1999). Depletion of GSH via a 24 hr incubation of astrocytes 
with buthionine sulfoximine (BSO), a γ-glutamylcysteinyl ligase inhibitor, can 
render a sub-lethal concentration of tBOOH (0.3 mM) toxic demonstrating the 
necessity of GSH for tBOOH elimination in our model system (Figure 4.6). 
Astrocytes were treated with IL-1β or vehicle for 48 hr then incubated with 
tBOOH (0-0.7 mM) for 2.5 hr after which cell death and cell viability were 
evaluated. tBOOH exposure produces a concentration-dependent injury which is 
attenuated by IL-1β treatment (Figure 4.7), implicating significant glioprotective 
properties of IL-1β. Finally, mixed cultures were treated with IL-1β (10 ng/ml) or 
vehicle for 48 hr then incubated with tBOOH (1.5 mM) for 30-120 min, after which 
a sample of tissue supernatant was collected for LDH analysis, the media was 
replaced with MS, and injury allowed to progress until 165 min had elapsed at 
which point MTT was added to the wells to terminate the experiment. Little injury 
occurs during the acute tBOOH exposure as demonstrated by minor LDH 
accumulation in the media (gray bars) prior to media replacement. Notably, injury 
evolves over time. Neuronal injury becomes statistically significant after tBOOH 
exposure for 60-120 minutes in untreated cultures or after a 120 minute exposure 
in IL-1β treated cultures (Figure 4.8A). Importantly, neurons are protected against 
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a 90 and 120 min exposure to tBOOH if they were previously incubated with IL-
1β (Figure 4.8A). Further, a 120 min exposure to tBOOH injures both neurons 
and astrocytes as demonstrated by visual inspection of the astrocyte monolayer 
and by neuronal cell death percentages greater than 100%. Importantly, 
pretreatment with IL-1β attenuates the toxicity of tBOOH in mixed cultures at this 
time point (Figure 4.8B).   
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Figure 4.6. tBOOH toxicity is GSH-dependent. (A) Pure astrocytes 
were incubated with BSO (3-300 µM) or vehicle for 24 hr, after which 
intracellular GSH levels were assessed. Data are expressed as 
mean ± SEM GSH expressed as a percent of control levels (0 µM 
BSO). An asterisk (*) denotes values different from untreated 
astrocytes as assessed by one-way ANOVA followed by Dunnett’s 
post hoc test. n = 4 from 2 experiments. (B) Pure astrocytes were 
incubated with BSO (3-100 µM) or vehicle for 24 hr, after which 
cultures were exposed to a sub-lethal concentration of tBOOH (0.3 
mM) for 3.5 hr. Data are expressed as mean ± SEM percent viable 
astrocytes. n = 6 from three experiments. An asterisk (*) denotes 
values different from untreated (-tBOOH) astrocytes as assessed by 
two-way ANOVA followed by Bonferroni’s post hoc test. 
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Figure 4.7. IL-1β protects astrocytes against tBOOH-
mediated oxidative injury. Pure astrocytes were incubated with 
IL-1β (3 ng/ml) or vehicle (-IL-1β) for 48 hr, after which cells were 
incubated with tBOOH (0.1-0.9 mM; 2.5 h). (A) Supernatant was 
collected for LDH analysis of cell death (A) and oxidative injury 
was terminated with the addition of MTT to assess cell viability. 
(B) Data are expressed as mean ± SEM percent viable 
astrocytes. An asterisk (*) denotes values different from 
untreated astrocytes as assessed by two-way ANOVA followed 
by Bonferroni’s post hoc test. n = 8-14 from two-three 
experiments. 
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Figure 4.7. IL-1β protects against tBOOH-mediated oxidative 
injury in mixed cultures. Mixed cortical cultures were incubated 
with IL-1β (10 ng/ml) or vehicle (-IL-1β) for 48 h, after which cells 
were incubated with tBOOH (1.5 mM) for 90-120 minutes, after 
which the media was replaced with MS. The experiment was 
terminated after 165 min when media was collected for 
assessment of cell death via LDH release (A) and MTT was 
added to the cultures to assess cell viability (B). Gray bars 
represent neuronal cell death arising from the acute tBOOH 
exposure. Data are expressed as mean ± SEM percent neuronal 
cell death and viability. An asterisk (*) denotes values different 
from untreated astrocytes as assessed by two-way ANOVA 
followed by Bonferroni’s post hoc test. n = 4-6 from three 
experiments.  
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4.5 Discussion  
Maintenance of a reduced intracellular environment is essential to cell 
survival as altered redox status in astrocytes in favor of pro-oxidant conditions 
impairs glutamate clearance via GLAST and GLT1 (Trotti et al., 1997), disturbs 
cell signaling and gene expression, and can damage nucleic acids, proteins, and 
lipids. Our laboratory has previously published that IL-1β regulates astrocyte 
system xc
-, a cystine-glutamate antiporter, essential for delivering cyst(e)ine the 
rate-limiting substrate for the synthesis of the antioxidant molecule GSH (Fogal et 
al., 2007; Jackman et al., 2010).  However, the physiological consequences of 
the IL-1β-mediated enhancement in system xc
- were unknown and it remained to 
be determined whether IL-1β regulated GSH levels in astrocytes as has been 
shown for other cell types following induction of system xc
- (Sato et al., 1995a; 
Sasaki et al., 2002).  
Since circulating GSH is unable to penetrate the blood brain barrier 
(Cornford et al., 1978), GSH within the CNS must be generated in situ. In the 
CNS, astrocytes function as the predominant provider of GSH and understanding 
the modulation of GSH levels is of great import.  Alterations in GSH content could 
directly influence astrocytic GSH flux, utilization of GSH precursors by other cell 
types, and confer resistance against or enhance vulnerability to oxidative insults. 
In our studies, IL-1β enhanced extracellular levels of GSH and these changes 
were associated with enhanced expression of xCT and reduced expression of 
GGT1. Importantly, the IL-1β-mediated changes in astrocytic antioxidant capacity 
reduces susceptibility to the oxidative stressor tert-butyl hydroperoxide in purified 
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astrocyte cultures and in mixed cortical cultures (Figures 4.7, 4.8). 
IL-1β and other cytokines have been demonstrated to participate in the 
regulation of antioxidant levels in non-neural tissue (Kayanoki et al., 1994; 
Antras-Ferry et al., 1997). In non-neural cells including mouse endothelial cells 
(Urata et al., 1996) and endometrial stromal cells (Lee et al., 2009),  IL-1β 
increases intracellular GSH levels. Our data are consistent with the previously 
reported observations that intravenous administration of IL-1β decreases GGT1 
activity in the rat hippocampus within 2 h (Kaiser et al., 2006) and in a human 
astrocytoma cell line following a 24 h exposure to IL-1β  (Malaplate-Armand et 
al., 2000).  
The notion that neuroprotection could be mediated by an inflammatory 
mediator is not unprecedented, as positive effects of IL-1β in the CNS and 
periphery have already been reported. For example, IL-1β protects mice against 
lethal challenge via radiation or infection when administered 20-24 hr prior to the 
insult (Neta et al., 1986; Schwartz et al., 1987; van der Meer et al., 1988). Within 
the brain, chronic overexpression of IL-1β ameliorates pathology observed in the 
hippocampus in a mouse model of Alzheimer’s disease (Shaftel et al., 2007). IL-
1β enhances neuronal sprouting and/or regeneration in vitro and in the 
hippocampus and ventral tegmental nucleus in vivo (Fagan and Gage, 1990; 
Wang et al., 1994; Temporin et al., 2008). IL-1β-deficient mice have impaired 
blood brain barrier repair compared to their WT counterparts following 
corticectomy as assessed via extravasation of IgG into brain parenchyma (Herx 
and Yong, 2001) and remyelination is impaired in these mice secondary to 
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delayed differentiation/maturation of oligodendrocytes (Mason et al., 2001; Vela 
et al., 2002). In a similar vein TNF-α, which is induced by IL-1β, promotes 
oligodendrocyte progenitor maturation and remyelination (Arnett et al., 2001). 
While the mechanisms are not yet fully elucidated one can speculate that some 
protective effects of IL-1β can be attributed to transcriptional regulation of genes 
intimately involved in neuronal and glial proliferation and/or survival including 
nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF) among others 
(Friedman et al., 1990; Spranger et al., 1990; Albrecht et al., 2002). 
It should be noted that a 24 hr exposure of astrocytes to IL-1β alters the 
expression of approximately 1400 hundred genes (John et al., 2005).  In addition 
to modulating the expression of trophic factors, the beneficial effects of IL-1β may 
arise via cytokine influence on antioxidant systems. In rat astroglial cultures, 
LPS-activated microglia induce numerous proteins in astrocytes with antioxidant 
properties including SOD2, peroxiredoxins, and glutathione S-transferase, and 
these changes are associated with protection from H2O2-induced oxidative stress 
(Röhl et al., 2008). IL-1β has been demonstrated to alter metallothionein 
expression in human fetal astrocytes (John et al., 2005). CNTF, a growth factor 
induced by IL-1β, increases the expression of the astrocyte-specific glutathione-
S-transferase (GST-µ) (Levison et al., 1996) important in the conjugation of 
harmful compounds to GSH and subsequent extrusion from the cell. Additionally, 
IL-1α regulates MnSOD expression (Mokuno et al., 1994) and IL-1β induces 
ceruloplasmin (Chang et al., 2001; Kuhlow et al., 2003) -- a copper and iron 
chelator -- potentially limiting the iron-mediated generation of reactive species via 
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Fenton chemistry. 
Given the opposing nature of “typical” pro- and anti-inflammatory 
mediators, it raises the intriguing possibility that specific cytokines regulate 
particular components of a system, and that single cytokines or combinations of 
cytokines may be responsible for the fine-tuning of antioxidant status based on 
the timing, concentration, and/or kinetics of cytokine expression in specific cell 
types. In support of this notion, in our studies and those by others IL-1β reduces 
GGT1 expression/activity, whereas TNF-α can induce GGT1 expression and 
activity (Reuter et al., 2009). In the liver and liver-derived cell line, IL-1β, and IL-6 
can induce Mrp1 mRNA expression (Lee and Piquette-Miller, 2001, 2003; 
Cherrington et al., 2004), but in primary rat astrocytes TNF-α, but not IL-1β or IL-
6, can increase Mrp1 (Ronaldson et al., 2010).  
The production of the antioxidant GSH is of obvious importance for the 
maintenance of cellular health.  Although, additional studies are necessary to 
elucidate the role of IL-1β in post-transcriptional regulation of GSH metabolism, 
this pleiotropic cytokine unequivocally enhances GSH levels in part via regulation 
of xCT and GGT1. These findings underscore the importance of understanding 
the effects of cytokines in various physiological as well as pathophysiological 
contexts. Ironically, while this pathway allows the CNS to rapidly upregulate GSH 
in response to an oxidative challenge, it also holds the potential to exacerbate 
CNS pathology as a consequence of increasing extracellular glutamate levels 
and the risk of excitotoxicity. The balance between these two possible outcomes 
must always be kept in mind when considering the physiological consequences 
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of alterations in system xc
- expression and function. Indeed, as Shaftel and 
colleagues articulated so eloquently: “IL-1 can no longer be regarded as simply 
the villain in the setting of brain injury and disease, but instead might be 
understood as a factor that can influence the balance between beneficial and 
detrimental outcomes” (Shaftel et al., 2008).  The same is certainly holds true for 
system xc
- .  
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CHAPTER 5 
Putative Mechanism of Regulation   
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5.1  Summary 
We recently demonstrated that interleukin-1β (IL-1β) increases system xc
- activity 
in mixed cortical cell cultures, resulting in an increase in hypoxic neuronal injury 
when glutamate clearance is impaired. System xc
- activity is also deleterious in 
the context of glucose deprivation in the presence of competent glutamate 
uptake. Interestingly, when cultures are not under conditions of energy 
deprivation, the enhancement in system xc
- by IL-1β produces an accumulation of 
glutathione in the extracellular space, which can protect both neurons and 
astrocytes against oxidant-induced injury. Given the context-dependent effects of 
system xc
- it is important to understand the mechanisms by which this transporter 
is regulated. Herein, we demonstrate that NF-κB appears to be a negative 
regulator with inhibition of NF-κB via BAY-11-7082 enhancing the expression of 
xCT in a manner that potentiates the effects of IL-1β. The protein kinase A/C/G 
inhibitor H7 prevents the IL-1β-mediated enhancement in xCT mRNA expression. 
Interestingly,  xCT mRNA expression is enhanced by application of PMA and 
dBcAMP, activators of PKC and PKA, respectively, but not by 8-Br-cGMP.  
Finally, the concentrations of H7 were efficacious as it could block the PMA and 
dBcAMP-mediated enhancement in xCT expression. Overall, our data 
demonstrate that NF-κB is not involved in system xc
- regulation by IL-1β and that 
protein kinase A and/or C likely participates in the regulation of xCT in the 
presence and absence of IL-1β.  
 
 
127 
 
5.2 Introduction 
This thesis documents that IL-1β enhances xCT mRNA and protein 
expression along with the activity of astrocytic system xc
- (Chapter 2), yet the 
mechanism(s) of regulation have not been elucidated. It has been well 
documented that many agents induce xCT expression and/or system xc
- activity 
including: electrophiles like diethyl maleate (Bannai, 1984a), cystine deprivation 
and deprivation of other amino acids (Bannai and Kitamura, 1982), oxidative 
stress via the generation of reactive species (Bridges et al., 2001; Dun et al., 
2006), oxygen (Bannai et al., 1989), oxidized low-density lipoprotein (LDL) (Sato 
et al., 1995b),  the HIV tat (transactivation of transcription) protein (Bridges et al., 
2004), Aβ (Qin et al., 2006), erythropoietin (Sims et al.), dBcAMP (Gochenauer 
and Robinson, 2001; Seib et al., in press), and pertinent to this thesis, the 
inflammatory mediators LPS and TNF-α (Sato et al., 1995a). 
Transcriptional regulation of xCT has been demonstrated in non-neural 
cells (Itoh et al., 1999; Sato et al., 2001; Sasaki et al., 2002; Qiang et al., 2004; 
Sato et al., 2004) and the xCT 3’ UTR contains numerous AU-rich elements (our 
unpublished observations), the occupation of which by trans-acting factors is 
known to influence mRNA stability (Brennan and Steitz, 2001). The xCT 
promoter contains several cis-acting regulatory elements including four 
antioxidant response elements (ARE, also referred to as the electrophile 
response element, EpRE), two amino acid response elements (AARE), and 
putative AP-1 and NF-κB binding sites (Sato et al., 2000; Sato et al., 2001; 
Sasaki et al., 2002; Sato et al., 2004). Depletion of GSH facilitates the nuclear 
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translocation of the transcription factor NF-E2-related factor (Nrf2), which 
regulates gene expression through its subsequent interaction with AREs (Itoh et 
al., 1999; Qiang et al., 2004). The transcription factor ATF4 mediates the 
enhancement of xCT following amino acid deprivation via binding to the AARE 
(Sato et al., 2004). Other mechanisms by which system xc
- is regulated remain to 
be ascertained. 
5.3  Materials and Methods 
5.3.1 Cell culture 
 Cell culture media, experimental buffer compositions, and primary 
astrocyte cultures have been previously described (see section 2.3.1).  
 
2.3.2 Cell Treatment 
Cells were treated with recombinant murine IL-1β, dBcAMP, PMA, or 8-Br-
cGMP for the times indicated in the figure legends in an incubation buffer of MS 
supplemented with 0.1% fatty-acid free BSA (Sigma). Cells were then returned to 
a humidified 37˚C normoxic (21% O2) incubator containing 6% CO2. 
 
5.3.3 qPCR  
RNA isolation and qPCR have been described in detail previously (see section 
2.3.4 and 2.3.5). 
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5.4 Results 
Since signaling in response to IL-1β in astrocytes is preferentially 
mediated by NF-κB (Srinivasan et al., 2004) and the xCT promoter contains a 
putative NF-κB consensus sequence (Sato et al., 2001), NF-κB was evaluated as 
a potential transcriptional regulator of xCT. NF-κB activation was assessed by 
nuclear translocation of p65 which was rapid and robust, with peak p65 nuclear 
translocation occurring 15 minutes after IL-1β stimulation then declining over time 
and returning to baseline levels within 60 minutes (Figure 5.1). Astrocytes were 
incubated with the NF-κB inhibitor BAY 11-7082, which inhibits phosphorylation 
of IκB-α (Pierce et al., 1997) for 1 hour after which IL-1β was added to the 
cultures for 6 h. Importantly, 30 µM BAY 11-7082 is sufficient to block IL-1β-
induced translocation of p65 into the nucleus (Figure 5.2A). Inhibition of NF-κB 
signaling by BAY 11-7082 did not block the IL-1β-mediated enhancement of xCT 
expression, rather, it potentiated the effects of IL-1β (Figure 5.2B). Similar 
enhancements in xCT mRNA expression were obtained in experiments utilizing 
an alternate NF-κB inhibitor PDTC (Appendix Figure A3).  These findings are 
consistent with the observation that low concentrations of LPS induce xCT 
expression in the absence of NF-κB activation (Sato et al., 2001), suggesting that 
changes in xCT gene-expression can occur independently of TLR4-mediated NF-
κB activation.  
Parallel studies were conducted utilizing a variety of inhibitors to identify 
potential candidates involved in the IL-1β-mediated enhancement of xCT mRNA. 
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While not an exhaustive screen, the only inhibitor tested that blocked the effect 
was H7, a pan-protein kinase A/C/G inhibitor (Figure 5.3). 
To elucidate which protein kinase has the potential to enhance xCT 
expression astrocytes were incubated with dibutyryl cAMP (dBcAMP), phorbol 
12-myristate 13-acetate (PMA), and 8-Br-cGMP to activate PKA, PKC, and PKG, 
respectively. dBcAMP and PMA enhance xCT mRNA expression whereas 8-Br-
cGMP does not (Figure 5.4). Importantly, the concentration of H7 utilized in the 
previous experiment is efficacious as it is sufficient to block the IL-1β- , dBcAMP-, 
and PMA-mediated enhancement in xCT mRNA  (Figure 5.5).  
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Figure 5.1. Time course of NF
were incubated with vehicle (0 min) or 3 ng/ml IL
harvested, nuclear and cytoplasmic fractions isolated, and 10 mg protein was 
separated by SDS-PAGE (12% gel). Western blot analysis was performed using 
antibodies directed against p65 (NF
(nuclear marker). Representative of six blots. 
densitometry performed using Gelpro Analyzer software. Nuclear p65 protein levels 
were normalized to their corresponding 
increase (mean ± SEM) over control (0 min; set to 1). An asterisk (*) denotes values 
that are significantly increased over control as assessed by one
by Dunnett’s post hoc test of the arc sin square ro
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Figure 5.2 NF-κB may negatively regulate xCT expression.
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after which IL-1β or vehicle was added for 
accumulation of p65 was assessed via immunocytochemistry.
Astrocytes (n=3) were incubated with 
7082 for 1 hour after which 
mRNA assessed via qPCR. Data are expresse
change in xCT mRNA compared to 
A 
B 
132 
 
 
0
   3          10         30         10
CTL       IL-1β
   BAY 11-7082 (µM)
vehicle or BAY 11-7082 (30 µM)
30 min then
various concentrations of BAY 11
 IL-1β or vehicle was added for 6 hr 
d as mean ± SEM fold 
untreated cells.  
 
 (A) 
 for 30 min 
 nuclear 
 (B) 
-
then xCT 
133 
 
S
B
20
35
80
SP
60
01
25
U
01
26
P
D
98
05
9
H
89
C
al
C
K
T5
82
3
H
7
LY
29
40
02
0.0
0.5
1.0
1.5
2.0
2.5
IL-1β
JNK
MEK
PKA
PKC
PKG
A,C,G
PI3-K
p38
x
C
T
 m
R
N
A
(f
o
ld
 c
h
a
n
g
e
)
 
Figure 5.3. The pan-PKA/PKC/PKG inhibitor H7 blocks the IL-1β-
mediated enhancement in xCT mRNA. Astrocytes (N=2) were incubated 
with the kinase inhibitors listed for 1 hour after which IL-1β (3 ng/ml) was 
added for 5 hr and xCT mRNA assessed via qPCR. Data are expressed as 
mean ± SEM fold change in xCT mRNA compared to IL-1β-treated cells (IL-
1β). Inhibitor concentrations were as follows SB203580, 3µM; SP600125, 30 
µM; UO126, 10 µM; PD98059, 50 µM;H89, 1 µM; Calphostin C (CalC), 1µM; 
KT5823, 1.5 µM; H7, 30 µM; LY294002, 5 µM.  
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Figure 5.4. PKA and PKC activation induce xCT expression. Pure 
astrocytes (n=2) were treated with IL-1β (3ng/ml), dBcAMP (500 µM), PMA 
(100 nM), 8-Br-cGMP (300µM) or its vehicle for 8 hr and xCT mRNA 
assessed via qPCR. Data are expressed as mean ± SEM fold change in 
xCT mRNA compared to untreated cells (CTL). 
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Figure 5.5. Inhibition of PKA/PKC prevents the IL-1β mediated induction of 
xCT. Pure astrocytes (n=2) were incubated with H7( 30 µM; 1 hr) after which  IL-
1β (3 ng/ml), PMA (100 nM) or its vehicle were added for 6 hr or dBcAMP (500 
µM) was added for 8 hr and xCT mRNA assessed via qPCR. Data are 
expressed as mean ± SEM fold change in xCT mRNA compared to untreated 
cells (CTL). 
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5.5 Discussion 
This data presented herein suggests that NF-κB is not the transcription 
factor responsible for the enhancement of xCT mRNA and may actually function 
as a negative regulator of system xc
-. We posit that there may be a constitutively 
active form of NF-κB in astrocytes, or in a distinct subpopulation of astrocytes, as 
constitutive NF-κB activation has been reported in mature B cells (Doerre and 
Corley, 1999), thymocytes (Korner et al., 1991), some thymomas (Hemar et al., 
1991) and monocytic cell lines (Griffin et al., 1989). Importantly, constitutive 
expression of NF-κB has been described in the CNS in some hippocampal and 
cortical neurons as measured by luciferase reporter assays and 
immunofluorescence (Kaltschmidt et al., 1994; Bhakar et al., 2002). This notion is 
plausible as p65 is observed in the nucleus in the absence of stimulation after 
incubation with the nuclear export inhibitor leptomycin B suggesting that NF-κB 
shuttles between the nucleus and cytoplasm in astrocytes (Zhai et al., 2004). As 
such, the role of NF-κB in regulation of xCT warrants further study and astrocytes 
derived from mutant mice containing a dominant negative form of IκB localized 
exclusively to astrocytes (GFAP-IκB-DN) or IKK knockout mice might be 
particularly useful for future inquiries (Li et al., 2000; Herrmann et al., 2005; 
Zhang et al., 2005).  
It should be noted that PMA and PKA can activate NF-κB (Shirakawa et 
al., 1989; Shirakawa and Mizel, 1989; Ghosh and Baltimore, 1990), yet activation 
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of NF-κB by TNF-α appears to occur in a PKC-independent fashion (Meichle et 
al., 1990). It has previously been reported that a chronic exposure of astrocytes 
to dBcAMP for seven to ten days enhances xCT mRNA and protein expression 
and system xc
- activity (Gochenauer and Robinson, 2001; Seib et al., in press), 
yet acute induction of xCT by dBcAMP to the best of our knowledge has not been 
previously reported. There is also evidence for PKC-mediated regulation of 
system xc
- activity levels in neutrophils where xCT mRNA is enhanced after 
incubation with PMA (Sakakura et al., 2007). However Tang and colleagues 
demonstrate a PMA-mediated reduction in cystine uptake in rat cortical 
astrocytes at identical concentrations (100nM)  to those utilized in the studies 
presented herein (Tang and Kalivas, 2003).  Further studies are required to 
understand the discrepancies between Tang’s studies and the data presented in 
this dissertation. 
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CHAPTER 6 
 
Conclusion, Discussion, and Future Directions  
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6.1 Main Findings 
The main findings of this dissertation are that: (1) IL-1β enhances system 
xc
- activity and xCT mRNA and protein expression in astrocytes, but not neurons 
or microglia. Further, there is some specificity to this response as IL-1β does not 
influence expression of the system xc
- heavy chains (4F2hc or RBAT), LAT2 (the 
light chain of the system L amino acid transporter), or the predominant glutamate 
transporters in astrocytes (EAAT1/GLAST and EAAT2/Glt-1). (2) The activity of 
astrocytic system xc
- is contributory to neuronal injury following energy 
deprivation (specifically the IL-1β-mediated enhancement of hypoxic injury and 
hypoglycemic injury), and (3) astrocytic system xc
- protects both astrocytes and 
neurons against cytotoxicity caused by oxidant stress (tert-butyl hydroperoxide).  
 
6.2 Cell specificity: The importance of astrocytes 
 Astrocytes are the most numerous cell type in the brain and while 
originally viewed simply as structural support for neurons, we are continuing to 
learn how astrocyte physiology is critical for the maintenance of homeostasis, in 
general, and neuronal physiology specifically. In addition to providing structural 
support, astrocytes provide metabolic support via delivery of energy substrates 
and buffering of pH and K+, promotion of growth, regulation of synaptogenesis 
and synaptic maintenance, modulation of neuronal excitability, participation in the 
formation and maintenance of the blood brain barrier, and regulation of vascular 
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tone and microcirculation such that functional hyperemia -- the coupling of 
cerebral blood flow and neuronal activity -- occurs. (Ransom and Sontheimer, 
1992; Ullian et al., 2001; Nedergaard et al., 2003; Maragakis and Rothstein, 
2006; Markiewicz and Lukomska, 2006; Sidoryk-Wegrzynowicz et al., 2011).  
Organizationally, astrocytes only overlap in a narrow interface, such that 
they are predominantly arranged into non-overlapping domains (Bushong et al., 
2002; Halassa et al., 2007b). Despite the non-overlapping organization of 
astrocytes, there is significant inter-astrocyte communication via a  ‘glial 
syncytium’ which creates an integrated functional unit capable of distributing 
energy substrates, metabolites, and second messengers widely (Scemes and 
Spray, 2004). This may be particularly important since astrocytes are a 
heterogeneous population [for a detailed review see (Hewett, 2009; Zhang and 
Barres, 2010)]  and extensive coupling likely fosters coordinated responses over 
long distances. 
Further, astrocytes participate in gliotransmission via the release of 
neurotransmitters such as glutamate and other neuromodulators (Nedergaard, 
1994; Parpura et al., 1994; Haydon, 2001) enabling bidirectional communication 
between neurons and astrocytes. This spatial and functional association of the 
pre- and post-synaptic neurons and the astrocyte processes ensheathing the 
synapse is referred to as the tripartite synapse (Halassa et al., 2007a). Important 
in this respect is the finding that a single astrocyte contacts 300-600 neuronal 
dendrites (Halassa et al., 2007b) and that its foot processes can ensheath up to 
100,000 synapses (Bushong et al., 2002; Ogata and Kosaka, 2002). This 
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structural organization perfectly positions the astrocyte to activate neighboring 
neurons and influence neurotransmission  (Nedergaard, 1994; Parpura et al., 
1994).  
In addition to releasing glutamate, astrocytes remove glutamate from 
synaptic and extra-synaptic spaces to reduce the probability of excitotoxic 
neuronal injury. Glutamate is converted to glutamine, by astrocytic glutamine 
synthetase (Norenberg and Martinez-Hernandez, 1979) prior to being shuttled to 
neurons for the re-synthesis of the neurotransmitter glutamate (Danbolt, 2001). In 
a similar vein, as discussed earlier astrocytes synthesize and export the 
antioxidant molecule glutathione which is broken down extracellularly and utilized 
by neurons and glia for cellular antioxidant defense.  The protective capacity of 
astrocytes is remarkable --   with only a small number of astrocytes (<1 % of total 
cell number) required to protect neurons against an oxidative stress-mediated 
injury in mixed neuron-glia co-cultures (Shih et al., 2003). Additionally, the ability 
of astrocytes to support and maintain neuron health may be attributed to the 
ability of the astrocyte to release numerous growth factors such as NGF, BDNF, 
PDGF, and more (Raff et al., 1988; Rudge, 1993). 
Despite the important homeostatic functions of astrocytes in the 
developing brain and in the repair of an injured CNS, astrocytic responses can 
also promote injury. In particular, astrocytes can be activated by glutamate or 
inflammatory mediators to induce expression and/or release factors that may 
participate in neuronal injury and/or neurodegeneration. Two mediators include 
COX2 and NOS2 which have the potential to contribute to neuronal and/or glial 
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injury (Galea et al., 1992; Simmons and Murphy, 1992; Hewett et al., 1993; 
Molina-Holgado et al., 2000; Maragakis and Rothstein, 2006).  
Results from this dissertation extend the role of astrocytes in both 
cytotoxicity and neuroprotection. Microarray data shows that a 24 h exposure of 
human fetal astrocytes to 10 ng/ml IL-1β alters the expression of approximately 
1400 genes (John et al., 2005). The alterations in astrocyte gene expression in 
response to IL-1β may be beneficial or deleterious depending on features such 
as the concentration, timing, and longevity of release (i.e., acute or chronic 
enhancement in expression), and the specific cell-type activated. 
 
6.3  Working model for contributions of system xc
- to injury and 
protection (Figure 6.1) 
System xc
- functions to exchange intracellular glutamate for extracellular 
cystine. Under physiological conditions, the activity of the transporter does not 
facilitate the toxic accumulation of glutamate (Baker et al., 2002c; Augustin et al., 
2007; Featherstone and Shippy, 2008; Massie et al., 2010b; De Bundel et al., 
2011), but rather contributes to basal extracellular glutamate levels and regulates 
intracellular GSH levels. However, when glutamate uptake is impaired, as it is 
under hypoxic conditions the increased activity of system xc
- via its regulation by 
the cytokine IL-1β results in the accumulation of extracellular glutamate and 
subsequent excitotoxic neuronal cell death (Fogal et al., 2007). Our laboratory 
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postulates that similar alterations in system xc
- activity may contribute to neuronal 
injury in vivo following cerebral ischemia in response to the upregulation of IL-1β.  
To our surprise, system xc
- also contributes to excitotoxic neuronal injury 
under hypoglycemic conditions in the absence of a detectable impairment in 
glutamate uptake. Further, IL-1β is not required for this toxicity. Thus, it appears 
that basal levels of glutamate released via system xc
- are sufficient to initiate 
injury when the energy substrate glucose is unavailable. What remains to be 
elucidated is precisely how system xc
- can release sufficient quantities of 
glutamate that are capable of overwhelming functional glutamate reuptake 
transporters.  
Finally, we have demonstrated that increased transporter activity in mixed 
cultures under normoxic and normoglycemic conditions does not produce 
neuronal injury (Fogal et al., 2005a). In fact, in pure astrocytes the enhancement 
of transporter activity induced by IL-1β actually increases synthesis and export of 
GSH, producing a net accumulation in extracellular GSH that is associated with 
neuroprotection.  
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Figure 6.1 Consequences of system xc
- activity under physiological and 
pathophysiological conditions. Under physiological conditions (normoxia and 
normoglycemia; left panel), cystine transported into the cell via system xc
- is 
rapidly reduced and incorporated into GSH. IL-1β enhances the activity of the 
transporter, which results in increased delivery of the rate-limiting substrate for 
GSH synthesis and enhanced export of GSH into the extracellular space which 
can protect pure astrocytes and mixed cortical cultures against tBOOH-mediated 
toxicity. Under hypoxic conditions (middle panel), upregulation of system xc
- by 
IL-1β enhances the delivery of glutamate to the extracellular space. Hypoxia also 
impairs EAAT/ system XAG
- function leading to the net accumulation of glutamate 
in the extracellular space which results in excitotoxic neuronal cell death. 
Importantly, system xc
- does not contribute to pure hypoxic neuronal injury (i.e. 
neuronal cell death occurring under hypoxic conditions in the absence of IL-1β). 
In contrast, under hypoglycemic conditions (right panel), the activity of system xc
- 
expels glutamate into the extracellular space which initiates processes (currently 
uncharacterized) that lead to the accumulation of extracellular glutamate. The 
precise mechanism by which hypoglycemic neuronal injury occurs remains to be 
elucidated, but neuronal cell death occurs independently of alterations in EAAT/ 
system xAG
- activity and synaptically-derived neuronal glutamate. [Based on 
results described herein as well as those found in (Fogal et al., 2005a; Fogal et 
al., 2007).     
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6.4  Hypoglycemic neuronal injury in the presence of competent 
glutamate reuptake 
What remains to be determined is precisely how system xc
- induces 
neuronal injury in the absence of impaired glutamate uptake as assessed via 3H-
D-aspartate uptake. This finding is consistent with the literature (Swanson and 
Benington, 1996; Bakken et al., 1998), and estimates of glutamate reuptake 
transporter expression suggest that 2,500 – 10,000 transporters per µm3 are 
expressed in the brain (Bergles and Jahr, 1997; Lehre and Danbolt, 1998). 
These high-affinity, highly expressed glutamate transporters should be able to 
efficiently remove the glutamate that is fluxed through system xc
-,  especially 
given the fact that glutamate transporters could theoretically reduce extracellular 
glutamate to a concentration of ≈2 nM (Zerangue and Kavanaugh, 1996; Cavelier 
et al., 2005). Based on studies by Wyatt and colleagues, heteroexchange via 
system xc
- is predicted to increase extracellular glutamate at a maximal rate of 
0.6 µM/s (Cavelier et al., 2005), which is critically dependent on extracellular 
cystine concentrations, the levels of which are disputed [estimates range from 
0.13 µM reported in the nucleus accumbens (Baker et al., 2003), to 100-200 µM 
which is routinely used in tissue culture studies (Murphy et al., 1989; Fogal et al., 
2005a; Fogal et al., 2007; Jackman et al., 2010)].  This begs the question are 
there additional cellular sources of glutamate that contribute to injury or are the 
techniques employed in our study not sensitive enough to detect changes in 
glutamate uptake?  
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As mentioned previously, in vivo deafferentation experiments and in vitro 
studies utilizing tetanus toxin implicate neuronal release of glutamate as 
contributory to hypoglycemic neuronal injury (Wieloch et al., 1985; Monyer et al., 
1992). Yet in our hands, a concentration of tetanus toxin (300 ng/ml) that cleaves 
neuronal synaptobrevin-2 and blocks depolarization-induced glutamate release 
(Taylor and Hewett, 2002; Fogal et al., 2005b) — fails to attenuate neuronal 
injury in this paradigm (Figure 3.1D). Further experimentation revealed that when 
3 µg/ ml tetanus toxin (the highest concentration utilized by Monyer and 
colleagues) was applied to our mixed cultures one day prior to glucose 
deprivation there was some protection (15% neuronal protection), but it does not 
recapitulate the robust finding of 40% neuronal protection reported in their 
studies (Monyer et al., 1992). It suggests that there is a small contribution of 
neuronally-derived glutamate to injury, yet still leaves room to consider additional 
mechanisms of astrocytic glutamate release as participatory in hypoglycemic 
neuronal cell death. 
 
6.5 Future Directions 
Logical future directions include elucidation of the molecular mechanisms 
by which IL-1β regulates system xc
- in astrocytes and to determine whether PKA 
and PKC are involved in this process. Clearly, the finding that NF-κB inhibitors 
enhance the expression of xCT mRNA is intriguing and deserves further 
attention. Similarly, Nrf2, a known regulator of astrocytic xCT and other 
antioxidant molecules (Sasaki et al., 2002; Lewerenz et al., 2009b), that requires 
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PKC-mediated phosphorylation for activation (Huang et al., 2002; Numazawa et 
al., 2003) should be examined closely as a candidate transcription factor 
regulating the processes described herein. 
Macroscopically, the biological relevance of this transporter to pathology in 
the entire organism needs to be evaluated. As such, in vivo studies should be 
carried out to characterize the role of energy deprivation-induced injury in sut/sut 
mice following middle cerebral artery occlusion (MCAO) as a model of cerebral 
ischemia and determine whether insulin-induced hypoglycemia in sut/sut mice 
recapitulates the in vitro hypoglycemia findings. In vivo oxidative stress models 
should be utilized to determine whether IL-1β can enhance GSH and/or confer 
protection in vivo. However, discrepancies between in vivo and in vitro findings 
may arise because animals have compensatory mechanisms which allow them 
to thrive, whereas in vitro preparations require functional system xc
- activity or a 
reducing agent such as β-ME for survival. For example, one might hypothesize 
that the loss of system xc
- function would render animals more sensitive to 
neuronal injury following MCAO due to reduced GSH levels. In fact, preliminary 
data suggests the opposite and sut/sut mice appear to be protected against 
ischemic injury (Figure 6.2). Interestingly, xCT-null mice do not have reduced 
tissue GSH levels (Sato et al., 2005; Massie et al., 2010b; De Bundel et al., 
2011), although plasma GSH levels are reduced (Sato et al., 2005). Moreover, 
recent work by Massie and colleagues demonstrates that the loss of system xc
- 
does not decrease striatal or hippocampal GSH levels and actually protects 
neurons against 6-hydroxydopamine-induced injury and elevates the threshold 
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for limbic seizures induced by intravenous infusion of kainate (an ionotropic 
kainate glutamate receptor agonist) and pilocarpine (a muscarinic cholinergic 
receptor agonist) or intraperitoneal administration of NMDA (an ionotropic 
glutamate receptor agonist) in mutant mice (Massie et al., 2010b; De Bundel et 
al., 2011). This paradoxical finding is attributed to the decrease in glutamate 
release via system xc
-, a mechanism that would also produce protection in the 
setting of ischemia.  
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6.6 System xc
- as a therapeutic target 
 System xc
- is an important biological transporter that has already been 
utilized as a therapeutic target in the clinics. Sulfasalazine is a system xc
- inhibitor 
utilized for the treatment of inflammatory bowel diseases including Crohn’s 
disease and ulcerative colitis, and rheumatoid arthritis (Linares et al., 2011). In 
the immune system, the proliferation of T cells is regulated by antigen-presenting 
cells such as dendritic cells and macrophages via the availability of the amino 
acid cysteine (Gmunder et al., 1990; Angelini et al., 2002) because T cells lack 
system xc
- (Bannai, 1984b; Gmunder et al., 1991). Hence, reducing cysteine 
delivery to T cells by inhibiting system xc
- might be a useful strategy to limit 
lymphocyte activation and related pathology in T-cell mediated autoimmune 
diseases. Further, sulfasalazine and other system xc
- inhibitors show promise as 
adjuvant chemotherapeutics in certain cancers, including gliomas (Chung et al., 
2005; Lo et al., 2008; Savaskan et al., 2008; Chung and Sontheimer, 2009; 
Pham et al., 2010). Whether inhibition of system xc
- can limit excitotoxic neuronal 
degeneration in humans remains to be ascertained, but preliminary experiments 
in a model of experimental ischemia seem promising (see section 5.5) especially 
in light of the findings that brain GSH levels are not compromised by loss of 
system xc
- function in vivo (Massie et al., 2010b; De Bundel et al., 2011).   
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6.7 Overall significance 
 Neuroinflammation is a feature of a variety of neurological diseases and 
disorders. While traditional views asserting that inflammation and the 
inflammatory mediator IL-1β contribute to disease pathology in the CNS are 
recapitulated in our model of inflammatory hypoxic neuronal injury, the data 
contained in this dissertation demonstrate that IL-1β promotes GSH synthesis 
and export which serves to protect both neurons and astrocytes against oxidative 
injury.  Understanding the regulation of system xc
- by IL-1β could help to devise 
strategies to harness the beneficial effects of system xc
- to increase intracellular 
GSH, and when appropriate, to reduce its activity to decrease the probability of 
excitotoxic neuronal injury. Knowledge of the mechanisms by which one can 
modulate system xc
- activity and the resultant effects on neural physiology and 
pathophysiology will continue to inform researchers and clinicians of the diverse 
contributions of astrocytes and inflammation to health and disease states and 
may guide the design of novel therapies that target astrocytes rather than 
neurons.   
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Supplemental Figure A1. Sut/sut astrocytes require β-
mercaptoethanol (β-ME) to support growth. Primary astrocyte 
cultures were prepared from sut/sut mice as described in the methods. 
One half of the cells were cultured in astrocyte plating media that was 
supplemented with β-ME (55 µM), whereas the other half received 
standard astrocyte plating media. Cells were incubated for eight (A) or 
fifteen (B) days, after which MTT (3 ng/ml in PBS) was added to the 
wells to assess cell viability (as described in section 4.3.7). Cell viability 
was normalized to acidifed isopropanol alone (defined as 0 % cell 
viability). n = 12. 
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Supplemental Figure A2. Hypoxic neuronal cell death is reduced in 
cultures containing sut/sut astrocytes derived from single pup 
dissections. Chimeric mixed cortical cell cultures were obtained by 
plating WT neurons on astrocytes derived from sut/sut mice (black bars). 
These and control cultures (WT neurons on WT astrocytes; white bars) 
were treated with 3 ng/ml IL-1β or vehicle for 20-24 hr, washed, and then 
deprived of oxygen for 4-5 hr. The percentage of total neuronal cell 
death was determined 20-24 hr later (n =6-9). An asterisk (*) indicates a 
significant within-group difference, while a pound (#) sign indicates a 
significant between-group difference as determined by a two-way 
ANOVA followed by Bonferroni’s post hoc test. Significance was set at p 
< 0.05. 
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Supplemental Figure A3. Additional evidence that NF-κB may 
negatively regulate xCT expression. Astrocytes (n=2) were incubated 
with various concentrations of the NF-κB inhibitor, PDTC for 1 hour after 
which  IL-1β or vehicle was added for 6 hr then xCT mRNA assessed via 
qPCR. Data are expressed as mean ± SEM fold change in xCT mRNA 
compared to IL-1β-treated  cells (set at 1).   
157 
 
References 
Albrecht PJ, Dahl JP, Stoltzfus OK, Levenson R, Levison SW (2002) Ciliary 
neurotrophic factor activates spinal cord astrocytes, stimulating their 
production and release of fibroblast growth factor-2, to increase motor 
neuron survival. Exp Neurol 173:46-62. 
Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat 
Rev Immunol 5:629-640. 
Andre R, Moggs JG, Kimber I, Rothwell NJ, Pinteaux E (2006) Gene regulation 
by IL-1beta independent of IL-1R1 in the mouse brain. Glia 53:477-483. 
Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A (2004) 
Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: 
Implications for inflammatory processes. Proc Natl Acad Sci U S A 
101:9745-9750. 
Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, Clarke F, 
Sitia R, Rubartelli A (2002) Antigen-presenting dendritic cells provide the 
reducing extracellular microenvironment required for T lymphocyte 
activation. Proc Natl Acad Sci U S A 99:1491-1496. 
Antras-Ferry J, Maheo K, Morel F, Guillouzo A, Cillard P, Cillard J (1997) 
Dexamethasone differently modulates TNF-alpha- and IL-1beta-induced 
transcription of the hepatic Mn-superoxide dismutase gene. FEBS Lett 
403:100-104. 
Araque A, Parpura V, Sanzgiri RP, Haydon PG (1998) Glutamate-dependent 
astrocyte modulation of synaptic transmission between cultured 
hippocampal neurons. Eur J Neurosci 10:2129-2142. 
Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of 
cytokines. Immunol Rev 223:20-38. 
Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP (2001) TNF 
alpha promotes proliferation of oligodendrocyte progenitors and 
remyelination. Nat Neurosci 4:1116-1122. 
Auer RN, Wieloch T, Olsson Y, Siesjo BK (1984) The distribution of 
hypoglycemic brain damage. Acta Neuropathol 64:177-191. 
158 
 
Augustin H, Grosjean Y, Chen K, Featherstone DE (2007) Nonvesicular release 
of glutamate by glial xCT transporters suppresses glutamate receptor 
clustering in vivo. J Neurosci 27:111-123. 
Avital A, Goshen I, Kamsler A, Segal M, Iverfeldt K, Richter-Levin G, Yirmiya R 
(2003) Impaired interleukin-1 signaling is associated with deficits in 
hippocampal memory processes and neural plasticity. Hippocampus 
13:826-834. 
Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ (1998) Maturation-dependent 
vulnerability of oligodendrocytes to oxidative stress-induced death caused 
by glutathione depletion. J Neurosci 18:6241-6253. 
Backus KH, Kettenmann H, Schachner M (1989) Pharmacological 
characterization of the glutamate receptor in cultured astrocytes. J 
Neurosci Res 22:274-282. 
Baker DA, Shen H, Kalivas PW (2002a) Cystine/glutamate exchange serves as 
the source for extracellular glutamate: modifications by repeated cocaine 
administration. Amino Acids 23:161-162. 
Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW (2002b) The origin and 
neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22:9134-
9141. 
Baker DA, Xi Z, Shen H, Swanson CJ, Kalivas PW (2002c) The origin and 
neuronal function of in vivo nonsynaptic glutamate. J Neurosci 22:9134-
9141. 
Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, 
Raju I (2008) Contribution of cystine-glutamate antiporters to the 
psychotomimetic effects of phencyclidine. Neuropsychopharmacology 
33:1760-1772. 
Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW 
(2003) Neuroadaptations in cystine-glutamate exchange underlie cocaine 
relapse. Nat Neurosci 6:743-749. 
Bakken IJ, White LR, Unsgard G, Aasly J, Sonnewald U (1998) [U-
13C]glutamate metabolism in astrocytes during hypoglycemia and 
hypoxia. J Neurosci Res 51:636-645. 
159 
 
Bannai S (1984a) Induction of cystine and glutamate transport activity in human 
fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem 
259:2435-2440. 
Bannai S (1984b) Transport of cystine and cysteine in mammalian cells. Biochim 
Biophys Acta 779:289-306. 
Bannai S (1986) Exchange of cystine and glutamate across plasma membrane of 
human fibroblasts. J Biol Chem 261:2256-2263. 
Bannai S, Kitamura E (1980) Transport interaction of L-cystine and L-glutamate 
in human diploid fibroblasts in culture. J Biol Chem 255:2372-2376. 
Bannai S, Kitamura E (1982) Adaptive enhancement of cystine and glutamate 
uptake in human diploid fibroblasts in culture. Biochim Biophys Acta 
721:1-10. 
Bannai S, Tateishi N (1986) Role of membrane transport in metabolism and 
function of glutathione in mammals. J Membr 89:1-8. 
Bannai S, Sato H, Ishii T, Sugita Y (1989) Induction of cystine transport activity in 
human fibroblasts by oxygen. J Biol Chem 264:18480-18484. 
Barger SW, Basile AS (2001) Activation of microglia by secreted amyloid 
precursor protein evokes release of glutamate by cystine exchange and 
attenuates synaptic function. J Neurochem 76:846-854. 
Barger SW, Goodwin ME, Porter MM, Beggs ML (2007) Glutamate release from 
activated microglia requires the oxidative burst and lipid peroxidation. J 
Neurochem 101:1205-1213. 
Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martín R, Zorzano A, 
Borsani G, Palacín M (2001) Identification and characterisation of human 
xCT that co-expresses, with 4F2 heavy chain, the amino acid transport 
activity system xc
-. Pflugers Arch 442:286-296. 
Basu A, Krady JK, Levison SW (2004) Interleukin-1: A master regulator of 
neuroinflammation. J Neurosci Res 78:151-156. 
Basu A, Lazovic J, Krady JK, Mauger DT, Rothstein RP, Smith MB, Levison SW 
(2005) Interleukin-1 and the interleukin-1 type 1 receptor are essential for 
the progressive neurodegeneration that ensues subsequent to a mild 
hypoxic/ischemic injury. J Cereb Blood Flow Metab 25:17-29. 
160 
 
Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J (2000) 
Extracellular glutamate and other metabolites in and around RG2 rat 
glioma: an intracerebral microdialysis study. J Neurooncol 47:11-22. 
Bellinger FP, Madamba S, Siggins GR (1993) Interleukin 1 beta inhibits synaptic 
strength and long-term potentiation in the rat CA1 hippocampus. Brain 
Res 628:227-234. 
Bender AS, Reichelt W, Norenberg MD (2000) Characterization of cystine uptake 
in cultured astrocytes. Neurochem Int 37:269-276. 
Benveniste H, Huttemeier PC (1990) Microdialysis--theory and application. Prog 
Neurobiol 35:195-215. 
Bergles DE, Jahr CE (1997) Synaptic activation of glutamate transporters in 
hippocampal astrocytes. Neuron 19:1297-1308. 
Bergsbaken T, Fink SL, Cookson BT (2009) Pyroptosis: host cell death and 
inflammation. Nat Rev Microbiol 7:99-109. 
Bernardino L, Xapelli S, Silva AP, Jakobsen B, Poulsen FR, Oliveira CR, Vezzani 
A, Malva JO, Zimmer J (2005) Modulator effects of interleukin-1beta and 
tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse 
organotypic hippocampal slice cultures. J Neurosci 25:6734-6744. 
Betz AL, Yang GY, Davidson BL (1995) Attenuation of stroke size in rats using 
an adenoviral vector to induce overexpression of interleukin-1 receptor 
antagonist in brain. J Cereb Blood Flow Metab 15:547-551. 
Bezzi P, Carmignoto G, Pasti L, Vesce S, Rossi D, Rizzini BL, Pozzan T, Volterra 
A (1998) Prostaglandins stimulate calcium-dependent glutamate release 
in astrocytes. Nature 391:281-285. 
Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, Park DS, MacPherson S, 
Barker PA (2002) Constitutive nuclear factor-kappa B activity is required 
for central neuron survival. J Neurosci 22:8466-8475. 
Bianco F, Pravettoni E, Colombo A, Schenk U, Moller T, Matteoli M, Verderio C 
(2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta 
release from microglia. J Immunol 174:7268-7277. 
161 
 
Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ (2001) Role 
of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 21:5528-
5534. 
Brennan CM, Steitz JA (2001) HuR and mRNA stability. Cell Mol Life Sci 58:266-
277. 
Brewer GJ, Torricelli JR, Evege EK, Price PJ (1993) Optimized survival of 
hippocampal neurons in B27-supplemented Neurobasal, a new serum free 
medium combination. J Neurosci Red 35:567-576. 
Bridges C, Kekuda R, Wang H, Prasad P, Mehta P, Huang W, Smith S, 
Ganapathy V (2001) Structure, function, and regulation of human 
cystine/glutamate transporter in retinal pigment epithelial cells. Invest 
Ophthalmol Vis Sci 42:47-54. 
Bridges CC, Hu H, Miyauchi S, Siddaramappa UN, Ganapathy ME, Ignatowicz L, 
Maddox DM, Smith SB, Ganapathy V (2004) Induction of cystine-
glutamate transporter xc- by human immunodeficiency virus type 1 
transactivator protein tat in retinal pigment epithelium. Invest Ophthalmol 
Vis Sci 45:2906-2914. 
Brikos C, Wait R, Begum S, O'Neill LA, Saklatvala J (2007) Mass spectrometric 
analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling 
complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-
4 as the stable components. Mol Cell Proteomics 6:1551-1559. 
Brissoni B, Agostini L, Kropf M, Martinon F, Swoboda V, Lippens S, Everett H, 
Aebi N, Janssens S, Meylan E, Felberbaum-Corti M, Hirling H, Gruenberg 
J, Tschopp J, Burns K (2006) Intracellular trafficking of interleukin-1 
receptor I requires Tollip. Curr Biol 16:2265-2270. 
Brough D, Rothwell NJ (2007) Caspase-1-dependent processing of pro-
interleukin-1beta is cytosolic and precedes cell death. J Cell Sci 120:772-
781. 
Burdo J, Dargusch R, Schubert D (2006) Distribution of the cystine/glutamate 
antiporter system xc- in the brain, kidney, and duodenum. J Histochem 
Cytochem 54:549-557. 
Burger PM, Mehl E, Cameron PL, Maycox PR, Baumert M, Lottspeich F, De 
Camilli P, Jahn R (1989) Synaptic vesicles immunoisolated from rat 
cerebral cortex contain high levels of glutamate. Neuron 3:715-720. 
162 
 
Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplasmic 
astrocytes in CA1 stratum radiatum occupy separate anatomical domains. 
J Neurosci 22:183-192. 
Buttini M, Sauter A, Boddeke HW (1994) Induction of interleukin-1 beta mRNA 
after focal cerebral ischemia in the rat. Brain Res Mol Brain Res 23:126-
134. 
Camacho A, Massieu L (2006) Role of glutamate transporters in the clearance 
and release of glutamate during ischemia and its relation to neuronal 
death. Arch Med Res 37:11-18. 
Carroll TP, Greene CM, Taggart CC, McElvaney NG, O'Neill SJ (2005) 
Interleukin-1, neutrophil elastase, and lipopolysaccharide: Key pro-
inflammatory stimuli regulating inflammation in cystic fibrosis. Current 
Respiratory Medicine Reviews 1:43-67. 
Cataldo AM, Broadwell RD (1986) Cytochemical identification of cerebral 
glycogen and glucose-6-phosphatase activity under normal and 
experimental conditions. I. Neurons and glia. J Elec Micro Techn 3:413-
437. 
Cavelier P, Attwell D (2005) Tonic release of glutamate by a DIDS-sensitive 
mechanism in rat hippocampal slices. J Physiol 564:397-410. 
Cavelier P, Hamann M, Rossi D, Mobbs P, Attwell D (2005) Tonic excitation and 
inhibition of neurons: ambient transmitter sources and computational 
consequences. Prog Biophys Mol Biol 87:3-16. 
Chan PH, Chu L, Chen S (1990) Effects of MK-801 on glutamate-induced 
swelling of astrocytes in primary cell culture. J Neurosci Res 25:87-93. 
Chang JW, Young DA, Coleman PD, O'Banion MK (2001) Two-dimensional gel 
analysis of secreted proteins induced by interleukin-1 beta in rat 
astrocytes. Neurochem Int 39:349-359. 
Chen Y, Vartiainen NE, Ying W, Chan PH, Koistinaho J, Swanson RA (2001) 
Astrocytes protect neurons from nitric oxide toxicity by a glutathione-
dependent mechanism. J Neurochem 77:1601-1610. 
Cherrington NJ, Slitt AL, Li N, Klaassen CD (2004) Lipopolysaccharide-mediated 
regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 
32:734-741. 
163 
 
Chillaron J, Roca R, Valencia A, Zorzano A, Palacin M (2001) Heteromeric amino 
acid transporters: biochemistry, genetics, and physiology. Am J Physiol 
Renal Physiol 281:F995-1018. 
Chintala S, Li W, Lamoreux ML, Ito S, Wakamatsu K, Sviderskaya EV, Bennett 
DC, Park YM, Gahl WA, Huizing M, Spritz RA, Ben S, Novak EK, Tan J, 
Swank RT (2005) Slc7a11 gene controls production of pheomelanin 
pigment and proliferation of cultured cells. PNAS USA 102:10964-10969. 
Cho Y, Bannai S (1990) Uptake of glutamate and cysteine in C-6 glioma cells 
and in cultured astrocytes. J Neurochem 55:2091-2097. 
Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. 
Neuron 1:623-634. 
Choi DW (1992) Excitotoxic cell death. J Neurobiol 23:1261-1276. 
Choi IY, Lee SP, Kim SG, Gruetter R (2001) In vivo measurements of brain 
glucose transport using the reversible Michaelis-Menten model and 
simultaneous measurements of cerebral blood flow changes during 
hypoglycemia. J Cereb Blood Flow Metab 21:653-663. 
Choi JW, Shin CY, Choi MS, Yoon SY, Ryu JH, Lee JC, Kim WK, El Kouni MH, 
Ko KH (2008) Uridine protects cortical neurons from glucose deprivation-
induced death: possible role of uridine phosphorylase. J Neurotrauma 
25:695-707. 
Chung WJ, Sontheimer H (2009) Sulfasalazine inhibits the growth of primary 
brain tumors independent of nuclear factor-kappaB. J Neurochem 
110:182-193. 
Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, 
Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of 
primary brain tumors. J Neurosci 25:7101-7110. 
Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M 
(2010) P2X7-dependent release of interleukin-1beta and nociception in 
the spinal cord following lipopolysaccharide. J Neurosci 30:573-582. 
Clements JD, Lester RA, Tong G, Jahr CE, Westbrook GL (1992) The time 
course of glutamate in the synaptic cleft. Science 258:1498-1501. 
164 
 
Colotta F, Dower SK, Sims JE, Mantovani A (1994) The type II 'decoy' receptor: 
a novel regulatory pathway for interleukin 1. Immunol Today 15:562-566. 
Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, 
Sims JE, Mantovani A (1993) Interleukin-1 type II receptor: a decoy target 
for IL-1 that is regulated by IL-4. Science 261:472-475. 
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate 
receptors. Annu Rev Pharmacol Toxicol 37:205-237. 
Coogan AN, O'Neill LA, O'Connor JJ (1999) The P38 mitogen-activated protein 
kinase inhibitor SB203580 antagonizes the inhibitory effects of interleukin-
1beta on long-term potentiation in the rat dentate gyrus in vitro. 
Neuroscience 93:57-69. 
Cornford EM, Braun LD, Crane PD, Oldendorf WH (1978) Blood-brain barrier 
restriction of peptides and the low uptake of enkephalins. Endocrinology 
103:1297-1303. 
Cunningham AJ, Murray CA, O'Neill LA, Lynch MA, O'Connor JJ (1996) 
Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit 
long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 
203:17-20. 
Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105. 
Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced 
sickness behavior. Brain Behav Immun 21:153-160. 
Davies CA, Loddick SA, Toulmond S, Stroemer RP, Hunt J, Rothwell NJ (1999) 
The progression and topographic distribution of interleukin-1beta 
expression after permanent middle cerebral artery occlusion in the rat. J 
Cereb Blood Flow Metab 19:87-98. 
De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, 
Vermoesen K, Bannai S, Sato H, Michotte Y, Smolders I, Massie A (2011) 
Loss of System xFormula Does Not Induce Oxidative Stress But 
Decreases Extracellular Glutamate in Hippocampus and Influences 
Spatial Working Memory and Limbic Seizure Susceptibility. J Neurosci 
31:5792-5803. 
Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 
257:L163-173. 
165 
 
Desagher S, Glowinski J, Premont J (1996) Astrocytes protect neurons from 
hydrogen peroxide toxicity. J Neurosci 16:2553-2562. 
Dinarello CA (1988) Interleukin-1. Ann N Y Acad Sci 546:122-132. 
Dinarello CA (1991) Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-
1652. 
Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 
receptor antagonist. Int Rev Immunol 16:457-499. 
Dinarello CA (2004) Infection, fever, and exogenous and endogenous pyrogens: 
some concepts have changed. J Endotoxin Res 10:201-222. 
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-
1 family. Annu Rev Immunol 27:519-550. 
Dinarello CA, Gatti S, Bartfai T (1999) Fever: links with an ancient receptor. Curr 
Biol 9:R147-150. 
Dingledine R, McBain CJ (1999) Glutamate and Aspartate. In: Basic 
Neurochemistry: Molecular, Cellular and Medical Aspects, 6th Edition 
(Siegel GJ, Agranoff BW, Albers RWea, eds). Philadelphia: Lippincott-
Raven. 
Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor 
ion channels. Pharmacol Rev 51:7-61. 
Doerre S, Corley RB (1999) Constitutive nuclear translocation of NF-kappa B in 
B cells in the absence of I kappa B degradation. J Immunol 163:269-277. 
Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK (2006) Serum IL-1beta, 
IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 
2006:59206. 
Domercq M, Sánchez-Gómez MV, Sherwin C, Etxebarria E, Fern R, Matute C 
(2007) System xc- and glutamate transporter inhibition mediates microglial 
toxicity to oligodendrocytes. J Immunol 178:6549-6556. 
Dringen R (2000) Metabolism and functions of glutathione in brain. Progress in 
Neurobiology 62:649-671. 
166 
 
Dringen R, Hamprecht B (1998) Glutathione restoration as indicator for cellular 
metabolism of astroglial cells. Dev Neurosci 20:401-407. 
Dringen R, Kussmaul L, Hamprecht B (1998) Rapid clearance of tertiary butyl 
hydroperoxide by cultured astroglial cells via oxidation of glutathione. Glia 
23:139-145. 
Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant 
glutathione in neurons: Supply by astrocytes of CysGly as precursor for 
neuronal glutathione. J Neurosci 19:562-569. 
Dringen R, Kranich O, Loschmann PA, Hamprecht B (1997) Use of dipeptides for 
the synthesis of glutathione by astroglia-rich primary cultures. J 
Neurochem 69:868-874. 
Dringen R, Gutterer JM, Gros C, Hirrlinger J (2001) Aminopeptidase N mediates 
the utilization of the GSH precursor CysGly by cultured neurons. J 
Neurosci Res 66:1003-1008. 
Duan S, Anderson CM, Keung EC, Chen Y, Chen Y, Swanson RA (2003) P2X7 
receptor-mediated release of excitatory amino acids from astrocytes. J 
Neurosci 23:1320-1328. 
Dun Y, Mysona B, Van Ells T, Amarnath L, Ola MS, Ganapathy V, Smith SB 
(2006) Expression of the cystine-glutamate exchanger (xc-) in retinal 
ganglion cells and regulation by nitric oxide and oxidative stress. Cell 
Tissue Res 324:189-202. 
Dunne A, O'Neill LA (2003) The interleukin-1 receptor / Toll-like receptor 
superfamily: signal transduction during inflammation and host defense. Sci 
STKE 171:re3. 
Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, Tyrrell PJ 
(2005) A randomised phase II study of interleukin-1 receptor antagonist in 
acute stroke patients. J Neurol Neurosurg Psychiatry 76:1366-1372. 
Fagan AM, Gage FH (1990) Cholinergic sprouting in the hippocampus: a 
proposed role for IL-1. Exp Neurol 110:105-120. 
Featherstone DE, Shippy SA (2008) Regulation of synaptic transmission by 
ambient extracellular glutamate. Neuroscientist 14:171-181. 
167 
 
Fogal B, Hewett SJ (2008) Interleukin-1β: a bridge between inflammation and 
excitotoxicity? J Neurochem 106:1-23. 
Fogal B, Hewett JA, Hewett SJ (2005a) Interleukin-1beta potentiates neuronal 
injury in a variety of injury models involving energy deprivation. J 
Neuroimmunol 161:93-100. 
Fogal B, Trettel J, Uliasz TF, Levine ES, Hewett SJ (2005b) Changes in 
secondary glutamate release underlie the developmental regulation of 
excitotoxic neuronal cell death. Neuroscience 132:929-942. 
Fogal B, Li J, Lobner D, McCullough LD, Hewett SJ (2007) System x(c)- activity 
and astrocytes are necessary for interleukin-1β-mediated hypoxic 
neuronal injury. J Neurosci 27:10094-10105. 
Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. J 
Neurochem 42:1-11. 
Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI (2008) The central role of 
glutathione in the pathophysiology of human diseases. Arch Physiol 
Biochem 113:234-258. 
Friedman WJ, Larkfors L, Ayer-LeLievre C, Ebendal T, Olson L, Persson H 
(1990) Regulation of beta-nerve growth factor expression by inflammatory 
mediators in hippocampal cultures. J Neurosci Res 27:374-382. 
Gadient RA, Cron KC, Otten U (1990) Interleukin-1 beta and tumor necrosis 
factor-alpha synergistically stimulate nerve growth factor (NGF) release 
from cultured rat astrocytes. Neurosci Lett 117:335-340. 
Galea E, Feinstein DL, Reis DJ (1992) Induction of calcium-independent nitric 
oxide synthase activity in primary rat glial cultures. Proc Natl Acad Sci U S 
A 89:10945-10949. 
Gasol E, Jiménez-Vidal M, Chillarón J, Zorzano A, Palacín M (2004) Membrane 
topology of system xc- light subunit reveals a re-entrant loop with 
substrate-restricted accessibility. J Biol Chem 279:31228-31236. 
Gegg ME, Clark JB, Heales SJR (2005) Co-culture of neurones with glutathione 
deficient astrocytes leads to increased neuronal susceptibility to nitric 
oxide and increased glutamate-cysteine ligase activity. Brain Res 1036:1-
6. 
168 
 
Ghezzi P, Dinarello CA, Bianchi M, Rosandich ME, Repine JE, White CW (1991) 
Hypoxia increases production of interleukin-1 and tumor necrosis factor by 
human mononuclear cells. Cytokine 3:189-194. 
Ghosh S, Baltimore D (1990) Activation in vitro of NF-kappa B by 
phosphorylation of its inhibitor I kappa B. Nature 344:678-682. 
Gmunder H, Eck HP, Droge W (1991) Low membrane transport activity for 
cystine in resting and mitogenically stimulated human lymphocyte 
preparations and human T cell clones. Eur J Biochem 201:113-117. 
Gmunder H, Eck HP, Benninghoff B, Roth S, Droge W (1990) Macrophages 
regulate intracellular glutathione levels of lymphocytes. Evidence for an 
immunoregulatory role of cysteine. Cell Immunol 129:32-46. 
Gochenauer GE, Robinson MB (2001) Dibutyryl-cAMP (dbcAMP) up-regulates 
astrocytic chloride-dependent L-[3H]glutamate transport and expression of 
both system xc(-) subunits. J Neurochem 78:276-286. 
Gosselin D, Rivest S (2007) Role of IL-1 and TNF in the brain: twenty years of 
progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. 
Brain Behav Immun 21:281-289. 
Gray PW, Glaister D, Chen E, Goeddel DV, Pennica D (1986) Two interleukin 1 
genes in the mouse: cloning and expression of the cDNA for murine 
interleukin 1 beta. J Immunol 137:3644-3648. 
Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G (1995) 
Molecular cloning and characterization of a second subunit of the 
interleukin 1 receptor complex. J Biol Chem 270:13757-13765. 
Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ (1989) Activation of HIV gene 
expression during monocyte differentiation by induction of NF-kappa B. 
Nature 339:70-73. 
Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW (1994) 
Microglial interleukin-1 alpha expression in human head injury: 
correlations with neuronal and neuritic beta-amyloid precursor protein 
expression. Neurosci Lett 176:133-136. 
Grosjean Y, Grillet M, Augustin H, Ferveur JF, Featherstone DE (2008) A glial 
amino-acid transporter controls synapse strength and courtship in 
Drosophila. Nat Neurosci 11:54-61. 
169 
 
Halassa MM, Fellin T, Haydon PG (2007a) The tripartite synapse: roles for 
gliotransmission in health and disease. Trends Mol Med 13:54-63. 
Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG (2007b) Synaptic islands 
defined by the territory of a single astrocyte. J Neurosci 27:6473-6477. 
Hamby ME, Uliasz TF, Hewett SJ, Hewett JA (2006a) Characterization of an 
improved procedure for the removal of microglia from confluent 
monolayers of primary astrocytes. J Neurosci Methods 150:128-137. 
Hamby ME, Uliasz TF, Hewett SJ, Hewett JA (2006b) Characterization of an 
improved procedure for the removal of microglia from confluent 
monolayers of primary astrocytes. J Neurosci Methods 150:128-137. 
Hara H, Fink K, Endres M, Friedlander RM, Gagliardini V, Yuan J, Moskowitz MA 
(1997a) Attenuation of transient focal cerebral ischemic injury in 
transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood 
Flow Metab 17:370-375. 
Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-
Sasamata M, Yuan J, Moskowitz MA (1997b) Inhibition of interleukin 
1beta converting enzyme family proteases reduces ischemic and 
excitotoxic neuronal damage. Proc Natl Acad Sci U S A 94:2007-2012. 
Haskill S, Johnson C, Eierman D, Becker S, Warren K (1988) Adherence induces 
selective mRNA expression of monocyte mediators and proto-oncogenes. 
J Immunol 140:1690-1694. 
Haydon PG (2001) GLIA: listening and talking to the synapse. Nat Rev Neurosci 
2:185-193. 
Heguy A, Baldari C, Bush K, Nagele R, Newton RC, Robb RJ, Horuk R, Telford 
JL, Melli M (1991) Internalization and nuclear localization of interleukin 1 
are not sufficient for function. Cell Growth Differ 2:311-315. 
Hemar A, Cereghini S, Cornet V, Blank V, Israel A, Greene WC, Dautry-Varsat A 
(1991) Kappa B binding proteins are constitutively expressed in an IL-2 
autocrine human T cell line. J Immunol 146:2409-2416. 
Herman MA, Jahr CE (2007) Extracellular glutamate concentration in 
hippocampal slice. J Neurosci 27:9736-9741. 
170 
 
Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, 
Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Burke JR, 
Hasan MT, Bujard H, Wirth T, Pasparakis M, Schwaninger M (2005) IKK 
mediates ischemia-induced neuronal death. Nat Med 11:1322-1329. 
Herx LM, Yong VW (2001) Interleukin-1 beta is required for the early evolution of 
reactive astrogliosis following CNS lesion. J Neuropathol Exp Neurol 
60:961-971. 
Hewett J, Hewett S, Winkler S, Pfeiffer S (1999) Inducible nitric oxide synthase 
expression in cultures enriched for mature oligodendrocytes is due to 
microglia. J Neurosci Res 57:411. 
Hewett JA (2009) Determinants of regional and local diversity within the astroglial 
lineage of the normal central nervous system. J Neurochem 110:1717-
1736. 
Hewett SJ, Corbett JA, McDaniel ML, Choi DW (1993) Interferon-gamma and 
interleukin-1 beta induce nitric oxide formation from primary mouse 
astrocytes. Neurosci Let 164:229-232. 
Hirrlinger J, Schulz JB, Dringen R (2002) Glutathione release from cultured brain 
cells: multidrug resistance protein 1 mediates the release of GSH from rat 
astroglial cells. J Neurosci Res 69:318-326. 
Hogquist KA, Unanue ER, Chaplin DD (1991) Release of IL-1 from mononuclear 
phagocytes. J Immunol 147:2181-2186. 
Hosoya KI, Tomi M, Ohtsuki S, Takanaga H, Saeki S, Kanai Y, Endou H, Naito 
M, Tsuruo T, Terasaki T (2002) Enhancement of L-cystine transport 
activity and its relation to xCT gene induction at the blood-brain barrier by 
diethyl maleate treatment. J Pharmacol Exp Ther 302:225-231. 
Howard AD, Kostura MJ, Thornberry N, Ding GJ, Limjuco G, Weidner J, Salley 
JP, Hogquist KA, Chaplin DD, Mumford RA, et al. (1991) IL-1-converting 
enzyme requires aspartic acid residues for processing of the IL-1 beta 
precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha. J 
Immunol 147:2964-2969. 
Huang HC, Nguyen T, Pickett CB (2002) Phosphorylation of Nrf2 at Ser-40 by 
protein kinase C regulates antioxidant response element-mediated 
transcription. J Biol Chem 277:42769-42774. 
171 
 
Ichijo H (1999) From receptors to stress-activated MAP kinases. Oncogene 
18:6087-6093. 
Ikemoto H, Tani E, Matsumoto T, Nakano A, Furuyama J (1995) Apoptosis of 
human glioma cells in response to calphostin C, a specific protein kinase 
C inhibitor. J Neurosurg 83:1008-1016. 
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M 
(1999) Keap1 represses nuclear activation of antioxidant responsive 
elements by Nrf2 through binding to the amino-terminal Neh2 domain. 
Genes Dev 13:76-86. 
Jabaudon D, Shimamoto K, Yasuda-Kamatani Y, Scanziani M, Gahwiler BH, 
Gerber U (1999) Inhibition of uptake unmasks rapid extracellular turnover 
of glutamate of nonvesicular origin. Proc Natl Acad Sci U S A 96:8733-
8738. 
Jackman N, Hewett SJ (2009) Interleukin-1beta regulates astrocytic system xc- 
activity and expression. J Neurochem 108:117. 
Jackman N, Hewett JA, Hewett SJ (2009) Enhanced astrocytic system xc- 
expression and activity mediate the neurotoxic effect of interleukin-1beta. 
Program No. 545.2. In: Society for  Neuroscience. Online. Chicago, IL: 
Neuroscience Meeting Planner. 
Jackman NA, Uliasz TF, Hewett JA, Hewett SJ (2010) Regulation of system 
x(c)(-)activity and expression in astrocytes by interleukin-1beta: 
implications for hypoxic neuronal injury. Glia 58:1806-1815. 
Jakel RJ, Townsend JA, Kraft AD, Johnson JA (2007) Nrf2-mediated protection 
against 6-hydroxydopamine. Brain Res 1144:192-201. 
Janssens N, Lesage AS (2001) Glutamate receptor subunit expression in primary 
neuronal and secondary glial cultures. J Neurochem 77:1457-1474. 
Jeremic A, Jeftinija K, Stevanovic J, Glavaski A, Jeftinija S (2001) ATP stimulates 
calcium-dependent glutamate release from cultured astrocytes. J 
Neurochem 77:664-675. 
Jimenez-Vidal M, Gasol E, Zorzano A, Nunes V, Palacin M, Chillaron J (2004) 
Thiol modification of cysteine 327 in the eighth transmembrane domain of 
the light subunit xCT of the heteromeric cystine/glutamate antiporter 
172 
 
suggests close proximity to the substrate binding site/permeation pathway. 
J Biol Chem 279:11214-11221. 
Jobling SA, Auron PE, Gurka G, Webb AC, McDonald B, Rosenwasser LJ, 
Gehrke L (1988) Biological activity and receptor binding of human 
prointerleukin-1 beta and subpeptides. J Biol Chem 263:16372-16378. 
John GR, Lee SC, Song X, Rivieccio M, Brosnan CF (2005) IL-1-regulated 
responses in astrocytes: relevance to injury and recovery. Glia 49:161-
176. 
Kaiser M, Mares V, Stastny F, Bubenikova-Valesova V, Lisa V, Suchomel P, 
Balcar VJ (2006) The influence of interleukin-1beta on gamma-glutamyl 
transpepidase activity in rat hippocampus. Physiol Res 55:461-465. 
Kakuda D, MacLeod C (1994) Na(+)-independent transport (uniport) of amino 
acids and glucose in mammalian cells. J Exp Biol 196:93-108. 
Kalivas PW (2009) The glutamate homeostasis hypothesis of addiction. Nat Rev 
Neurosci 10:561-572. 
Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA (1994) 
Constitutive NF-kappa B activity in neurons. Mol Cell Biol 14:3981-3992. 
Kato S, Negishi K, Mawatari K, Kuo CH (1992) A mechanism for glutamate 
toxicity in the C6 glioma cells involving inhibition of cystine uptake leading 
to glutathione depletion. Neuroscience 48:903-914. 
Kayanoki Y, Fujii J, Suzuki K, Kawata S, Matsuzawa Y, Taniguchi N (1994) 
Suppression of antioxidative enzyme expression by transforming growth 
factor-beta 1 in rat hepatocytes. J Biol Chem 269:15488-15492. 
Kim CH, Lee J, Lee JY, Roche KW (2008) Metabotropic glutamate receptors: 
phosphorylation and receptor signaling. J Neurosci Res 86:1-10. 
Kim J, Kanai Y, Chairoungdua A, Cha S, Matsuo H, Kim D, Inatomi J, Sawa H, 
Ida Y, Endou H (2001) Human cystine/glutamate transporter: cDNA 
cloning and upregulation by oxidative stress in glioma cells. Biochim 
Biophys Acta 1512:335-344. 
Kim JP, Koh JY, Choi DW (1987) L-homocysteate is a potent neurotoxin on 
cultured cortical neurons. Brain Res 437:103-110. 
173 
 
Kimelberg HK, Goderie SK, Higman S, Pang S, Waniewski RA (1990) Swelling-
induced release of glutamate, aspartate, and taurine from astrocyte 
cultures. J Neurosci 10:1583-1591. 
Klatt P, Lamas S (2000) Regulation of protein function by S-glutathiolation in 
response to oxidative and nitrosative stress. Eur J Biochem 267:4928-
4944. 
Knickelbein RG, Seres T, Lam G, Johnston RB, Warshaw JB (1997) 
Characterization of multiple cysteine and cystine transporters in rat 
alveolar type II cells. Am J Physiol 273:L1147-1155. 
Korner M, Tarantino N, Debre P (1991) Constitutive activation of NF-kB in human 
thymocytes. Biochem Biophys Res Commun 181:80-86. 
Kranich O, Hamprecht B, Dringen R (1996) Different preferences in the utilization 
of amino acids for glutathione synthesis in cultured neurons and astroglial 
cells derived from rat brain. Neurosci Let 219:211-214. 
Kranich O, Dringen R, Sandberg M, Hamprecht B (1998) Utilization of cysteine 
and cysteine precursors for the synthesis of glutathione in astroglial 
cultures: preference for cystine. Glia 22:11-18. 
Kuhlow CJ, Krady JK, Basu A, Levison SW (2003) Astrocytic ceruloplasmin 
expression, which is induced by IL-1beta and by traumatic brain injury, 
increases in the absence of the IL-1 type 1 receptor. Glia 44:76-84. 
Kussmaul L, Hamprecht B, Dringen R (1999) The detoxification of cumene 
hydroperoxide by the glutathione system of cultured astroglial cells hinges 
on hexose availability for the regeneration of NADPH. J Neurochem 
73:1246-1253. 
La Bella V, Valentino F, Piccoli T, Piccoli F (2007) Expression and developmental 
regulation of the cystine/glutamate exchanger (xc-) in the rat. Neurochem 
Res 32:1081-1090. 
Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, Eggler 
JF, Dombroski MA, Geoghegan KF, Gabel CA (2003) Glutathione s-
transferase omega 1-1 is a target of cytokine release inhibitory drugs and 
may be responsible for their effect on interleukin-1beta posttranslational 
processing. J Biol Chem 278:16567-16578. 
174 
 
Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, Martin MU 
(1998) The type II IL-1 receptor interacts with the IL-1 receptor accessory 
protein: a novel mechanism of regulation of IL-1 responsiveness. J 
Immunol 161:6871-6877. 
Langan SJ, Deary IJ, Hepburn DA, Frier BM (1991) Cumulative cognitive 
impairment following recurrent severe hypoglycaemia in adult patients with 
insulin-treated diabetes mellitus. Diabetologia 34:337-344. 
Lee G, Piquette-Miller M (2001) Influence of IL-6 on MDR and MRP-mediated 
multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 
79:876-884. 
Lee G, Piquette-Miller M (2003) Cytokines alter the expression and activity of the 
multidrug resistance transporters in human hepatoma cell lines; analysis 
using RT-PCR and cDNA microarrays. J Pharm Sci 92:2152-2163. 
Lee SR, Kim SH, Lee HW, Kim YH, Chae HD, Kim CH, Kang BM (2009) 
Increased expression of glutathione by estradiol, tumor necrosis factor-
alpha, and interleukin 1-beta in endometrial stromal cells. Am J Reprod 
Immunol 62:352-356. 
Lehre KP, Danbolt NC (1998) The number of glutamate transporter subtype 
molecules at glutamatergic synapses: chemical and stereological 
quantification in young adult rat brain. J Neurosci 18:8751-8757. 
Levison SW, Ducceschi MH, Young GM, Wood TL (1996) Acute exposure to 
CNTF in vivo induces multiple components of reactive gliosis. Exp Neurol 
141:256-268. 
Lewerenz J, Albrecht P, Tien ML, Henke N, Karumbayaram S, Kornblum HI, 
Wiedau-Pazos M, Schubert D, Maher P, Methner A (2009a) Induction of 
Nrf2 and xCT are involved in the action of the neuroprotective antibiotic 
ceftriaxone in vitro. J Neurochem. 
Lewerenz J, Albrecht P, Tien ML, Henke N, Karumbayaram S, Kornblum HI, 
Wiedau-Pazos M, Schubert D, Maher P, Methner A (2009b) Induction of 
Nrf2 and xCT are involved in the action of the neuroprotective antibiotic 
ceftriaxone in vitro. J Neurochem 111:332-343. 
Li Q, Estepa G, Memet S, Israel A, Verma IM (2000) Complete lack of NF-
kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect 
in neurulation. Genes Dev 14:1729-1733. 
175 
 
Liberto CM, Albrecht PJ, Herx LM, Yong VW, Levison SW (2004) Pro-
regenerative properties of cytokine-activated astrocytes. J Neurochem 
89:1092-1100. 
Linares V, Alonso V, Domingo JL (2011) Oxidative stress as a mechanism 
underlying sulfasalazine-induced toxicity. Expert Opin Drug Saf 10:253-
263. 
Liu HT, Tashmukhamedov BA, Inoue H, Okada Y, Sabirov RZ (2006) Roles of 
two types of anion channels in glutamate release from mouse astrocytes 
under ischemic or osmotic stress. Glia 54:343-357. 
Liu T, McDonnell P, Young P, White R, Siren AH, JM, Barone F, Feurestein G 
(1993) Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 
24:1746-1750. 
Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD (1999) Mice 
deficient in interleukin-1 converting enzyme are resistant to neonatal 
hypoxic-ischemic brain damage. J Cereb Blood Flow Metab 19:1099-
1108. 
Lo M, Wang YZ, Gout PW (2008) The x(c)- cystine/glutamate antiporter: a 
potential target for therapy of cancer and other diseases. J Cell Physiol 
215:593-602. 
Lobner D (2000) Comparison of the LDH and MTT assays for quantifying cell 
death: validity for neuronal apoptosis? J Neurosci Methods 96:147-152. 
Loddick SA, Rothwell NJ (1996) Neuroprotective effects of human recombinant 
interlekin-1 receptor antagonist in focal cerebral ischaemia in the rat. J 
Cereb Blood Flow Metab 16:932-940. 
Longuemare MC, Swanson RA (1995) Excitatory amino acid release from 
astrocytes during energy failure by reversal of sodium-dependent uptake. 
J Neurosci Res 40:379-386. 
Longuemare MC, Rose CR, Farrell K, Ransom BR, Waxman SG, Swanson RA 
(1999) K(+)-induced reversal of astrocyte glutamate uptake is limited by 
compensatory changes in intracellular Na+. Neuroscience 93:285-292. 
Lord KA, Hoffman-Liebermann B, Liebermann DA (1990) Nucleotide sequence 
and expression of a cDNA encoding MyD88, a novel myeloid 
176 
 
differentiation primary response gene induced by IL6. Oncogene 5:1095-
1097. 
Lynch MA (1998) Age-related impairment in long-term potentiation in 
hippocampus: a role for the cytokine, interleukin-1 beta? Prog Neurobiol 
56:571-589. 
Lyons SA, Kettenmann H (1998) Oligodendrocytes and microglia are selectively 
vulnerable to combined hypoxia and hypoglycemia injury in vitro. J Cereb 
Blood Flow Metab 18:521-530. 
Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine 
glutamate signaling promotes glioma cell invasion. Cancer Res 67:9463-
9471. 
MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A 
(2001) Rapid secretion of interleukin-1beta by microvesicle shedding. 
Immunity 15:825-835. 
Malaplate-Armand C, Gueguen Y, Bertrand P, Ferrari L, Batt AM (2000) U373-
MG response to interleukin-1beta-induced oxidative stress. Cell Biol 
Toxicol 16:155-163. 
Mantovani A, Muzio M, Ghezzi P, Colotta C, Introna M (1998) Regulation of 
inhibitory pathways of the interleukin-1 system. Ann N Y Acad Sci 
840:338-351. 
Maragakis NJ, Rothstein JD (2006) Mechanisms of Disease: astrocytes in 
neurodegenerative disease. Nat Clin Pract Neurol 2:679-689. 
Markiewicz I, Lukomska B (2006) The role of astrocytes in the physiology and 
pathology of the central nervous system. Acta Neurobiol Exp (Wars) 
66:343-358. 
Mason JL, Suzuki K, Chaplin DD, Matsushima GK (2001) Interleukin-1beta 
promotes repair of the CNS. J Neurosci 21:7046-7052. 
Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D, 
Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, 
Michotte Y (2010a) Dopaminergic neurons of system xc--deficient mice 
are highly protected against 6-hydroxydopamine-induced toxicity. Faseb J. 
177 
 
Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D, 
Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, 
Michotte Y (2010b) Dopaminergic neurons of system xc--deficient mice 
are highly protected against 6-hydroxydopamine-induced toxicity. Faseb J 
25:1359-1369. 
McBean GJ (2002) Cerebral cystine uptake: a tale of two transporters. Trends 
Pharmacol Sci 23:299-302. 
McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin 
CE, Wignall JM, Jenkins NA, Brannan CI, Copeland NG, Huebner K, 
Croce CM, Cannizzarro LA, Benjamin D, Dower SK, Spriggs MK, Sims JE 
(1991) A novel IL-1 receptor, cloned from B cells by mammalian 
expression, is expressed in many cell types. EMBO Journal 10:2821-
2832. 
Meeuwsen S, Persoon-Deen C, Bsibsi M, Ravid R, van Noort JM (2003) 
Cytokine, chemokine and growth factor gene profiling of cultured human 
astrocytes after exposure to proinflammatory stimuli. Glia 43:243-253. 
Meichle A, Schutze S, Hensel G, Brunsing D, Kronke M (1990) Protein kinase C-
independent activation of nuclear factor kappa B by tumor necrosis factor. 
J Biol Chem 265:8339-8343. 
Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760. 
Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of 
physiology and pathology. J Nutr 130:1007S-1015S. 
Melendez RI, Vuthiganon J, Kalivas PW (2005) Regulation of extracellular 
glutamate in the prefrontal cortex: focus on the cystine glutamate 
exchanger and group I metabotropic glutamate receptors. J Pharmacol 
Exp Ther 314:139-147. 
Miller LG, Galpern WR, Dunlap K, Dinarello CA, Turner TJ (1991) Interleukin-1 
augments gamma-aminobutyric acidA receptor function in brain. Mol 
Pharmacol 39:105-108. 
Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M (1992) Induction of 
interleukin-1beta mRNA in rat brain after transient forebrain ischemia. J 
Neurochem 58:390-392. 
178 
 
Minich T, Riemer J, Schulz JB, Wielinga P, Wijnholds J, Dringen R (2006) The 
multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of 
glutathione and glutathione disulfide from brain astrocytes. J Neurochem 
97:373-384. 
Miura K, Ishii T, Sugita Y, Bannai S (1992) Cystine uptake and glutathione level 
in endothelial cells exposed to oxidative stress. Am J Physiol 262:C50-
C58. 
Mokuno K, Ohtani K, Suzumura A, Kiyosawa K, Hirose Y, Kawai K, Kato K 
(1994) Induction of manganese superoxide dismutase by cytokines and 
lipopolysaccharide in cultured mouse astrocytes. J Neurochem 63:612-
616. 
Molina-Holgado E, Ortiz S, Molina-Holgado F, Guaza C (2000) Induction of COX-
2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-
activated protein kinases in murine astrocytes. Br J Pharmacol 131:152-
159. 
Monyer H, Goldberg MP, Choi DW (1989) Glucose deprivation neuronal injury in 
cortical culture. Brain Res 483:347-354. 
Monyer H, Giffard RG, Hartley DM, Dugan LL, Goldberg MP, Choi DW (1992) 
Oxygen or glucose deprivation-induced neuronal injury in cortical cell 
cultures is reduced by tetanus toxin. Neuron 8:967-973. 
Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK (2005) 
Cystine/glutamate exchange regulates metabotropic glutamate receptor 
presynaptic inhibition of excitatory transmission and vulnerability to 
cocaine seeking. J Neurosci 25:6389-6393. 
Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA (2003) Delayed administration of 
interleukin-1 receptor antagonist protects against transient cerebral 
ischaemia in the rat. Br J Pharmacol 140:471-476. 
Murphy TH, Schnaar RL, Coyle JT (1990) Immature cortical neurons are 
uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. 
FASEB J 4:1624-1633. 
Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Glutamate 
toxicity in a neuronal cell line involves inhibition of cystine transport 
leading to oxidative stress. Neuron 2:1547-1558. 
179 
 
Murray CA, Lynch MA (1998) Evidence that increased hippocampal expression 
of the cytokine interleukin-1 beta is a common trigger for age- and stress-
induced impairments in long-term potentiation. J Neurosci 18:2974-2981. 
Mysona B, Dun Y, Duplantier J, Ganapathy V, Smith SB (2009) Effects of 
hyperglycemia and oxidative stress on the glutamate transporters GLAST 
and system xc- in mouse retinal Muller glial cells. Cell Tissue Res 
335:477-488. 
Nakamura E, Sato M, Yang H, Miyagawa F, Harasaki M, Tomita K, Matsuoka S, 
Noma A, Iwai K, Minato N (1999) 4F2 (CD98) heavy chain is associated 
covalently with an amino acid transporter and controls intracellular 
trafficking and membrane topology of 4F2 heterodimer. J Biol Chem 
274:3009-3016. 
Nakamura Y, Ohmaki M, Murakami K, Yoneda Y (2003) Involvement of protein 
kinase C in glutamate release from cultured microglia. Brain Res 962:122-
128. 
Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, 
Yamaguchi S, Kawabata S, Okada M (1998) Glutamate receptors: brain 
function and signal transduction. Brain Res Brain Res Rev 26:230-235. 
Nedergaard M (1994) Direct signaling from astrocytes to neurons in cultures of 
mammalian brain cells. Science 263:1768-1771. 
Nedergaard M, Takano T, Hansen AJ (2002) Beyond the role of glutamate as a 
neurotransmitter. Nat Rev Neurosci 3:748-755. 
Nedergaard M, Ransom B, Goldman SA (2003) New roles for astrocytes: 
redefining the functional architecture of the brain. Trends Neurosci 26:523-
530. 
Neta R, Douches S, Oppenheim JJ (1986) Interleukin 1 is a radioprotector. J 
Immunol 136:2483-2485. 
Nguyen HT, Dalmasso G, Yan Y, Obertone TS, Sitaraman SV, Merlin D (2008) 
Ecto-phosphorylation of CD98 regulates cell-cell interactions. PLoS One 
3:e3895. 
Nguyen MD, Julien JP, Rivest S (2002) Innate immunity: the missing link in 
neuroprotection and neurodegeneration? Nat Rev Neurosci 3:216-227. 
180 
 
Nicholls D, Attwell D (1990) The release and uptake of excitatory amino acids. 
Trends Pharmacol Sci 11:462-468. 
Norenberg MD, Martinez-Hernandez A (1979) Fine structural localization of 
glutamine synthetase in astrocytes of rat brain. Brain Res 161:303-310. 
Nosoya K, Tomi M, Ohtsuki S, Takanaga H, Saeki S, Kanai Y, Endou H, Naito M, 
Tsuruo T, Terasaki T (2002) Enhancement of L-cystine transport activity 
and its relation to xCT gene induction at the blood-brain barrier by diethyl 
maleate treatment. J Pharmacol Exp Ther 302:225-231. 
Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes 
neurotoxic via the N-methyl-D-aspartate receptor when intracellular 
energy levels are reduced. Brain Res 451:205-212. 
Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T (2003) Atypical 
protein kinase C mediates activation of NF-E2-related factor 2 in response 
to oxidative stress. Am J Physiol Cell Physiol 285:C334-342. 
Nyitrai G, Kekesi KA, Juhasz G (2006) Extracellular level of GABA and Glu: in 
vivo microdialysis-HPLC measurements. Curr Top Med Chem 6:935-940. 
O'Neill LA (2008) The interleukin-1 receptor/Toll-like receptor superfamily: 10 
years of progress. Immunol Rev 226:10-18. 
O'Neill LA, Greene C (1998) Signal transduction pathways activated by the IL-1 
receptor family: ancient signaling machinery in mammals, insects, and 
plants. J Leukoc Biol 63:650-657. 
Ogata K, Kosaka T (2002) Structural and quantitative analysis of astrocytes in 
the mouse hippocampus. Neuroscience 113:221-233. 
Ogawa Y, Saito Y, Nishio K, Yoshida Y, Ashida H, Niki E (2008) Gamma-
tocopheryl quinone, not alpha-tocopheryl quinone, induces adaptive 
response through up-regulation of cellular glutathione and cysteine 
availability via activation of ATF4. Free Radic Res 42:674-687. 
Ogunrinu TA, Sontheimer H (2010) Hypoxia increases the dependence of glioma 
cells on glutathione. J Biol Chem 285:37716-37724. 
Ohtaki H, Funahashi H, Dohi K, Oguro T, Horai R, Asano M, Iwakura Y, Yin L, 
Matsunaga M, Goto N, Shioda S (2003) Suppression of oxidative neuronal 
181 
 
damage after transient middle cerebral artery occlusion in mice lacking 
interleukin-1. Neurosci Res 45:313-324. 
Ohtsuki T, Ruetzler CA, Tasaki K, Hallenbeck JM (1996) Interleukin-1 mediates 
induction of tolerance to global ischemia in gerbil hippocampal CA1 
neurons. J Cereb Blood Flow Metab 16:1137-1142. 
Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ (1993) Vulnerability of 
oligodendroglia to glutamate: pharmacology, mechanisms, and 
prevention. J Neurosci 13:1441-1453. 
Olney JW (1969) Brain lesions, obesity, and other disturbances in mice treated 
with monosodium glutamate. Science 164:719-721. 
Orlando S, Polentarutti N, Mantovani A (2000) Selectivity release of the type II 
decoy IL-1 receptor. Cytokine 12:1001-1006. 
Ottersen OP, Zhang N, Walberg F (1992) Metabolic compartmentation of 
glutamate and glutamine: morphological evidence obtained by quantitative 
immunocytochemistry in rat cerebellum. Neuroscience 46:519-534. 
Owen JB, Butterfield DA (2010) Measurement of oxidized/reduced glutathione 
ratio. Methods Mol Biol 648:269-277. 
Oxender DL, Lee M, Moore PA, Cecchini G (1977) Neutral amino acid transport 
systems of tissue culture cells. J Biol Chem 252:2675-2679. 
Palacin M, Kanai Y (2004) The ancillary proteins of HATs: SLC3 family of amino 
acid transporters. Pflugers Arch 447:490-494. 
Pampliega O, Domercq M, Soria FN, Villoslada P, Rodriguez-Antiguedad A, 
Matute C (2011) Increased expression of cystine/glutamate antiporter in 
multiple sclerosis. J Neuroinflammation 8:63. 
Parish CL, Finkelstein DI, Tripanichkul W, Satoskar AR, Drago J, Horne MK 
(2002) The role of interleukin-1, interleukin-6, and glia in inducing growth 
of neuronal terminal arbors in mice. J Neurosci 22:8034-8041. 
Parker LC, Luheshi GN, Rothwell NJ, Pinteaux E (2002) IL-1 beta signalling in 
glial cells in wildtype and IL-1RI deficient mice. Br J Pharmacol 136:312-
320. 
182 
 
Parpura V, Fang Y, Basarsky T, Jahn R, Haydon PG (1995) Expression of 
synaptobrevin II, cellubrevin and syntaxin but not SNAP-25 in cultured 
astrocytes. FEBS Lett 377:489-492. 
Parpura V, Basarsky TA, Liu F, Jeftinija K, Jeftinija S, Haydon PG (1994) 
Glutamate-mediated astrocyte-neuron signalling. Nature 369:744-747. 
Patneau DK, Mayer ML (1990) Structure-activity relationships for amino acid 
transmitter candidates acting at N-methyl-D-aspartate and quisqualate 
receptors. J Neurosci 10:2385-2399. 
Pearson VL, Rothwell NJ, Toulmond S (1999) Excitotoxic brain damage in the rat 
induces interleukin-1beta protein in microglia and astrocytes: correlation 
with the progression of cell death. Glia 25:311-323. 
Penton-Rol G, Orlando S, Polentarutti N, Bernasconi S, Muzio M, Introna M, 
Mantovani A (1999) Bacterial lipopolysaccharide causes rapid shedding, 
followed by inhibition of mRNA expression, of the IL-1 type II receptor, 
with concomitant up-regulation of the type I receptor and induction of 
incompletely spliced transcripts. J Immunol 162:2931-2938. 
Pham AN, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y (2010) 
Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate 
antiporter in growth and celastrol resistance of glioma cell lines. J 
Pharmacol Exp Ther 332:949-958. 
Piani D, Fontana A (1994) Involvement of the cystine transport system xc- in the 
macrophage-induced glutamate-dependent cytotoxicity to neurons. J 
Immunol 152:3578-3585. 
Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen 
ME (1997) Novel inhibitors of cytokine-induced IkappaBalpha 
phosphorylation and endothelial cell adhesion molecule expression show 
anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103. 
Pinteaux E, Trotter P, Simi A (2009) Cell-specific and concentration-dependent 
actions of interleukin-1 in acute brain inflammation. Cytokine 45:1-7. 
Pinteaux E, Parker LC, Rothwell NJ, Luheshi GN (2002) Expression of 
interleukin-1 receptors and their role in interleukin-1 actions in murine 
microglial cells. J Neurochem 83:754-763. 
183 
 
Plata-Salaman CR, Ffrench-Mullen JM (1992) Interleukin-1 beta depresses 
calcium currents in CA1 hippocampal neurons at pathophysiological 
concentrations. Brain Res Bull 29:221-223. 
Plata-Salaman CR, ffrench-Mullen JM (1994) Interleukin-1 beta inhibits Ca2+ 
channel currents in hippocampal neurons through protein kinase C. Eur J 
Pharmacol 266:1-10. 
Poot M, Teubert H, Rabinovitch PS, Kavanagh TJ (1995) De novo synthesis of 
glutathione is required for both entry into and progression through the cell 
cycle. J Cell Physiol 163:555-560. 
Pow DV (2001) Visualising the activity of the cystine-glutamate antiporter in glial 
cells using antibodies to aminoadipic acid, a selectively transported 
substrate. Glia 34:27-38. 
Pringle AK, Niyadurupola N, Johns P, Anthony DC, Iannotti F (2001) Interleukin-
1beta exacerbates hypoxia-induced neuronal damage, but attenuates 
toxicity produced by simulated ischaemia and excitotoxicity in rat 
organotypic hippocampal slice cultures. Neurosci Lett 305:29-32. 
Qiang W, Cahill JM, Liu J, Kuang X, Liu N, Scofield VL, Voorhees JR, Reid AJ, 
Yan M, Lynns WS, Wong PK (2004) Activation of transcription factor Nrf-2 
and its downstream targets in response to moloney murine leukemia virus 
ts1-induced thiol depletion and oxidative stress in astrocytes. J Virol 
78:11926-11938. 
Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M (2006) System Xc- and 
apolipoprotein E expressed by microglia have opposite effects on the 
neurotoxicity of amyloid-beta peptide 1-40. J Neurosci 26:3345-3356. 
Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1 beta secretion 
stimulated by P2X7 receptors is dependent on inflammasome activation 
and correlated with exosome release in murine macrophages. J Immunol 
179:1913-1925. 
Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD (1988) Platelet-derived 
growth factor from astrocytes drives the clock that times oligodendrocyte 
development in culture. Nature 333:562-565. 
Ransom BR, Sontheimer H (1992) The neurophysiology of glial cells. J Clin 
Neurophysiol 9:224-251. 
184 
 
Raps SP, Lai JC, Hertz I, Cooper AJ (1989) Glutathione is present in high 
concentrations in cultured astrocytes but not in cultured neurons. Brain 
Res 493:398-401. 
Ratan RR, Murphy TH, Baraban JM (1994) Macromolecular synthesis inhibitors 
prevent oxidative stress-induced apoptosis in embryonic cortical neurons 
by shunting cysteine from  protein synthesis to glutathione. J Neurosci 
14:4385-4392. 
Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, Colotta F 
(1994) The type II "receptor" as a decoy target for interleukin 1 in 
polymorphonuclear leukocytes: characterization of induction by 
dexamethasone and ligand binding properties of the released decoy 
receptor. J Exp Med 179:739-743. 
Reichelt W, Stabel-Burow J, Pannicke T, Weichert H, Heinemann U (1997) The 
glutathione level of retinal Muller glial cells is dependent on the high-
affinity sodium-dependent uptake of glutamate. Neuroscience 77:1213-
1224. 
Relton JK, Rothwell NJ (1992) Interleukin-1 receptor antagonist inhibits 
ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 
29:243-246. 
Reuter S, Schnekenburger M, Cristofanon S, Buck I, Teiten MH, Daubeuf S, 
Eifes S, Dicato M, Aggarwal BB, Visvikis A, Diederich M (2009) Tumor 
necrosis factor alpha induces gamma-glutamyltransferase expression via 
nuclear factor-kappaB in cooperation with Sp1. Biochem Pharmacol 
77:397-411. 
Riveros N, Fiedler J, Lagos N, Munoz C, Orrego F (1986) Glutamate in rat brain 
cortex synaptic vesicles: influence of the vesicle isolation procedure. Brain 
Res 386:405-408. 
Röhl C, Armbrust E, Kolbe K, Lucius R, Maser E, Venz S, M. G (2008) Activated 
microglia modulate astroglial enzymes involved in oxidative and 
inflammatory stress and increase the resistance of astrocytes to oxidative 
stress in vitro. Glia 56:1114-1126. 
Ronaldson PT, Ashraf T, Bendayan R (2010) Regulation of multidrug resistance 
protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement 
of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. 
Mol Pharmacol 77:644-659. 
185 
 
Ross FM, Allan SM, Rothwell NJ, Verkhratsky A (2003) A dual role for 
interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol 
144:61-67. 
Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, 
Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of 
glutamate transporters reveals a major role for astroglial transport in 
excitotoxicity and clearance of glutamate. Neuron 16:675-686. 
Rudge JS (1993) Astrocyte-derived neurotrophic factors. San Diego,CA: 
Academic Press. 
Ryan CM, Atchison J, Puczynski S, Puczynski M, Arslanian S, Becker D (1990) 
Mild hypoglycemia associated with deterioration of mental efficiency in 
children with insulin-dependent diabetes mellitus. J Pediatr 117:32-38. 
Sagara J, Makino N, Bannai S (1996) Glutathione efflux from cultured astrocytes. 
J Neurochem 66:1876-1881. 
Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial 
cells. J Neurochem 61:1672-1676. 
Sairanen TR, Lindsberg PJ, Brenner M, Siren AL (1997) Global forebrain 
ischemia results in differential cellular expression of interleukin-1 beta (IL-
1 beta) and its receptor at mRNA and protein level. J Cereb Blood Flow 
Metab 17:1107-1120. 
Sakakura Y, Sato H, Shiiya A, Tamba M, Sagara J, Matsuda M, Okamura N, 
Makino N, Bannai S (2007) Expression and function of cystine/glutamate 
transporter in neutrophils. J Leukoc Biol 81:974-982. 
Sandberg M, Butcher SP, Hagberg H (1986) Extracellular overflow of neuroactive 
amino acids during severe insulin-induced hypoglycemia: in vivo dialysis 
of the rat hippocampus. J Neurochem 47:178-184. 
Santello M, Bezzi P, Volterra A (2011) TNFalpha controls glutamatergic 
gliotransmission in the hippocampal dentate gyrus. Neuron 69:988-1001. 
Sanz JM, Di Virgilio F (2000) Kinetics and mechanism of ATP-dependent IL-1 
beta release from microglial cells. J Immunol 164:4893-4898. 
Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, Tamba 
M, Itoh K, Yamamoto M, Bannai S (2002) Electrophile response element-
186 
 
mediated induction of the cystine/glutamate exchange transporter gene 
expression. J Biol Chem 277:44765-44771. 
Sather W, Dieudonne S, MacDonald JF, Ascher P (1992) Activation and 
desensitization of N-methyl-D-aspartate receptors in nucleated outside-out 
patches from mouse neurones. J Physiol 450:643-672. 
Sato H, Watanabe H, Ishii T, Bannai S (1987) Neutral amino acid transport in 
mouse peritoneal macrophages. J Biol Chem 262:13015-13019. 
Sato H, Fujiwara K, Sagara J, Bannai S (1995a) Induction of cystine transport 
activity in mouse peritoneal macrophages by bacterial lipopolysaccharide. 
Biochem J 310 (Pt 2):547-551. 
Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma 
membrane cystine/glutamate exchange transporter composed of two 
distinct proteins. J Biol Chem 274:11455-11458. 
Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S (2000) Molecular 
cloning and expression of human xCT, the light chain of amino acid 
transport system xc-. Antioxid Redox Signal 2:665-671. 
Sato H, Takenaka Y, Fujiwara K, Yamaguchi M, Abe K, Bannai S (1995b) 
Increase in cystine transport activity and glutathione level in mouse 
peritoneal macrophages exposed to oxidized low-density lipoprotein. 
Biochem Biophys Res Commun 215:154-159. 
Sato H, Nomura S, Maebara K, Sato K, Tamba M, Bannai S (2004) 
Transcriptional control of cystine/glutatmate transporter gene by amino 
acid deprivation. Biochem Biophys Res Commun 325:109-116. 
Sato H, Tamba M, Okuno S, Sato K, Keino-Masu K, Masu M, Bannai S (2002) 
Distribution of cystine/glutamate exchange transporter, system x(c)-, in the 
mouse brain. J Neurosci 22:8028-8033. 
Sato H, Kuriyama-Matsumura K, Hashimoto T, Sasaki H, Wang H, Ishii T, Mann 
GE, Bannai S (2001) Effect of oxygen on induction of the cystine 
transporters by bacterial lipopolysaccharide in mouse peritoneal 
macrophages. J Biol Chem 276:10407-10412. 
Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, 
Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) 
187 
 
Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol 
Chem 280:37423-37429. 
Sattler R, Tymianski M (2000) Molecular mechanisms of calcium-dependent 
excitotoxicity. J Mol Med 78:3-13. 
Sattler R, Tymianski M (2001) Molecular mechanisms of glutamate receptor-
mediated excitotoxic neuronal cell death. Mol Neurobiol 24:107-129. 
Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, 
Nimsky C, Buchfelder M, Eyupoglu IY (2008) Small interfering RNA-
mediated xCT silencing in gliomas inhibits neurodegeneration and 
alleviates brain edema. Nat Med 14:629-632. 
Scemes E, Spray DC (2004) The astrocytic syncytium. Advances in Molecular 
and Cell Biology 31:165-179. 
Schielke GP, Yang GY, Shivers BD, Betz AL (1998) Reduced ischemia brain 
injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb 
Blood Flow Metab 18:180-185. 
Schindler R, Clark BD, Dinarello CA (1990) Dissociation between interleukin-1 
beta mRNA and protein synthesis in human peripheral blood mononuclear 
cells. J Biol Chem 265:10232-10237. 
Schneider H, Pitossi F, Balschun D, Wagner A, del Rey A, Besedovsky HO 
(1998) A neuromodulatory role of interleukin-1beta in the hippocampus. 
Proc Natl Acad Sci U S A 95:7778-7783. 
Schwartz GN, MacVittie TJ, Vigneulle RM, Patchen ML, Douches SD, 
Oppenheim JJ, Neta R (1987) Enhanced hematopoietic recovery in 
irradiated mice pretreated with interleukin-1 (IL-1). Immunopharmacol 
Immunotoxicol 9:371-389. 
Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y (1999) 
Identification and functional characterization of a Na+-independent neutral 
amino acid transporter with broad substrate selectivity. J Biol Chem 
274:19745-19751. 
Seib TM, Patel SA, Bridges RJ (in press) Regulation of the System xc- cystine / 
glutamate exchanger by intracellular glutathione levels in rat astrocyte 
primary cultures. Glia. 
188 
 
Shaftel SS, Griffin WS, O'Banion MK (2008) The role of interleukin-1 in 
neuroinflammation and Alzheimer disease: an evolving perspective. J 
Neuroinflammation 5:7. 
Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK 
(2007) Sustained hippocampal IL-1 beta overexpression mediates chronic 
neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin 
Invest 117:1595-1604. 
Shanker G, Aschner M (2001) Identification and characterization of uptake 
systems for cystine and cysteine in cultured astrocytes and neurons: 
evidence for methylmercury-targeted disruption of astrocyte transport. J 
Neurosci Res 66:998-1002. 
Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH (2006) 
Cystine/glutamate exchange modulates glutathione supply for 
neuroprotection from oxidative stress and cell proliferation. J Neurosci 
26:10514-10523. 
Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy 
TH (2003) Coordinate regulation of glutathione biosynthesis and release 
by Nrf-2 expressing glia potently protects neurons from oxidative stress. J 
Neurosci 23:3394-3406. 
Shirakawa F, Mizel SB (1989) In vitro activation and nuclear translocation of NF-
kappa B catalyzed by cyclic AMP-dependent protein kinase and protein 
kinase C. Mol Cell Biol 9:2424-2430. 
Shirakawa F, Chedid M, Suttles J, Pollok BA, Mizel SB (1989) Interleukin 1 and 
cyclic AMP induce kappa immunoglobulin light-chain expression via 
activation of an NF-kappa B-like DNA-binding protein. Mol Cell Biol 9:959-
964. 
Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M 
(2011) Role of astrocytes in brain function and disease. Toxicol Pathol 
39:115-123. 
Silver IA, Erecinska M (1994) Extracellular glucose concentration in mammalian 
brain: continuous monitoring of changes during increased neuronal activity 
and upon limitation in oxygen supply in normo-, hypo-, and hyperglycemic 
animals. J Neurosci 14:5068-5076. 
189 
 
Silverstein FS, Simpson J, Gordon KE (1990) Hypoglycemia alters striatal amino 
acid efflux in perinatal rats: an in vivo microdialysis study. Ann Neurol 
28:516-521. 
Simmons ML, Murphy S (1992) Induction of nitric oxide synthase in glial cells. J 
Neurochem 59:897-905. 
Sims B, Clarke M, Njah W, Hopkins ES, Sontheimer H (2010) Erythropoietin-
induced neuroprotection requires cystine glutamate exchanger activity. 
Brain Res 1321:88-95. 
Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nat Rev 
Immunol 10:89-102. 
Sims JE, March CJ, Cosman D, Widmer MB, MacDonald HR, McMahan CJ, 
Grubin CE, Wignall JM, Jackson JL, Call SM, et al. (1988) cDNA 
expression cloning of the IL-1 receptor, a member of the immunoglobulin 
superfamily. Science 241:585-589. 
Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, 
Mantovani A, Shanebeck K, et al. (1993) Interleukin 1 signaling occurs 
exclusively via the type I receptor. Proc Natl Acad Sci U S A 90:6155-
6159. 
Singer, II, Scott S, Hall GL, Limjuco G, Chin J, Schmidt JA (1988) Interleukin 1 
beta is localized in the cytoplasmic ground substance but is largely absent 
from the Golgi apparatus and plasma membranes of stimulated human 
monocytes. J Exp Med 167:389-407. 
Sklar MD, Tereba A, Chen BD, Walker WS (1985) Transformation of mouse 
bone marrow cells by transfection with a human oncogene related to c-
myc is associated with the endogenous production of macrophage colony 
stimulating factor 1. J Cell Physiol 125:403-412. 
Soiampornkul R, Tong L, Thangnipon W, Balazs R, Cotman CW (2008) 
Interleukin-1beta interferes with signal transduction induced by 
neurotrophin-3 in cortical neurons. Brain Res 1188:189-197. 
Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, 
Gabel CA (2001) Altered cytokine production in mice lacking P2X(7) 
receptors. J Biol Chem 276:125-132. 
190 
 
Sontheimer H (2008) A role for glutamate in growth and invasion of primary brain 
tumors. J Neurochem 105:287-295. 
Spranger M, Lindholm D, Bandtlow C, Heumann R, Gnahn H, Naher-Noe M, 
Thoenen H (1990) Regulation of Nerve Growth Factor (NGF) Synthesis in 
the Rat Central Nervous System: Comparison between the Effects of 
Interleukin-1 and Various Growth Factors in Astrocyte Cultures and in 
vivo. Eur J Neurosci 2:69-76. 
Srinivasan D, Yen JH, Jospeh DJ, Friedman W (2004) Cell type-specific 
interleukin-1 beta signaling in the CNS. J Neurosci 24:6482-6488. 
Stamler JS, Hausladen A (1998) Oxidative modifications in nitrosative stress. Nat 
Struct Biol 5:247-249. 
Stevens BR, Vo CB (1998) Membrane transport of neuronal nitric oxide synthase 
substrate L-arginine is constitutively expressed with CAT1 and 4F2hc, but 
not CAT2 or rBAT. J Neurochem 71:564-570. 
Strijbos PJ, Rothwell NJ (1995) Interleukin-1 beta attenuates excitatory amino 
acid-induced neurodegeneration in vitro: involvement of nerve growth 
factor. J Neurosci 15:3468-3474. 
Suh SW, Hamby AM, Swanson RA (2007) Hypoglycemia, brain energetics, and 
hypoglycemic neuronal death. Glia 55:1280-1286. 
Sun X, Shih AY, Johannssen HC, Erb H, Li P, Murphy TH (2006) Two-photon 
imaging of glutathione levels in intact brain indicates enhanced redox 
buffering in developing neurons and cells at the cerebrospinal fluid and 
blood-brain interface. J Biol Chem 281:17420-17431. 
Swank RT, Reddington M, Novak EK (1996) Inherited prolonged bleeding time 
and platelet storage pool deficiency in the subtle gray (sut) mouse. Lab 
Anim Sci 46:56-60. 
Swanson RA, Choi DW (1993) Glial glycogen stores affect neuronal survival 
during glucose deprivation in vitro. J Cereb Blood Flow Metab 13:162-169. 
Swanson RA, Benington JH (1996) Astrocyte glucose metabolism under normal 
and pathological conditions in vitro. Dev Neurosci 18:515-521. 
191 
 
Szatkowski M, Barbour B, Attwell D (1990) Non-vesicular release of glutamate 
from glial cells by reversed electrogenic glutamate uptake. Nature 
348:443-446. 
Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, 
Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces 
neurotoxicity via glutamate release from hemichannels of activated 
microglia in an autocrine manner. J Biol Chem 281:21362-21368. 
Tanaka J, Toku K, Zhang B, Ishihara K, Sakanaka M, Maeda N (1999) 
Astrocytes protect neuronal death induced by reactive oxygen and 
nitrogen species. Glia 28:85-96. 
Tanaka S, Ide M, Shibutani T, Ohtaki H, Numazawa S, Shioda S, Yoshida T 
(2006) Lipopolysaccharide-induced microglial activation induces learning 
and memory deficits without neuronal cell death in rats. J Neurosci Res 
83:557-566. 
Tang X, Kalivas PW (2003) Bidirectional modulation of cystine/glutamate 
exchanger activity in cultured cortical astrocytes. Ann NY Acad Sci 
1003:472-475. 
Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, 
Tarkowski A (1995) Early intrathecal production of interleukin-6 predicts 
the size of brain lesion in stroke. Stroke 26:1393-1398. 
Taylor AL, Hewett SJ (2002) Potassium-evoked glutamate release liberates 
arachidonic acid from cortical neurons. J Biol Chem 277:43881-43887. 
Temporin K, Tanaka H, Kuroda Y, Okada K, Yachi K, Moritomo H, Murase T, 
Yoshikawa H (2008) IL-1beta promotes neurite outgrowth by deactivating 
RhoA via p38 MAPK pathway. Biochem Biophys Res Commun 365:375-
380. 
Tomi M, Hosoya K, Takanaga H, Ohtsuki S, Terasaki T (2002) Induction of xCT 
gene expression and L-cystine transport activity by diethyl maleate at the 
inner blood-retinal barrier. Invest Opthalmol Vis Sci 43:774-779. 
Tomi M, Funaki T, Abukawa H, Katayama K, Kondo T, Ohtsuki S, Ueda M, 
Obinata M, Terasaki T, Hosoya K (2003) Expression and regulation of L-
cystine transporter, system xc-, in the newly developed rat retinal Müller 
cell line (TR-MUL). Glia 43:208-217. 
192 
 
Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW (2008) 
Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal 
transduction. Neurobiol Aging 29:1380-1393. 
Touzani O, Boutin H, LeFeuvre R, Parker L, Miller A, Luheshi G, Rothwell N 
(2002) Interleukin-1 influences ischemic brain damage in the mouse 
independently of the interleukin-1 type I receptor. J Neurosci 22:38-43. 
Trackey JL, Uliasz TF, Hewett SJ (2001) SIN-1-induced cytotoxicity in mixed 
cortical cell culture: peroxynitrite-dependent and -independent induction of 
excitotoxic cell death. J Neurochem 79:445-455. 
Trotti D, Rizzini BL, Rossi D, Haugeto O, Racagni G, Danbolt NC, Volterra A 
(1997) Neuronal and glial glutamate transporters possess an SH-based 
redox regulatory mechanism. Eur J Neurosci 9:1236-1243. 
Uliasz TF, Hewett SJ (2000) A microtiter trypan blue absorbance assay for the 
quantitative determination of excitotoxic neuronal injury in cell culture. J 
Neurosci Methods 100:157-163. 
Ullian EM, Sapperstein SK, Christopherson KS, Barres BA (2001) Control of 
synapse number by glia. Science 291:657-661. 
Urata Y, Yamamoto H, Goto S, Tsushima H, Akazawa S, Yamashita S, Nagataki 
S, Kondo T (1996) Long exposure to high glucose concentration impairs 
the responsive expression of gamma-glutamylcysteine synthetase by 
interleukin-1beta and tumor necrosis factor-alpha in mouse endothelial 
cells. J Biol Chem 271:15146-15152. 
van der Meer JW, Barza M, Wolff SM, Dinarello CA (1988) A low dose of 
recombinant interleukin 1 protects granulocytopenic mice from lethal 
gram-negative infection. Proc Natl Acad Sci U S A 85:1620-1623. 
Vela JM, Molina-Holgado E, Arevalo-Martin A, Almazan G, Guaza C (2002) 
Interleukin-1 regulates proliferation and differentiation of oligodendrocyte 
progenitor cells. Mol Cell Neurosci 20:489-502. 
Verrey F, Meier C, Rossier G, Kuhn LC (2000) Glycoprotein-associated amino 
acid exchangers: broadening the range of transport specificity. Pflugers 
Arch 440:503-512. 
193 
 
Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and 
HATs: the SLC7 family of amino acid transporters. Pflugers Arch 447:532-
542. 
Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ (1997) Crystal structure of the 
type-I interleukin-1 receptor complexed with interleukin-1beta. Nature 
386:190-194. 
Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee R (2006) A 
functional transsulfuration pathway in the brain links to glutathione 
homeostasis. J Biol Chem 281:35785-35793. 
Wang D, Zhang S, Li L, Liu X, Mei K, Wang X (2010) Structural insights into the 
assembly and activation of IL-1beta with its receptors. Nat Immunol 
11:905-911. 
Wang H, Tamba M, Kimata M, Sakamoto K, Bannai S, Sato H (2003) Expression 
of the activity of cystine/glutamate exchange transporter, system (xc-), by 
xCT and rBAT. Biochem Biophys Res Commun 305:611-618. 
Wang J, Bankiewicz KS, Plunkett RJ, Oldfield EH (1994) Intrastriatal implantation 
of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal 
sprouting from residual dopaminergic neurons in the ventral tegmental 
area of the midbrain. J Neurosurg 80:484-490. 
Wang X, Li X, Currie RW, Willette RN, Barone FC, Feuerstein GZ (2000) 
Application of real-time polymerase chain reaction to quantitate induced 
expression of interleukin-1beta mRNA in ischemic brain tolerance. J 
Neurosci Res 59:238-246. 
Wang XF, Cynader MS (2000) Astrocytes provide cysteine to neurons by 
releasing glutathione. J Neurochem 74:1434-1442. 
Warr O, Takahashi M, Attwell D (1999) Modulation of extracellular glutamate 
concentration in rat brain slices by cystine-glutamate exchange. J Physiol 
514 (Pt 3):783-793. 
Watanabe H, Bannai S (1987) Induction of cystine transport activity in mouse 
peritoneal macrophages. J Exp Med 165:628-640. 
Webb AC, Collins KL, Auron PE, Eddy RL, Nakai H, Byers MG, Haley LL, Henry 
WM, Shows TB (1986) Interleukin-1 gene (IL1) assigned to long arm of 
human chromosome 2. Lymphokine Res 5:77-85. 
194 
 
Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 
3:cm1. 
Wieloch T (1985) Hypoglycemia-induced neuronal damage prevented by an N-
methyl-D-aspartate antagonist. Science 230:681-683. 
Wieloch T, Engelsen B, Westerberg E, Auer R (1985) Lesions of the 
glutamatergic cortico-striatal projections in the rat ameliorate 
hypoglycemic brain damage in the striatum. Neurosci Lett 58:25-30. 
Wu G, Fang YZ, Yang S, Lupton J, Turner N (2004) Glutathione metabolism and 
its implications for health. J Nutr 134:489-492. 
Yamasaki Y, Matsuura N, Shozuhra H, Onodera H, Itoyama Y, Kogure K (1995) 
Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. 
Stroke 26:676-680. 
Yan Y, Vasudevan S, Nguyen HT, Merlin D (2008) Intestinal epithelial CD98: an 
oligomeric and multifunctional protein. Biochim Biophys Acta 1780:1087-
1092. 
Yang GY, Zhao YJ, Davidson BL, Betz AL (1997) Overexpression of interleukin-1 
receptor antagonist in the mouse brain reduces ischemic brain injury. 
Brain Res 751:181-188. 
Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of 
glutamate. Cancer Research 59:4383-4391. 
Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in 
human glioma cells: reduction-mislocalization of sodium-dependent 
glutamate transporters and enhanced activity of cystine-glutamate 
exchange. J Neurosci 19:10767-10777. 
Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR (2003) Functional 
hemichannels in astrocytes: a novel mechanism of glutamate release. J 
Neurosci 23:3588-3596. 
Zerangue N, Kavanaugh MP (1996) Flux coupling in a neuronal glutamate 
transporter. Nature 383:634-637. 
Zhai Q, Luo Y, Zhang Y, Berman MA, Dorf ME (2004) Low nuclear levels of 
nuclear factor-kappa B are essential for KC self-induction in astrocytes: 
requirements for shuttling and phosphorylation. Glia 48:327-336. 
195 
 
Zhang W, Potrovita I, Tarabin V, Herrmann O, Beer V, Weih F, Schneider A, 
Schwaninger M (2005) Neuronal activation of NF-kappaB contributes to 
cell death in cerebral ischemia. J Cereb Blood Flow Metab 25:30-40. 
Zhang Y, Barres BA (2010) Astrocyte heterogeneity: an underappreciated topic 
in neurobiology. Curr Opin Neurobiol 20:588-594. 
Zhao B, Schwartz JP (1998) Involvement of cytokines in normal CNS 
development and neurological diseases: recent progress and 
perspectives. J Neurosci Res 52:7-16. 
 
 
